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Abstract 
The human vaginal microbiome undoubtedly has a significant role in reproductive health and 
for protection from infectious organisms. Recent efforts to characterize the bacterial species 
of the vagina using molecular techniques have uncovered an unexpected diversity. Using 
high-throughput sequencing I sought to describe the structure and function of the vaginal 
microbiome under different physiological states including healthy, bacterial vaginosis (BV), 
post-menopausal vaginal atrophy, and acute vulvovaginal candidiasis (VVC). 
Partial 16S rRNA gene sequencing revealed that healthy, asymptomatic women most often 
have vaginal biotas dominated by Lactobacillus iners or L. crispatus. In contrast, BV is a 
heterogeneous, highly diversified condition with reduced Lactobacillus abundance. Similar 
to BV, post-menopausal women experiencing vaginal dryness were depleted in lactobacilli 
and had a more diverse vaginal profile. In the case of VVC, the biotas were not significantly 
altered compared to healthy women despite the fungal overgrowth. 
One organism, Lactobacillus iners was ubiquitously present in all conditions, and became 
predominant following antibiotic and probiotic treatment of BV. To uncover the potential 
role of this bacterium, I used whole genome sequencing of vaginal isolate AB-1. The genome 
is predicted to be the smallest of any Lactobacillus at 1.3 Mbp, but having a higher 
proportion of horizontally acquired genes. These results, along with predicted adhesins and a 
cholesterol-dependent cytolysin, indicate L. iners is highly adapted for the vagina and could 
have an uncharacterized role in the etiology of BV. 
As BV is the most common vaginal ailment with severe implications on acquisition and 
transmission of sexually transmitted infections, and complications during pregnancy, I sought 
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to examine the functional contribution of the organisms during BV using meta-RNA 
sequencing. L. iners drastically modulates gene expression in response to BV, and notably 
increases expression of a cholesterol-dependent cytolysin, mucin and glycerol transport and 
metabolic enzymes, and genes belonging to a CRISPR system - suggestive of bacteriophage 
influence in the community. Although diverse in taxonomic membership, there is evidence of 
functional conservation in BV including preference for glycogen and glycerol as carbon 
sources, and predicted end products of metabolism including an abundance of succinate and 
short-chain fatty acids. These studies add significantly to our understanding of the role 
lactobacilli can play in vaginal and reproductive health. 
 
Keywords 
Human microbiome, bacterial vaginosis, women’s health, next-generation sequencing, 16S 
tag sequencing 
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Chapter 1  
1 General Introduction 
Sometimes referred to as our “second genome”, the human microbiome consists of all the 
microorganisms living on and in our human body. The number of microbial cells 
outnumber our own somatic cells 10 to 1 (1) and the genomic potential of these 
organisms is estimated to be 30X our own genome (2). These microbes exert an 
enormous influence on their hosts via the production of metabolic end products, acting as 
a line of defense against exogenous pathogens, and modulating host immune function. In 
the human vagina, the resident microbes reside in and on the surface of the vaginal 
epithelium relying primarily on host products for nutrients and in turn establishing a first 
line of defense against exogenous disturbances. 
The broad goal of my thesis was to characterize the vaginal microbiome under healthy 
and altered states using high-throughput sequencing techniques. I also sought to describe 
the genome and transcriptome of Lactobacillus iners (Chapter 3 and Chapter 4) - the 
most prevalent organism of the human vaginal microbiome. Over the course of my thesis 
I helped develop new computational pipelines and tools for targeted 16S rRNA gene 
sequencing (Chapter 1 and Chapter 1), genome annotation (Chapter 3), and statistical 
evaluation of differential expression using mRNAseq (Chapter 4). We used these 
methodologies to show how the vaginal microbiota adapts upon antimicrobial and 
probiotic therapy of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) 
(Chapter 5). 
1.1 The human microbiome 
Although consisting of prokaryotic, archaea, viral, and eukaryotic organisms, the “human 
microbiome” colloquially refers mainly to the bacterial populations detected in 
association with the human body as these are the most easily detectable organisms. Many 
of these bacterial communities are thought to have a commensal or mutualistic 
relationship with the host. For example, organisms in the gastro-intestinal tract (GIT) 
receive nutrients primarily from the host ingesting food, while in return maintain the 
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immune environment of the GIT, counter pathogenesis (3), and release nutrients from 
otherwise indigestible components of our diet (4). Some organisms may have pathogenic 
potential, but it is typically thought that a healthy microbiome maintains an ecological 
balance whereby the pathogenic organisms are kept under control by the rest of the 
population. Fluctuations in abundance or structure of these populations are common but 
typically the system returns to homeostasis in healthy individuals (5). A large and 
sustained disturbance can result in, or be associated with, a dysbiotic state and lead to 
conditions or diseases associated with changes in the normal bacterial ecology. Examples 
include inflammatory bowel disease (6), dental caries (7), and obesity (5). 
Our current understanding of the human microbiome has largely been due to the 
advancement in sequencing technologies allowing for high-throughput assessment of 
microbiome population structures (the sequencing techniques are reviewed in Section 
1.8). These studies have shown different body sites have distinct microbiological 
communities, and these communities differ between individuals (8). 
1.2 The vaginal microbiome 
From birth and over a woman’s lifetime there are changes associated with the vaginal 
physiology and correspondingly with the vaginal microbiome. From birth, babies born 
via vaginal delivery have biota of the skin, mouth, and gut that resemble their mother’s 
vaginal microbiome (9). As the infant grows, the different body sites acquire unique 
communities that increase the overall diversity of bacteria and differentiate the sites by 
their composition (10). Before puberty, the vaginal microbiome is dominated by 
anaerobes (11), after which estrogen levels increase, the vaginal lining responds with 
increased glycogen production, and the vagina of most women is colonized by species of 
Lactobacillus (12). The lactobacilli and other lactic acid bacteria convert the vaginal 
glycogen to lactic acid and acidify the vagina to a pH ≤4.5 (13). This balance is typically 
maintained until menopause when a decrease in estrogen results in a loss of glycogen and 
a loss of the lactobacilli (14). 
Culture-based techniques dominated microbiology for many decades and a superficial 
understanding of the vaginal bacterial community was gained. Although isolation of 
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bacteria allows researchers to assay their biochemical abilities, most of the species that 
make up the human microbiome have not yet been cultured due to strict requirements that 
we cannot replicate in vitro (15, 16). The culture bias has carried over to the vaginal 
microbiota; for example, Lactobacillus iners is now known to be a major constituent of 
the vaginal microbiota, but it wasn’t isolated or described until relatively recently (17). 
Currently, there are several “bacterial vaginosis-associated bacteria” (BVAB) of which 
only one member has been isolated, and none have been fully described taxonomically, 
yet are detectable by molecular techniques (18, 19). 
1.3 What is “normal”? 
It’s theorized that the vagina is maintained at a slightly acidic pH to prevent the growth of 
harmful microorganisms (20). For most women, the production of lactic acid is driven by 
members of the Lactobacillus genus which dominate during healthy conditions. Vaginal 
lactobacilli were first described by Albert Döderlein in 1892 and their presence in 
discharge was quickly accepted as part of the normal status (21). Later studies reveled 
there were several related but distinct species of Lactobacillus in the human vagina 
including L. jensenii, L. crispatus, L. gasseri, L. fermentum, and L. reuteri (22, 23). 
Although the idea of a healthy Lactobacillus-dominated biota prevailed for some time, 
more recent molecular descriptions have expanded our knowledge of the species present 
and have indicated that the vaginal biota of up to 20% of women deemed to be healthy 
are not dominated by lactobacilli but have a more complex microbiota and an associated 
higher pH (24). Still, a Lactobacillus-dominated vaginal microbiota seems to be a 
uniquely human trait as sequencing studies of non-human primates show them to be rare 
constituents of the vaginal microbiota (25). Instead, non-human primates have low 
glycogen, higher pH, and a vaginal biota generally resembling human BV (25). 
Early studies using 16S ribotyping still relied on isolating strains by culture before 
extracting their DNA and sequencing the 16S rRNA gene directly (26, 27), or by using 
gel separation(28). These revealed a diverse collection of species in the vagina that were 
not previously differentiated by biochemical assays and suggested that women were 
dominantly colonized by one species of Lactobacillus. Culture-independent 16S 
sequencing by direct isolation of total DNA from vaginal swabs revealed several species 
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previously rarely detected, like Lactobacillus iners (29), Atopobium vaginae, 
Megasphaera, Leptotrichia (30), Bifidobacterium, Prevotella, and Streptococcus (31, 32) 
as major constituents of the vaginal microbiome. 
When technological advances allowed 16S sequencing to become high-throughput, the 
complexity of the vaginal microbiome was revealed. Papers by Sundquist et al. (33) and 
Spear et al. (34) have outlined some of the first approaches to distinguishing bacterial 
species in the vagina using partial 16S sequence and high-throughput pyrosequencing. 
Compared to other body sites like the gut and mouth, fewer species were detected and a 
healthy vaginal environment is now generally associated with a low diversity community 
(35). For other sites, a highly diversified community is often associated with health, and a 
loss in diversity is correlated with several conditions. The largest study to date of the 
healthy vaginal microbiome used partial 16S sequencing to determine the vaginal profiles 
of 396 reproductive-aged women of various self-reported ethnicities (white, black, Asian, 
and Hispanic) amongst Americans (24). The results suggested vaginal profiles fell into 5 
distinct groups based on the organism dominance: four Lactobacillus groups dominated 
by one species (L. iners, L. crispatus, L. gasseri, or L. jensenii) and a fifth with a high 
proportion of mixed anaerobic bacteria. Interestingly, the distribution of the groups by 
ethnicities was not equal and a Lactobacillus-dominated profile was more likely for white 
and Asian women, while black and Hispanic more often had mixed communities. This 
also corresponded to an increased vaginal pH measured in black and Hispanic women 
compared to white and Asian women. These results support an earlier study (36) that 
concluded black women have a higher vaginal pH than other ethnicities. This possibly 
explains the apparent higher prevalence of ‘asymptomatic’ BV in African or black 
women (37). Another partial 16S rRNA gene sequencing study targeting 220 women 
with and without BV (as assessed by Amsel’s criteria which is based upon pH, discharge, 
and odor) also found women without signs of BV were dominated by either L. iners or L. 
crispatus with other Lactobacillus species co-existing in smaller proportions (38). Data 
from the Vaginal Human Microbiome Project at Virginia Commonwealth University has 
also shown the majority of women without obvious signs or symptoms of abnormal 
vaginal conditions are dominated with Lactobacillus, but the remaining show greater 
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diversity with a more even mixture of species (39). This implies that low diversity in the 
vagina is associated with health, contrary to the GIT and mouth. 
There are few longitudinal studies of the vaginal microbiome, and little is known about 
the short-term changes in the community structure. The most extensive, to date, by Gajer 
et al. (40) sampled 32 women over a 16 week period and used partial 16S rRNA gene 
sequencing to track the changes in community composition. Notably, there was a lot of 
variation reported: some women had very stable communities, while others fluctuated 
rapidly over the study period. The authors theorized that most of the changes to 
community structure are tolerable because the functions, such as lactic acid production, 
are maintained. However, there were also clear perturbations to the environment 
represented by changes in detectable metabolic products and in response to menses. In 
another study using quantitative polymerase chain reaction (qPCR), Srinivasan et al. (19) 
described fluctuations of bacterial species during menses with an increase of L. iners and 
G. vaginalis. Such environmental perturbations may therefore lead to changes in the 
community structure and possibly allow pathogenic, or disease-associate organisms to 
establish. 
As a consequence of achieving a high-resolution molecular picture of the vaginal 
microbiome via high-throughput sequencing, the point of view shifted from organism-
centric to an ecological perspective, and the next step was to understand the interactions 
between all the organisms, environment, and the host’s response. 
1.4 Conditions of the vaginal microbiome 
1.4.1 Bacterial vaginosis (BV) 
Bacterial vaginosis is the most common vaginal condition causing women to visit their 
doctors. Recent estimates have suggested 1 in 3 women will experience BV in their 
lifetime and the prevalence is up to 50% in some populations (41). First referred to as 
“non-specific vaginitis” early cases were described as having abundant discharge and a 
“fishy” odor not caused by infectious Candida or Trichomonas, and with a causative 
agent of Haemophilus vaginalis (later, Gardnerella vaginalis) (42). Examinations of 
vaginal smears and cultures in the early 1990s indicated there were notably fewer 
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lactobacilli and an overgrowth, sometimes in excess of 10 to 100-fold increase, of 
anaerobic species (43). However, the isolation of G. vaginalis from ~50% of those 
diagnosed with BV (44) from women without any signs of vaginal abnormalities (45) 
meant that G. vaginalis does not fulfill the criteria of Koch’s postulates (46) for causal 
relationship to BV. Indeed, despite many years of study, no single organism has been 
indicated as the causative factor in BV (47), and recent evidence has shifted the paradigm 
from an infectious disease to a polymicrobial dysbiosis. 
The molecular descriptions of the BV microbiota using 16S rRNA gene sequencing have 
shown there are multiple diverse communities represented in this condition (18, 38, 48, 
49). Most often, these communities show an increased abundance of anaerobic bacteria 
with a loss of lactobacilli. The predominant genera detected during BV include 
Prevotella, Mobiluncus, Atopobium, Clostridiales, Leptotrichia, Sneathia, and 
Megasphaera. Some studies have attempted to define bacterial clusters or groups of BV 
based on organism abundance and presence across individuals (38, 48-50) (and Figure 
1-1). However, unlike healthy profiles that can generally be divided into distinct subtypes 
based on the dominating Lactobacillus species, BV clusters are not well defined due to 
the higher diversity and the difficulty in comparing data between studies. Whether 
different BV subtypes represent different relative risks for the host or not is still unclear. 
BV affects the quality of life for women and their partners and presents an emotional and 
physical burden (51, 52). It is associated with more serious complications including an 
increased rate of HIV and other STIs (53), pelvic inflammatory disease, cervicitis (54), 
and higher incidence of pre-term labour (55). 
The triggers that shift the microbiota to BV are not well understood, but the biggest risk 
factors include a past history of the condition (56), having multiple male sex partners or 
having female sex partners (57), and douching (58). 
Clinically and in the laboratory there are two primary methods used to diagnose BV: the 
Amsel criteria as mentioned previously (44) and Nugent scoring (59). The Amsel criteria 
uses 3 of 4 of the following results to confirm BV: 1) Thin, white, homogenous 
discharge, 2) Clue cells (epithelial cells covered in bacteria) under microscopic 
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examination of a vaginal swab smear, 3) Vaginal fluid pH >4.5, 4) Positive “whiff” test: 
release of a fishy odor after adding 10% potassium hydroxide to vaginal fluid. The 
Nugent score is assessed from a vaginal smear viewed under 100X oil immersion 
microscopy. After Gram staining, the cell morphologies are counted under several fields 
of view. Gram-positive rods are presumptive Lactobacillus and are scored low, while 
small Gram-variable rods (presumptive Gardnerella), and curved Gram-variable rods 
(presumptive Mobiluncus) are scored higher. The final score ranges from 0-10 with 0-3 a 
“Normal” score, 4-6 “Intermediate”, and 7-10 as BV. Variations and alternatives to the 
Nugent or Amsel criteria are sometimes used to assess vaginal microbiota health 
clinically, such as Hays method (60), or wet mount microscopy (61). Other kits, such as 
the BV Blue (62) and FemExam (63) have been tried with some success but not yet 
widely utilized, perhaps due to cost. 
Evaluating the effectiveness of BV diagnosis methods is difficult considering the lack of 
consensus of what BV actually is, and whether signs (such as discharge and odor) are 
required for the condition to exist, or if a change in microbiological profile regardless of 
symptomatic presentation is indicative of BV. Additionally, there is weak correlation 
between Amsel and Nugent criteria (38, 64, 65) - the two most widely used diagnostic 
methods. Srinivasan et al. (38) attempted to correlate individual taxa defined by partial 
16S rRNA gene sequencing with the four components of the Amsel criteria. Only 
Leptotrichia amnionii and Eggerthella sp. were correlated with all four criteria, and G. 
vaginalis and A. vaginae were associated with 3 of 4 criteria each. The other criteria had 
various taxa associations suggesting that different bacterial components could impact the 
symptomology of BV, which might explain some of the disassociation between Nugent 
and Amsel diagnoses. 
Current clinical practices and diagnostic methods have not caught up with the molecular 
understanding of the diversity of vaginal microbiota. This has led to an association 
fallacy: although BV is nearly always associated with increased bacterial diversity, not all 
increases in bacterial diversity are associated with BV. Similarly, not all asymptomatic 
BV cases have Lactobacillus-dominated vaginal microbiota, but nearly all women with 
Lactobacillus-dominated vaginal microbiota are asymptomatic. 
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1.4.2 Other microbiological disorders 
BV is the most recognized and common vaginal microbiota disorder, but there is a lesser-
known bacterial dysbiotic condition known as aerobic vaginitis (AV) (66). Possibly due 
to lacking a routine microscopy based diagnostic testing in clinical settings, this condition 
is not often recognized. Like BV, AV is associated with a loss of lactobacilli, but instead 
of anaerobes the ecosystem has an overabundance of aerobic bacilli and cocci (such as 
Streptococcus species and E. coli). Unlike BV, AV is an inflammatory condition often 
occurring with tissue redness and inflammation, and presence of vaginal leukocytes 
visible under microscopic examination of vaginal smears (67). As expected, both 
conditions are deficient in lactate, but while BV is associated with end-products of 
anaerobic fermentation (mainly succinate), vaginal fluid from AV samples contain high 
levels of inflammatory cytokines interleukin (IL) 6, IL-8, and IL-1β (66). The medical 
implications of AV are not yet clear (68), although some association with preterm labour 
has been reported (68). 
There are several infectious conditions of the vagina caused by specific organisms 
invariably acquired through sexual transmission. These include human 
immunodeficiency virus (HIV), human papilloma virus (HPV), herpes simplex virus 
(HSV), Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, and 
others that can arise spontaneously like Candida (yeast), or group B Streptococcus 
infections. The vaginal mucosa and associated microbes provide the first line of defense 
against external or internal disturbances by other microorganisms. Thus when lactobacilli 
are displaced during BV, the risk for acquisition of several of these STIs increases (53). 
HIV infection is of particular interest in relation to BV because of the overlapping high 
incidence in many developing countries, particularly in Africa (69). Studies uncovering 
the potential relationship between BV and HIV have shown a BV-type microbiota can 
increase viral shedding and viral load in the vagina (70, 71). A recent study suggested 
succinate, abundantly produced by BV-associated organisms, could increase HIV gene 
expression and inflammatory interleukin-8 production in infected differentiated 
monocyte-derived macrophages (72). Other studies show that BV itself increases the risk 
of acquisition of HIV (73). 
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Our recent study of the vaginal microbiota of 132 HIV-positive women in Tanzania (48) 
suggested that BV profiles, though diverse, could be grouped into major clusters 
represented by the dominating taxa (Figure 1-1). As supported by another study of HIV-
positive women (34), we found that L. iners was the most commonly detected organism 
regardless of BV status, and that other Lactobacillus species were rare with the exception 
of one cluster of non-BV samples dominated by L. crispatus. The organisms associated 
with BV included Lachnospiraceae (later identified as BVAB1), Prevotella, 
Megasphaera, and Veillonella amongst others. These profiles are similar to those of BV+ 
HIV-negative women and so far there has been no evidence to suggest distinct BV 
profiles exist in HIV-positive women (74). 
 
 
Figure 1-1. The V6-sequenced vaginal bacterial profiles of 272 samples from 132 
women. 
Each bar is a sample and each color is an OTU or representative taxon. Samples were 
clustered by the similarity in organism abundance as visualized by the neighbor-
joining tree below the bar plot. The major clusters are identified above the bar plot by 
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the predominant organism(s). The sample numbers above the dendrogram are 
coloured according to Nugent categories with BV = red, intermediate = green, normal 
= blue. Amsel criteria are shown for each sample with present = grey, absent = white 
and missing data = black. Figure from (48). 
After BV, vulvovaginal candidiasis (VVC) is the next most common vaginal microbial 
disorder (75). It is caused by Candida albicans in 70-90% of cases (75), but is also 
associated with C. glabrata (7-16% of cases), amongst others (76). It’s estimated that 70-
75% of women will experience VVC in their lifetime (77). There is some evidence that 
the prevalence of VVC is higher in African-American women (78), and rare in post-
menopausal women unless they are receiving estrogen therapy (77, 79). Although 
patients with BV and VVC present similar signs and symptoms of discharge and 
irritation, specific symptoms associated with VVC include inflammation, itching, pain 
during sex (dyspareunia) or urination (dysuria), and lack of odor and abnormally high pH 
associated with BV (80). Diagnosis is confirmed with positive selective Candida culture, 
and/or the presence of Candida by microscopy on a wet mount or Gram stain in 
conjunction with the associated signs and symptoms (80). However, vaginal Candida 
colonization is common with one study showing 15% of unselected asymptomatic 
women (81), and a larger longitudinal study reporting 70% of women were positive for 
Candida in at least one of four samples taken over the course of one year (82). The 
isolation of Candida therefore does not necessarily equate to infection. 
The role of the bacterial microbiota in relation to VVC is largely unexplored. Antibiotic 
use is highly associated with incident of VVC with approximately 30% of treated women 
acquiring this condition after antibiotic use (83). The proposed mechanism of post-
antibiotic VVC is thought to be due to disruption of the protective vaginal bacterial 
community thus allowing for Candida overgrowth. In vitro studies have suggested that 
Lactobacillus species common in the vagina could produce compounds that inhibit 
growth or adhesion of C. albicans providing potential mechanisms of exclusion (84, 85). 
One that tested a supposed Lactobacillus probiotic did not show any effect in preventing 
post-antibiotic VVC (86). However, this study does not indicate strain designations or 
reasons for selection, and included strains not typically found in abundance in the vagina 
(L. delbrueckii, L. acidophilus, Streptococcus thermophilus). Only a few studies have 
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examined the association of the bacterial vaginal microbiota in relation to VVC. One by 
Sobel and Chaim (87) found no evidence of differential Lactobacillus abundance in 
women with acute VVC compared to healthy asymptomatic women. The study found no 
evidence of differential Lactobacillus abundance between the groups. Similarly, Vitali et 
al. using PCR denaturing gradient gel electrophoresis (PCR-DGGE) and real-time PCR 
demonstrated both healthy conditions and VVC were dominated by Lactobacillus while 
only BV showed a significant deviation in lactobacilli (88). A study by Zhou et al. (89) 
used terminal restriction fragment length polymorphisms (T-RFLP) of the 16S rRNA 
gene, and supplemented with cloning of 16S rRNA gene fragments for sequencing to 
show no evidence of a significantly altered profile in women who hadn’t had a yeast 
infection in the past 2 years and those with a history of VVC with most women both 
groups dominated by Lactobacillus species. Unfortunately these studies are limited in 
determining the community composition due to culture bias, low specificity, and so far 
lack of use of high-throughput sequencing methods. 
The function of the microbiome in other vaginal infections is not well understood. Only 
recently have studies emerged specifically examining the bacterial composition during 
Trichomonas vaginalis (90), Chlamydia trachomatis (91) and HPV (92, 93) infections. 
Considering the nearly 2-fold increased risk of acquiring these infections by having an 
abnormal BV-like profile (94, 95), and the interplay between host immunity and the 
vaginal microbiota (96) the composition and function of the vaginal microbiome is a key 
component to urogenital health and clearly needs to be investigated. 
1.5 Modulating the vaginal microbiome and treating 
aberrant conditions 
1.5.1 Antimicrobials 
The current standard of treatment for BV is either an oral or intravaginal application of 
metronidazole or clindamycin daily or twice a day for approximately 1 week (97). These 
antibiotic therapies have been unchanged for over two decades despite the high 
recurrence rate of BV. Up to 50% or more women have a recurrent BV episode within 12 
months of standard treatment (56), although the reasons are not known. Because of the 
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associated risks of BV, especially for complications during pregnancy, many women 
without symptoms but who show an abnormal Gram smear may be treated with 
antibiotics (98). However, this treatment, especially using metronidazole, has so far failed 
to prevent pre-term labour (98, 99). For VVC, topical or oral anti-fungals such as 
fluconazole are effective in eradicating Candida overgrowth and eliminate symptoms in 
90% of uncomplicated VVC cases (77), perhaps because of BV biofilms, poor specificity 
or rapid recovery of the pathogens (100). 
For VVC, topical or oral anti-fungals such as fluconazole are effective in eradicating 
Candida overgrowth and eliminating symptoms in 90% of uncomplicated VVC cases 
(77). VVC caused by non-albicans species are more likely to be resistant to standard 
treatment and are more associated with recurrent VVC (81). 
Because antibiotic usage has side effects including nausea, vomiting, diarrhea, and risks 
like thrombophlebitis, gastrointestinal upset, development of resistant organisms, and 
recurrent episodes, and in the case of BV especially, the general ineffectiveness of the 
application, there is an urgent need for more robust treatment. This will be optimized the 
more we understand what is actually happening in the microbiome. With no sign of new 
pharmaceutical agents being developed, other options have been explored by scientists, 
one of which has been probiotics. 
1.5.2 Probiotics 
Probiotics, literally meaning “for life”, is currently defined by the FAO/WHO as: "live 
microorganisms which when administered in adequate amounts confer a health benefit on 
the host" (101). Probiotics consists of single strains or mixtures administered via oral or 
topical application with the intended goal of effecting the site of action in one or more 
ways by: 1) displacing pathogens, 2) modulating local or systemic immunity, 3) altering 
the microbiota community directly or indirectly. The means these outcomes are 
accomplished can be multifaceted and include: adhesion by the probiotic organism to 
host mucosa, up-taking or releasing compounds and metabolic products, surface 
interaction with the host immune system, or direct competition with resident microbes 
(102). The most common probiotics for urogenital health are strains of Lactobacillus 
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administered vaginally or orally. Strains have been selected based upon their ability to 
promote lactobacilli colonization, inhibit pathogen growth and adhesion and modulate 
host immunity(85, 103-105, 105-107). Several clinical studies have assessed the effects 
of Lactobacillus probiotic for treatment or prevention of BV alone or in conjunction with 
antibiotic therapy (reviewed by (108-110)). These have used L. acidophilus (111), L. 
delbrueckii subsp. lactis DM8909 (112), L. brevis CD2 + L. salivarius FV2 + L. 
plantarum FV9 (113), and L. rhamnosus Lcr35 (114), and some have been used to 
prevent recurrent BV like L. gasseri (Lba EB01-DSM 14869) + L. rhamnosus (Lbp 
PB01-DSM 14870) (115) and L. rhamnosus + L. acidophilus, + Streptococcus 
thermophilus (116). Unfortunately, many of these studies are limited in sample size, trial 
design, strain selection and reporting, and choice of dosage and mode of administration. 
However, data from well-controlled, randomized trials suggest some evidence for 
beneficial effects of administered lactobacilli for vaginal health – in particular, the 
combination of L. reuteri RC-14 and L. rhamnosus GR-1 have been effective for 
treatment (63, 117-119) and prophylaxis (118, 120) of BV. 
The potential probiotic mechanisms of these strains have been well characterized. L. 
rhamnosus GR-1 adheres to uroepithelial cells, and can effectively exclude and inhibit 
growth of uropathogens (103). Along with the ability to adhere to uroepithelial cells 
(121), L. reuteri RC-14 is able to produce abundant hydrogen peroxide (122), and a 
biosurfactant that effectively inhibits adhesion by uropathogenic bacteria (123), and can 
disrupt G. vaginalis biofilms in vitro (124, 125). Both RC-14 and GR-1 strains have been 
shown to persist in the vaginal tract for up to 19 days post intravaginal application for 3 
days, while the probiotic gastrointestinal isolate L. rhamnosus GG was not detectable 
after 5 days (126). Reid et al. (127) were the first to show recovery from the vagina of 
orally administered L. rhamnosus GR-1 and L. reuteri RC-14; later independently 
confirmed (128, 129). Studies showed these orally administered organisms could alter the 
vaginal biota in healthy reproductive-aged women and post-menopausal women by 
increasing the lactobacilli load (63, 119, 130, 131). The reported effects of this 
combination probiotic treatment in most cases is approximately twice the BV cure rate 
compared to antibiotic therapy (117, 120, 132). 
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For VVC, the high prevalence and number of women seeking relief from recurrent or 
post-antibiotic VVC have lead to over-the-counter anti-fungal medications, often 
incorrectly administered when the patient actually has BV or another condition (133) and 
seeking treatment with probiotics. Approximately 40% of women reporting post-
antibiotic VVC have used probiotic or yogurt products for prevention or treatment. This 
is second only to over-the-counter antifungal usage for treatment (63%) or prevention 
(49%) of VVC (134). Of note, many women apparently use probiotics to treat VVC, 
when there is little evidence to suggest this is efficacious on its own. Few studies have 
actually assessed the effect of probiotic lactobacilli on VVC possibly due to lacking 
evidence that women with VVC have an altered vaginal biota as in the case of BV (77). 
The combination strains L. reuteri RC-14 and L. rhamnosus GR-1 with fluconazole 
improved the cure rate of VVC compared to fluconazole alone (135, 136). Chapter 5 
presents a follow-up to the Martinez study by examining the change in the vaginal 
microbiota following standard and probiotic-augmented treatment. Studies of potential 
mechanisms show that the combination strains can directly inhibit and kill Candida 
albicans (137), and RC-14 can reduce IL-8 and IP-10 secretion by VK2/E6E7 cells 
induced by C. albicans (138). Another study showed that these two lactobacilli suppress 
expression of NF-κB-related inflammatory genes, and may induce IL-1α and IL-1β 
expression by an alternate signal transduction pathway, such as MAPK/AP-1 (139). Still, 
with insufficient sample sized clinical data, it is too soon to make conclusions about the 
effectiveness of probiotic therapy for VVC (77). 
Probiotics have had varying success for treatment of other vaginal conditions. Post-
menopausal women represent a cohort deficient in vaginal lactobacilli compared to 
reproductive-aged women. In a double-blind, placebo-controlled study Petricevic et al. 
used orally administered L. reuteri RC-14 with L. rhamnosus GR-1 to restore 
Lactobacillus in the vagina resulting in a normalized Nugent score (131). The first 
evidence for intravaginal use of probiotics to reduce recurrences of urinary tract infection 
(UTI) came from L. rhamnosus GR-1 alone and with L. fermentum B-54 (140, 141). The 
failure of other Lactobacillus-based probiotics (109) demonstrates the importance of 
strain characteristics. A strain of Lactobacillus crispatus CTV-05 has been tested in an 
early phase study to prevent urinary tract infections (UTIs) by repopulating the vagina 
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(142). In general, studies using probiotics for treatment of urogenital conditions are 
successful when the strains are selected from the urogenital tract, and have properties 
allowing them to compete with the vaginal pathogens (121, 143). In the case of BV 
especially, probiotic lactobacilli can aid in restoring a Lactobacillus-dominated biota. 
Overall, probiotics are a promising therapy for vaginal and bladder health and 
understanding the mechanisms of actions and the interplay between host genetics, 
immunity, and natural microbiota will aid in designing or selecting strains with the most 
benefit for the individual condition. 
1.6 Other physiological states 
Hormone changes throughout a woman’s lifespan are associated with physiological 
responses that can affect the vaginal microbiota. Puberty, pregnancy and menopause are 
the biggest events causing hormone fluctuations. During pregnancy an influx of estrogen 
and progesterone from 50 to 1000 times pre-pregnancy levels (144) increases the 
glycogen content of the vaginal epithelial cells (12). Although the vaginal microbiota 
during pregnancy is largely unexplored, a recent 16S sequencing study by Aagaard et al. 
(145) suggests that compared to non-pregnant women there is a lower diversity of 
organisms with a dominance of Lactobacillus species. In preliminary studies, this has not 
been our experience when analyzing samples with the Illumina platform (unpublished 
data). Dominguez-Bello et al. (9) demonstrated that babies delivered by vaginal birth had 
whole-body biotas similar to their mother’s vaginal biota and dominated by lactobacilli, 
while babies born by cesarean section had biotas made up of predominantly skin bacteria 
such as Staphylococcus, Corynebacterium, and Propionibacterium. Babies born by C-
section have a greater incidence of allergies and asthma, and of methicillin-resistant S. 
aureus infection after birth (9). Thus the lactobacilli may be providing a protective role in 
pathogen exclusion and immune mediation in newborns, and changes in the vagina 
during pregnancy could theoretically prime the environment for establishment of 
lactobacilli before birth. Supporting this, a disrupted vaginal microbiota in the form of 
BV is associated with pregnancy complications leading to risk of pre-term labour (146), 
and several organisms found in the vagina, such as Ureaplasma, Dialister, Sneathia, 
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Gardnerella), have been detected in amniotic fluid after complications such as intra-
amniotic inflammation (147). 
Conversely to pregnancy, menopause is marked by a decreased production of estradiol 
and progesterone by the ovaries. The resulting 7-fold drop in plasma circulating estrogen 
(148) has effects on the vagina including thinning of the membranes, decreased blood 
flow, and loss of elasticity leading to vaginal dryness and atrophy (149). Associated with 
these changes is a loss of lactobacilli after menopause (14, 150, 151) and elevated vaginal 
pH above the normal 4.5 to 6.0-7.5 (152). In general, the lactobacilli depletion does not 
result in colonization by BV-associated organisms (14, 151), and the Nugent scoring 
system is unreliable to determine BV status post-menopause (14, 153). Indeed, when 
these women are colonized by large numbers of lactobacilli they have lower frequencies 
of vaginal E. coli – an organism significantly associated with UTI (154). Hormone 
replacement therapy is often administered to alleviate adverse symptoms of menopause, 
vaginal dryness (a result of atrophy and decreased vaginal secretions), and dyspareunia 
(painful sexual intercourse), by re-introducing estrogen, progesterone, and/or progestin 
orally or vaginally. As a result lactobacilli are restored to the vaginal microbiota (150, 
153, 155) and vaginal pH decreases to a normal 4.5 (156), and incidence of UTI are 
reduced (157). 
1.7 Key taxa and species-specific roles 
Species of Lactobacillus have long been associated with the human vaginal microbiota, 
though they are found in smaller proportions in the gastrointestinal tract and oral cavity 
(158). The genus is a member of the lactic acid bacteria group: a clade of Gram-positive, 
low-GC bacteria that produce lactic acid as a major fermentation product. This 
characteristic is thought to have a major functional role in the vagina where abundant 
lactic acid maintains a low pH unfavorable to pathogenic organisms (159, 160). This 
represents a potential mutualistic relationship where the vaginal epithelial cells produce 
glycogen that is converted by the bacteria to lactic acid (13). Lactobacillus species are 
also known to produce small antimicrobial molecules called bacteriocins, and hydrogen 
peroxide - both considered defense mechanisms against other organisms. Although recent 
studies have suggested H2O2 is not produced in sufficient quantities in the microaerobic 
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vaginal environment to have an antagonistic effect against other organisms (159, 160). 
Other than production of toxic metabolic byproducts, competitive exclusion by adherence 
to the mucosal surface and auto-aggregation has been proposed as an important protective 
strategy (161). 
Revealed by comparative genomics, the genus Lactobacillus is highly diverse with 
evidence for extensive gene loss and gain via horizontal gene transfer (162). Species 
found in the vagina (including L. crispatus, L. iners, L. gasseri, L. jensenii, L. johnsonii, 
L. vaginalis, L. reuteri) are phylogenetically more similar than other Lactobacillus 
species (163, 164). 
Notably, although BV is in general a low-Lactobacillus state, several studies have 
indicated L. iners can remain in relatively high abundance during BV (18, 48, 165) and 
post-antimicrobial treatment (166). This species was overlooked due to non-standard 
cultivation requirements until it was cultured on blood agar and described by Falsen et al. 
(17). Molecular sequencing techniques have uncovered L. iners as the most common 
constituent of the vaginal microbiota (24, 29, 48). Unlike other Lactobacillus species, L. 
iners seems to exclusively inhabit the human vagina and isn’t detectable in saliva or fecal 
samples (167), nor has it been reported in non-human primate vaginas (25). Although 
notably, the methods used in these studies may be limited in detection sensitivity. 
Genome sequencing and in vitro assays have uncovered functions of particular strains 
that could explain their role in the vagina during BV. Gardnerella vaginalis is abundant 
in many cases of BV, but is a common constituent of the normal vaginal biota (45). This 
observation has lead to studies that suggest different strains of G. vaginalis could have 
different functions and result in varied risks for the host (168). Genome studies of G. 
vaginalis, once thought to be a single organism, reveal a diverse complement of genes 
between different strains with as much as 31% divergence in gene content and order 
(169). Two studies have used comparative genomic analysis on strains isolated from 
healthy or asymptomatic women compared to BV-isolated strains. Harwich et al. (170) 
found a point mutation in the protein encoding vaginolysin, a cytolysin active against 
human cells (171), that rendered it less cytotoxic than the same protein from the health-
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associated strain. The same BV-associated strain had better adherence, aggregation, and 
biofilm formation. Biofilm formation is thought to be one of the major strategies G. 
vaginalis uses to persist (172) and resist antimicrobial compounds (173) and lactic acid 
(174). In addition, adherence of G. vaginalis biofilms to vaginal epithelial cells is 
responsible for the “clue cells” observed during BV and used as part of the Amsel 
diagnostic (175). The second comparative genomic study of four strains by Yeoman et al. 
(176) found a number of conserved genes with virulent potential including 
exopolysaccharide (EPS) biosynthesis for biofilm formation, pili, hemolytic/cytolytic 
potential, and several bactericidal toxins. Of the four strains, one (409-05) associated 
with a healthy asymptomatic woman was lacking genes encoding enzymes for mucin 
degradation – a trait associated with BV (177). In comparison to other BV isolates from 
different genera, G. vaginalis strains were determined to have a higher virulent potential 
by Patterson et al. (178) by assaying adherence, cytotoxicity, and biofilm activity. One 
study has implicated G. vaginalis in a symbiotic relationship with another BV-associated 
organism Prevotella bivia whereby amino acids produced by G. vaginalis supports the 
growth of P. bivia that in turn produces ammonia utilized by G. vaginalis (179). A 
similar symbiosis has been described between P. bivia and Peptostreptococcus 
anaerobius (180). Prevotella and Gardnerella species, and in particular P. bivia, have 
been shown to have sialidase activity (181) which is associated with risk of pre-term 
labour (182). 
Other bacteria associated with the vaginal microbiota are less characterized due to the 
effort required to culture them for biochemical assays and sequencing (183). Atopobium 
vaginae has only been described relatively recently (184), but has a high specificity with 
BV where it is detectible by sequencing methods (183, 185). Most strains are resistant to 
metronidazole (186), and at least one affects local immunity by inducing release of IL-6, 
IL-8, and β-defensin 4 from epithelial cells in vitro (187). Other recently detected 
organisms include the BV-associated bacteria (BVAB) of the Clostridiales order which 
have high specificity for BV (18). Many of these low abundance, difficult-to-culture 
species, could be forming co-occurrence networks with other species in the vagina, as 
suggested by Srinivasan et al. (38). The collective effort of the individual strains could 
benefit the community as a whole if, for example, several mucinases produced by 
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different members of the community allowed access to the vaginal epithelium where 
attachment and lysis can occur (46). These yet to be characterized organisms reflect the 
complexity of the vaginal environment and the potential interactions that can occur 
between multiple taxa contributing to the etiology of BV and other conditions. 
1.8 High-throughput sequencing techniques for 
characterizing the microbiome 
Recent years have seen an upsurge in sequencing techniques to characterize the microbes 
of various environments including the human microbiome. Thanks to the development of 
several “next-generation” technologies including 454 pyrosequencing (Roche), Illumina 
sequencing by synthesis (previously Solexa), and later SOLiD (ABI), and Ion Torrent 
(Life Technologies) the cost of sequencing has dropped and the throughput has risen 
dramatically – far outpacing the predicted rate of technological development by Moore’s 
Law (188). These sequencing technologies produce millions of short sequence fragments 
(reads) in a single run. This allows for multiplexing of samples (multiple samples can be 
sequenced on the same run) and enables a greater sequencing depth (more reads per 
sample) allowing detection of organisms in lower abundance. There are a few main 
strategies, described here and illustrated in Figure 1-2, which give different information 
about the community structure or function. Many of the biggest challenges lay in the 
computational analyses of these data that are highly diverse and multivariate. 
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Figure 1-2. “Omics” approaches for characterizing the human microbiome. 
The scope of this thesis uses next-generation sequencing and bioinformatics to 
describe the vaginal microbiome and the DNA and RNA level. Further information 
can be gained by examining the protein and metabolite populations in association to 
the microbiota. 
1.8.1 Targeted amplicon sequencing (16S) 
Currently the most common technique for characterizing a bacterial community is 
targeted 16S rRNA gene sequencing for molecular identification of bacterial taxa and 
their relative abundance in the sample. Using targeted PCR and high-throughput pooled 
sequencing, the relative abundance of assigned taxa can be determined for 100s or even 
1000s of samples at a time. The 16S rRNA gene is conserved in all bacterial species and 
forms part of the small ribosomal subunit. Woese and Fox (189) were the first to use 16S 
rRNA gene sequence to infer phylogenetic relationships between different organisms, a 
technique that is now pervasive in microbiology. The gene is well suited for targeted 
PCR because of several so-called “variable” regions flanked by more conserved sequence 
(Figure 1-3). These stretches of variable sequence often have enough differences between 
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organisms to distinguish genus, species, and sometimes strain taxonomic levels using 
sequencing information alone (190). 
 
Figure 1-3. Variability within the 16S rRNA gene 
From pre-aligned sequenced >1200 bp downloaded from RDP, the variability, 
measured as Shannon information entropy, was calculated at each sequence position, 
using only positions without a gap in E. coli. The graph shows the Shannon entropy 
(y-axis) averaged over 50 bp windows, centered at each position in the gene (x-axis). 
Shannon entropy at position x was calculated as –Σ p(xi) log2 p(xi), where p(xi) 
denotes the frequency of nucleotide i. Variable regions are marked V1 to V9, and 
numbering on the x-axis corresponds to the E. coli sequence. The V6 region was the 
target amplimer for the studies presented in this thesis. Figure is adapted from 
Andersson et al. (191). © 2008 Andersson et al. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited. 
High-throughput sequencing removed much of throughput restrictions of clone- and gel-
based sequencing methods, but at the cost of shorter sequence read lengths meaning only 
part of the 16S rRNA gene could be sequenced at a time. However, the majority of the 
taxonomic information from full-length 16S gene alignments can be captured with short 
fragments such as single variable regions (190), and sample clustering is robust to 
differing sequencing length and variable region (192). Though reads are short, high-
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throughput sequencing allows for greater depth (more reads per sample) and thus more 
power for detecting rare ribotypes in the community. 
The choice of variable region to sequence should depend on a number of factors: the 
length of the sequence read available, the complexity of the environment, and the number 
of closely related taxa in the environment. Though the 16S rRNA gene has become the 
gold standard, some groups have used other gene targets like cpn60 (193), and rpoB 
(194). For our studies we determined the V6 region offered the most distinguishing 
power for Lactobacillus species in the vagina (Gloor, G.B., personal communication), as 
one of our goals was to differentiate species like L. iners and L. crispatus. The V6 region 
has the most sequence information content (Figure 1-3), and other studies have shown it 
to be informative for genus and species differentiation (195) although automated tools 
designed for longer variable regions do not perform well with V6 sequences (196). For 
the 16S vaginal profiles presented in Chapter 1 and Chapter 5 we developed a sequencing 
methodology including a primer set with dual barcodes for paired-end sequencing on the 
Illumina platform (197). As outlined in Figure 1-4, the V6 region of the 16S rRNA gene 
is amplified with a unique sequence barcode for each sample, and then amplicons from 
all samples are pooled for sequencing. Downstream bioinformatic analysis overlaps the 
paired reads into full-length V6 sequence, and uses the barcode sequence to assign reads 
back to samples. As is standard in the field, the complexity of the dataset is reduced by 
clustering reads using sequence identity into operational taxonomic units (OTUs). The 
OTUs are arbitrarily defined at a percent identity cutoff representing a unit of taxonomy. 
By convention, most researchers pick a 97% identity cutoff as a proxy for species 
separation (198). However, this is merely a convenient binning strategy as the sequence 
variation is not constant across the entire rRNA gene (Figure 1-3) and may not represent 
the overall dissimilarity between species, and within different taxonomic lineages the 3% 
difference does not hold true (199). A representative sequence for each OTU cluster, 
usually the most commonly occurring sequence, is chosen for taxonomic assignment. 
This strategy can reduce tens of millions of reads to hundreds or fewer while retaining 
information on relative abundance in a table of read counts per OTU per sample (197). 
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Figure 1-4. Workflow used for multiplexed Illumina V6 sequencing for studies 
presented in this thesis 
Taxonomic assignment uses sequence alignment to make presumptive classification of 
reads based on similarity to known sequences. This is accomplished using BLAST 
alignment (e.g. default Greengenes (200) classifier), global alignment (GAST) or by 
comparing small fragments of the read called k-mers to a database of sequences with 
defined k-mer frequencies (ribosomal database project (RDP) (201), Greengenes). Other 
than ensuring a good alignment, taxonomic assignment is only as good as the database. 
As a result of being able to identify more sequences by high-throughput sequencing, there 
is now a massive amount of sequence data in the databases that is not characterized or 
assigned to a taxonomic lineage. In response to this, several manually curated databases 
like Greengenes (200), RDP (201), and SILVA (202), have arisen in attempt to filter out 
unreliable uncultured and unclassified sequences. For vaginal organisms, the databases 
are underrepresented (203) making confident taxonomic assignments even more difficult. 
At the community level there are two primary ways to evaluate diversity (204). Within a 
sample, the “alpha diversity” describes how many taxa are detected and their relative 
abundances. This can be calculated with a number of metrics, mostly borrowed from 
ecology, like Chao1 (205), Hill (206), Simpson’s (207), or Shannon’s (208) index. The 
“beta diversity” describes the overlapping taxa between samples, often accounting for 
differences in abundance as well as presence and absence. Based on taxa membership, a 
distance value is calculated for every sample against all other samples representing how 
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dissimilar one sample is to another. UniFrac is a popular distance metric developed for 
16S sequence data that can use presence/absence (unweighted) or abundance information 
(weighted) to create the distance matrix of sample distances (209). UniFrac builds a 
phylogenetic tree based on OTU sequence alignment and the sample distance is 
calculated based on the branch lengths shared and unshared between samples. 
Alternatively, sequence-independent methods, like Bray-Curtis (210), can also be used to 
build a distance matrix. The relative OTU abundances and distance matrix can be 
combined with multivariate statistics, and visualization and clustering tools in order to 
describe the relationship of the samples in regards to their microbiota composition (211). 
There are multiple tools (e.g. QIIME (212), Mothur (213), phyloseq (214) offering 
multiple strategies for 16S rRNA sequence analysis since the approach will depend on 
the type of data and goals of the study. In addition, the complexities of multivariate 
analysis for these data have not been conquered. For example, both alpha and beta 
diversity estimates make assumptions about the data and in certain cases, such as when 
there are abundant rare OTUs, the calculated diversity is not representative of reality 
(215). 
Using 16S and other tag-sequencing approaches might address “who is there”, but the 
data do not disclose the functional role of the detected OTUs without severe inferences, 
and given that strain differences are particularly hard to distinguish with partial 16S 
sequencing, there is considerable genomic variation not being accounted for. 
1.8.2 Genome sequencing, assembly, and annotation 
If 16S rRNA gene sequencing addresses “who is there?” in a microbial community, then 
whole genome sequencing addresses “what can they do?”. Once prohibitively expensive 
and time-consuming, high-throughput sequencing has allowed sequencing of bacterial 
genomes to become routine. As an example of the rapid pace, as of 2006 (one year after 
Roche released its GS20 pyosequencer) there were 10 published Lactobacillus genome 
sequences and 11 more in progress (216). By September 2013 there are more than 290 
Lactobacillus genome projects listed at the National Center for Biotechnology 
Information (NCBI). 
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Shotgun sequencing is the method of choice for most whole genome sequencing projects. 
Briefly, pure cultures of the strain of interest are grown and the total DNA is extracted 
from a large number of cells. The DNA is randomly fragmented, prepared as a sequence 
library for the platform of choice, and then sequenced. The resulting sequenced fragments 
can range from 35 to 800 nt in length, and are paired or single. Paired-end sequencing 
overcomes some of the limitations of short read length by instead partially sequencing 
both ends of a longer fragment of a known length. Since the input fragment length is 
known, the distance (in bp) between the sequenced paired ends is determinable and can 
be leveraged for downstream assembly. Single unpaired reads from pyrosequencing 
platforms are generally longer, but with the trade-off of fewer reads produced per run and 
higher error rates compared to shorter paired-end sequencing on the Illumina or SOLiD 
platforms (217). 
De-novo genome assembly algorithms find overlapping sequence between reads and 
combines the overlapping reads to build longer stretches of contiguous sequence 
(contigs). If paired-end reads are used, the distances between the pairs can be 
incorporated into the assembly algorithm to place paired reads in contigs at the correct 
distance apart (218). Generally, there are checks and restrictions built into the algorithms 
to avoid misassembled sequence not representative of the originating genome. Reads are 
not usually assembled unless there are multiple reads representing the same sequence 
(high coverage), the paired ends are the correct distance apart when assembled, and the 
bases in the read sequence have been confidently called by the sequencer. Repetitive 
sequences in bacterial genomes present a challenge as the reads are not usually long 
enough to span the repetitive region causing breaks or gaps in the assembly when an 
unambiguous path cannot be resolved (219). If available, contigs from an assembled 
genome can be scaffolded (placed in chromosomal order) by alignment to another 
finished related genome. Evidence for placing contigs together in scaffolds can also come 
from paired reads (if pairs span two contigs), contextual clues from annotated genes 
known to be near each other in on the chromosome, or with the aid of PCR and optical 
mapping. As finishing and closing a genome is costly and time-consuming with little 
information gained compared to assembled contigs, the vast majority of bacterial genome 
projects do not go beyond the “draft” stage (220). 
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Once contigs or scaffolds are built, open reading frames and other genomic elements 
(non-coding RNA, promoters, operons, regulatory regions) can be annotated and the 
functions predicted. There are a large number of computational tools available for these 
tasks, but the challenge remains in making confident and well-supported functional 
predictions. Though time-consuming and labour-intensive, manually annotated genomes 
are considered better quality than automated strategies (220). As functional predictions 
are generally made by alignments to other known sequences from a database, errors are 
easily propagated and misannotations are common (221). Without biochemical and 
molecular experimental validation, the functional annotations can only be inferred. 
Nonetheless, bacterial genome sequencing has provided incredible insight into 
pathogenic function, phylogeny and diversity, genome structure, horizontal gene transfer 
and genome evolution, novel genes, and targets for vaccines (222). 
In conjunction with high-throughput sequencing studies of the human microbiome, whole 
genomes are invaluable references allowing assignment of sequence information to 
specific organisms and functions. Whole genomes also provide contextual information of 
whole transcriptional units, operons, and cellular or metabolic networks for 
understanding how an organism functions. 
1.8.3 Metagenomics and metatranscriptomics 
One way to classify functions of a whole microbial community is to shotgun sequence all 
the genomic DNA (metagenomics) or RNA (metatranscriptomics) content from an 
environment. Like amplicon sequencing, metagenomic sequencing can be used to 
determine the bacterial abundances in the community, but with added information about 
gene function and abundance. There are fewer computational tools for metagenomic 
methods and the data analysis is more challenging (219). Short reads do not give as much 
information about functional assignment compared to full-length gene sequences where 
the predicted protein translation is generally more informative than nucleotide sequence 
(223). Translating and comparing hundreds of millions of small sequencing fragments is 
computationally intensive and time-consuming. To circumvent this, two main strategies 
are used: 1) mapping or binning data to known genomes or functional groups, 2) 
assembling the small fragments into larger contigs that can be better annotated. The first 
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case is reliant on the availability of sequenced and annotated genomes, while assembly is 
dependent on the read length and complexity of the sequences. For both cases, with the 
ultimate goal of assigning gene function, tools borrowed from genomic annotation can be 
used, or more high-throughput options such as MEGAN (224) or MG-RAST (225). 
Metatranscriptomics using RNA sequencing (RNAseq) is the most recent and most 
challenging ‘omics sequencing method, but can potentially provide more information 
about the adaptations of the microbes to their environment. There are relatively few 
studies employing metatranscriptomics due to the difficulty in sample collection to 
maintain RNA integrity, and overcoming the overabundance of rRNA molecules 
(upwards of 95% of the total RNA content in a bacterial cell) compared to the mRNA 
molecules of interest (226). Many of the first studies came from marine and soil 
microbiome studies (227-229) and only more recently have studies emerged evaluating 
the metatranscriptome of microbial communities associated with human health (230, 
231). With the approach only beginning to gain traction, the computational analysis tools 
and statistical framework are under active development and multiple methods are used to 
analyze transcriptional data. 
Evaluating metatranscriptome data has to take in account not only the fluctuating 
transcript abundances, but also those of the fluctuations in the bacterial populations. Like 
metagenomics, metatranscriptomic reads can be assembled into larger fragments for 
annotation (232), but most strategies leverage sequenced genomes to map RNA reads to 
annotated genes, or bin sequence fragments by function. Like 16S rRNA data, once reads 
are binned (by OTU, gene, or function) the data are represented in a table of read counts 
per bin per sample. 
Often the goal of RNAseq is to compare two or more conditions or time points in order to 
evaluate differential gene expression. There are two important concepts for consideration 
when attempting differential RNAseq analysis: the within-condition variation and the 
between-condition variation. Sources of variation include technical (sample preparation, 
RNA extraction, sequencing library preparation, different sequencing runs, sampling 
error, sampling depth/number of reads per sample), and biological (the underlying 
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differences between the samples or groups of samples). Tools for differential RNAseq 
often use parametric models to estimate variation. Poisson models have been shown to 
adequately model variation between technical replicates (233), but the higher biological 
variation is better accounted for with a dispersion estimate by the negative binomial 
model (234). Unfortunately for parametric tools, they only work as well as the data fits 
the underlying distribution. In a comparison of parametric methods PoissonSeq (Poisson 
model), DESeq, and edgeR (negative binomial models), Li and Tibshirani (235) found 
that outliers had significant impact on the performance with true false discovery rate 
(FDR) becoming “unacceptably high”, with the FDR being greatly underestimated. Using 
RNAseq data from cervical tumours and healthy control tissue, Li and Tibshirani also 
note many of the top significant features reported by edgeR were unlikely to follow a 
negative binomial distribution. Several of these features had a large number of reads in 
one sample of the group, while other samples in the group had few or no read counts. 
Although these example data come from human tissues, the same situation is arguably 
even more likely to occur in bacterial metaRNAseq data where, on top of biological 
disparity in gene expression between samples, variations in the community membership 
or abundances can affect the underlying genetic potential for the samples being 
compared. To overcome limitations of parametric approaches, a few non-parametric 
approaches have been proposed (NOIseq (236), SAMseq (235) which do not make 
assumptions about the underlying distribution of the count data. However, these methods 
require large sample sizes to have power (235) – a rare commodity for RNAseq 
experiments due to the prohibitively high cost of sample prep and sequencing. With the 
available tools being inadequate for the considerable variation in metaRNAseq analysis, 
we (myself included) developed a new approach called ALDEx (ANOVA-Like 
Differential Expression) (237) that explicitly identifies differential features with higher 
between-condition expression differences (i.e. the difference between non-BV and BV) 
than the within-condition expression differences (i.e. the differences between samples 
within the BV group). 
Other than good study design, with any of the aforementioned sequencing methods for 
describing the microbiome the greatest challenges are the computational analyses and 
29 
 
choosing the appropriate tools and statistical framework for the type of data and the 
hypotheses being addressed. 
1.9 Scope and objectives of the thesis 
At the outset of my thesis project there were very few studies using high-throughput 
sequencing methodologies to describe the vaginal microbiome. I started with the general 
hypothesis that understanding the composition and role of the vaginal microbiome would 
provide insights into BV, which is a poorly understood condition. I was involved in 
developing a pipeline using Illumina V6 sequencing in order to describe the vaginal 
profiles of HIV+ African women with and without BV (48, 197). This methodology was 
used in Chapter 1 and Chapter 5 to characterize the vaginal microbiota under different 
conditions. In Chapter 1, the objective was to associate the vaginal profiles of post-
menopausal women with the symptoms of vaginal atrophy – a prevalent problem for this 
cohort. I found that, similar to BV, abundant Lactobacillus was associated with healthy 
asymptomatic women while women who were experiencing symptoms of vaginal dryness 
had a lower abundance of lactobacilli and higher abundances of other genera 
(Gardnerella, Prevotella, Streptococcus, Veillonella). These dysbiotic profiles are 
associated with changes in gene expression of the vaginal epithelium (data contributed by 
Jordan Bisanz). Chapter 5 presents a follow-up to two clinical trials evaluating the 
effectiveness of probiotic adjunct therapy with standard antibiotic treatment for BV (132) 
and anti-fungal therapy for VVC (135). The goal was to evaluate the vaginal microbiota 
to determine if the conjoint treatment and clinical success resulted in changes to the 
microbiota. This is the first report using high-throughput sequencing to describe the 
bacterial community in relation to acute VVC. When women recovered from BV, the 
abundance of Lactobacillus was higher and the predominant species was L. iners. 
A common thread of the microbiota data examined was that L. iners is the predominant 
vaginal organism that can be found in association with healthy and aberrant conditions. In 
Chapter 3, I used whole genome sequencing on strain AB-1, a vaginal isolate of L. iners, 
to determine if there were elements in its genome that would explain its adaptability to 
the vagina. The secondary goal was to build a high-quality reference genome for future 
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studies targeting particular genes or evaluating the transcriptome as presented in Chapter 
4. 
Based on the apparent plasticity of L. iners’ genome, and its ability to persist in a variety 
of conditions, I hypothesized that this organism could be altering its gene expression in 
response to the environmental changes. Chapter 4 explores this concept by using 
metaRNAseq on four samples: two women with BV and two who were healthy and 
asymptomatic. Along with the description of the L. iners transcriptome, I sought to 
address the functional contribution of the whole community. In order to do so, I 
employed a tool developed by our group (237) that explicitly accounts for within and 
between condition variance and reports differences that are conserved within a condition. 
The goal of using this tool was to find functions that are conserved in healthy or BV 
states, and differentially abundant compared to the other condition. This allowed me to 
address the hypothesis of whether there are conserved functions in BV despite the 
differences in the community composition between samples. 
Overall, these studies present a comprehensive picture of the vaginal microbiota 
composition in different conditions. The studies have resulted in several computational 
tools and pipelines for evaluating 16S and RNAseq data, and for functional annotation by 
sequence information. The importance of understanding the functional contribution of the 
organisms is underscored, and resultant data will provide insight into future approaches 
for modulating the vaginal ecosystem. 
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Chapter 2  
2 Vaginal microbiome and epithelial gene expression of 
post-menopausal women with moderate to severe 
dryness 
This chapter is reproduced with permission (Appendix A) from: 
Hummelen, R.*, Macklaim, J.M.*, Bisanz, J.E.*, Hammond, J.A., McMillan, A., 
Vongsa, R., Koenig, D., Gloor, G.B., and Reid, G. (2011). Vaginal microbiome and 
epithelial gene array in post-menopausal women with moderate to severe dryness. 
PLoS One 6, e26602. *Joint first authors 
Supporting material for this chapter including Tables and Figures (labeled as S#) are 
available online: 
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0026602#s5 
 
2.1 Introduction 
The onset of menopause is accompanied by a dramatic increase in reported symptoms of 
vaginal dryness, soreness, irritation or itching, pain with intercourse and bleeding after 
intercourse (1). Collectively these symptoms affect 25-50% post-menopausal women (2, 
3) and significantly impact their quality of life. Vulvovaginal atrophy (VVA) is 
somewhat of a catchment term for these symptoms and is diagnosed by an assessment of 
vaginal dryness, irritation, soreness, and dyspareunia with urinary frequency, urgency, 
incontinence, and the presence of pale and dry vulvovaginal mucosa with petechiae, 
along with pH >4.6 (4). Though the use of estrogen replacement therapy (ERT) can 
rapidly reverse some of these changes (5), a large proportion of women are hesitant to use 
estrogens, even when applied topically (3). Interestingly, a proportion of women appear 
to remain symptom free, long after the onset of menopause.  
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A lactobacilli-dominated vaginal microbiota is associated with retention of health, but 
with menopause it has long been assumed that ERT is required to maintain the dominant 
lactobacilli and reduce the risk of infection (5). This is supported by studies of the vaginal 
microbiota using denaturing gradient gel electrophoresis (DGGE) (6, 7); a technique that 
separates different sequences on a polyacrylamide gel based on the denaturing chemicals 
and heat applied to the double-stranded PCR products. Next-generation deep sequencing 
provides a means to uncover the extent of bacterial presence in a given niche, including 
the vagina (8-10). 
The aim of the present study was to identify differences in microbiome composition and 
epithelial gene expression between post-menopausal women who were clinical 
asymptomatic compared to women who were suffering vaginal dryness. 
2.2 Materials and Methods 
2.2.1 Study population 
The institutional review board of the University of Western Ontario, London, Canada, 
approved the protocol. The study was registered at clinicaltrials.gov with ID# 
NCT01084616. 
From a practice with over 500 post-menopausal women, a total of 32 patients between 
ages 42 and 77 were identified and recruited at the Victoria Family Medical Center in 
London, Canada between January and February 2010, and followed until June 2010. 
Participants were recruited to the study via their physician (Jo-Anne Hammond), or 
information sheets posted in the doctors’ offices. All participants had at least 12 months 
of amenorrhea, had not used antibiotics or had any vaginal infection one month prior to 
screening, had not used systemic estrogen products 6 months prior to sampling, or a 
topical estrogen-containing product one week before sampling. Women were excluded if 
they had used douches or lubricants in the past week.  
After giving informed consent, each participant completed a questionnaire on 
demographics, history of vaginal or urinary tract symptoms or infections, and a self-
assessment of the severity of five vaginal symptoms: vaginal dryness, vaginal irritation or 
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itching, pain during urination not associated with infection, vaginal soreness, pain during 
sexual intercourse, bleeding after sexual intercourse. Symptoms were rated as none, mild, 
moderate, or severe. Pain with intercourse and bleeding after intercourse could be scored 
as “not applicable”.  
A gynecologic examination was performed by a nurse trained to detect dryness and 
atrophy to provide an “observed” assessment of vaginal color, dryness, blanching and 
integrity of tissue, vaginal tissue petechiae, and overall vaginal atrophy. Vaginal pH was 
measured using the pHem-Alert indicator (Gynex, Wyoming, USA). A cytobrush 
(Cytobrush plus GT, Cooper Surgical Inc. USA) was used to collect epithelial cells from 
the mid-vagina for human mRNA analysis. The cytobrush was immediately placed in a 
1.5 ml sterile RNase-free microtube containing 700 µl RNAlater stabilization agent 
(Applied Biosystems, Austin, Texas, USA) and stored at 4oC within 4 hours of collection. 
RNA extraction occurred within 72 hours of collection. Two polyester Dacron swabs 
were used to sample the mid-vagina for microbial analysis: one was archived at -80oC for 
later bacterial DNA extraction, and the other was rolled on a microscope glass slide and 
scored for bacterial vaginosis (BV) using the Nugent criteria (11). Sixteen participants 
with moderate to severe vaginal dryness were followed every 2 weeks for up to 10 weeks 
total.  
2.2.2 Bacterial DNA extraction, amplification, and sequencing 
Bacterial DNA was extracted using Instagene (Bio-Rad) and the V6 region of the 16S 
rRNA gene was PCR amplified as described previously (9, 12) using barcoded primers: 
L-V6 (5’-CAACGCGARGAACCTTACC-3’) and R-V6 (5’-
ACAACACGAGCTGACGAC-3’). Based on the intensity of the ethidium bromide-
stained band on an agarose gel (estimated by eye), an approximate equimolar ratio of 
PCR products were mixed together to give the final sample sent for Illumina paired-end 
sequencing at The Centre for Applied Genomics in Toronto, Canada. 
2.2.3 OTU clustering and taxonomic assignment 
Sequence filtering, processing, and microbial analysis was performed as described 
previously (9, 12) and summarized as follows. After overlapping paired reads to get full-
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length V6 sequence, the reads were clustered at 95% nt identity using Uclust version 
3.0.617 (http://www.drive5.com/usearch/index.html). The most abundant sequence in a 
cluster was selected as a representative OTU. Taxonomic assignments for the 
representative OTUs were made through alignments against the Greengenes (13) database 
using NAST (14) and further manual curation by BLAST to the NCBI non-redundant 
database. The representative OTU sequences occurring with at least 1% abundance in any 
one sample have been deposited in GenBank under accession numbers JF262791-
JF262909. 
2.2.4 Vaginal epithelial RNA extraction 
Each of the 32 subjects provided a single sample for human genomic array. Vaginal 
cytobrush samples were centrifuged (5000 xg, 10min, 4oC) and the supernatant was 
discarded before RNA extraction by TRIzol following the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA, USA). The pellet was resuspended in 20 µl RNase-free water 
and stored at -80oC until further analysis. RNA quantity and quality was assessed by a 
Nanodrop 2000c spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) to 
ensure a 260nm/280nm ratio above 1.8 and a 260nm/230nm ratio above 1.4 before 
quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent technologies, Santa 
Clara, CA, USA). All steps of GeneChip probe preparation and hybridization were 
performed by the LRGC using standard protocols. All liquid handling steps were 
performed by a GeneChip Fluidics Station 450 and GeneChips were scanned with the 
GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA) using Command Console 
v1.1. 
Sufficient quality (RIN ≥ 7) and quantity of RNA was received from 10 of the samples, 
four from the dryness group (age 57.0 ± 8.9 years, range: 50-70 years; with an average 
13.3 ± 11.4 years since last menses, range: 3-21 years) and six from the subjects with a 
normal Nugent score (age 56.2 ± 9.3 years, range: 48-74 years; with an average time 
since last menses of 11.3 ± 9.8 years, range: 6-30 years).  
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2.2.5 Gene expression analysis 
Probe level (.CEL file) data was generated using Affymetrix Command Console v1.1. 
Probes were summarized to gene level data in Partek Genomics Suite v6.5 (Partek, St. 
Louis, MO) using the RMA algorithm (15).  
Gene expression data has been deposited in the Gene Expression Omnibus Database 
under accession number GSE26761. 
2.2.6 Statistical analyses 
Shannon’s diversity index (16) was calculated for each subject at each time point as the 
abundance values of 119 operational taxonomic units (OTUs). The Shannon’s diversity 
index (S) was defined as 
€ 
S = − pi
i=1
119
∑ log(pi) where pi denotes the proportional abundance 
values at the ith OTU in each sample. The Lactobacillus ratio was calculated for each 
subject at each time point, as the ratio of total abundance value for the Lactobacillus 
OTUs versus all the OTUs. 
Hierarchical clustering was performed by calculating the Euclidean distance between 
microbiota samples using the hclust function in R (17) and the similarity is plotted in a 
dendrogram in Figure 2-1. 
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Figure 2-1. Microbiota profiles for 32 post-menopausal women clustered by biota 
similarity 
Each bar represents a single vaginal sample, and the colored segments represent the 
relative fraction of each bacterial taxon detected at 1% relative abundance or greater 
in any one sample. Sequences at less than 1% abundance have been included in the 
“remainder” fraction at the top of the bar (see color legend of bacterial taxa). The 
microbiota are clustered by similarity as represented in the dendrogram above. The 
sample name (participant ID-time point) is labeled in the dendrogram and corresponds 
to the bar below. The dryness score as observed by the examining nurse is represented 
below each microbiota bar. Color taxa legend can be found in Figure 2-2 
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Figure 2-2. Color taxa legend for Figure 2-1 and Figure 2-3 
Starting with the left column from bottom up, the order of the colors matches the 
order of the barplots read from bottom to top. 
To determine if the linear trends in the S trajectories differ significantly across subjects, 
the following linear mixed effect model (18) was applied to the data 
€ 
Yit = µ + ai + bit +ε it . 
The fixed effect being the intercept only and random effects being subject intercepts and 
slopes where Yit denoted the S value of subject i at time point t and µ is an unknown fixed 
constant, ai is a random subject intercept, bi a random subject slope, and ai, bi, and εit are 
independent normal random variables. 
In order to determine if a statistical relationship existed between microbial diversity and 
vaginal dryness, a weighted least squares analysis (19) was applied to the data. Observed 
dryness scores of “none”, “mild”, “moderate”, and “severe” were treated as ordinal 
values 0, 1, 2, and 3, respectively. The weighted least squares model 
€ 
Y id = µ0 + µ1d +ε id
was used to test the linear effect of observed dryness with respect to microbial diversity. 
Where  denotes the average S of subject i at dryness d. The quantities µ0 and µ1d are 
constants representing intercept and slope respectively. We also applied the Mann-
Whitney-Wilcoxon rank-sum to the OTUs by comparing the relative abundances between 
women with and without dryness at time point 0. 
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2.3 Results 
The reported and observed vaginal symptoms are presented in Figure S1. The observed 
vaginal dryness correlated well with observed atrophy (r2 = 0.84) supporting vaginal 
dryness as an appropriate proxy for the occurrence of vaginal atrophy. Moderate to severe 
scores were in agreement for three out of the four measures that included dryness, 
discoloration, blanching and petechiae in 11 participants 
Illumina sequencing resulted in 1,758,430 total V6 reads after quality filtering, with an 
average of 17410 ± 9917 reads per sample (range: 2,123-53,054). Figure 2-1 shows the 
microbiota findings for the 32 participants at the first sample time point. Using a cutoff of 
1% abundance in any sample, there were 119 distinct operational taxonomic units 
(OTUs) identified, each representing a bacterial taxon. 
Sixteen of the 32 participants were selected at their initial visit and followed for 
microbiota sampling every 2 weeks for 10 weeks total. This time series showed that the 
microbiome abundance profiles did not fluctuate greatly within a subject (Figure 2-3). 
When a linear mixed effect model was applied to the Shannon’s diversity index data, a 
statistical linear trend was not observed (p = 0.364) indicating that the abundance of 
microbial diversity from week to week did not change significantly within a subject. The 
biotas of women who were least symptomatic (“none” or “mild” dryness score) had low 
bacterial diversity with a dominance of lactobacilli (Figure 2-1 and Figure 2-3). 
Conversely, women with “moderate” or “severe” dryness have a decreased abundance of 
lactobacilli and a large diversity with number of species detected. In this group of women 
experiencing vaginal dryness, there was a high representation of Prevotella timonensis 
(OTU_6), Porphyromonas (OTU_9), Peptoniphilus (OTU_27), and Bacillus (OTU_34) 
using a Mann-Whitney-Wilcoxon rank-sum test (Supporting Figure S2). A weighted least 
squares model was applied to the data and a statistical linear trend was observed (p = 
0.00141) indicating an inverse correlation between Lactobacillus ratio and dryness. 
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Figure 2-3. 16S (V6) microbiota profiles for 16 post-menopausal women sampled 
every 2 weeks 
Each bar represents a single vaginal sample, and each cluster of bars is a single 
participant (starting at time 0 and sampled every 2 weeks for up to 10 weeks total). 
The colored segments represent the relative fraction of each bacterial taxon detected 
at 1% relative abundance or greater. Sequences at less than 1% abundance have been 
included in the “remainder” fraction at the top of the bar (see color legend of bacterial 
taxa). The dryness score as observed by the examining nurse is represented below 
each microbiota bar. Sample time points that were included in the microarray analysis 
are marked with an arrowhead: the first six green arrows are controls (no or mild 
dryness), and the last four red arrows are women experiencing moderate to severe 
dryness. Color taxa legend can be found in Figure 2-2 
 
Lactobacilli were dominant in many women, irrespective of age (participant 13 age 74 
versus participant 6 age 42), and in absence of ERT. We noted lactobacilli at an 
abundance of >10% in 29/32 (91%) women at time zero, while 17/32 (53%) had 
lactobacilli as the overall dominating organism (greater than 50% relative abundance). 
In order to perform human genomic array analysis, one sample was collected at random 
from each subject. Based upon successful high-quality RNA isolation, 10 resultant 
samples were divided into healthy controls and subjects experiencing vaginal dryness 
based on the observed dryness score (Figure 2-3). 
After importing intensity data into Partek GS 6.5, an ANOVA was applied to identify 
differentially expressed genes between the control and dryness groups. The list of genes 
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was filtered to only include those differentially expressed by at least 2-fold (p < 0.05), 
which yielded a list of 960 probe sets used for subsequent comparative analyses (Table 
S1). A heatmap of the filtered list (Figure 2-4) shows two main branches separating the 
dryness and control groups. Participant 4 had an intermediate gene expression profile 
between the dryness and control groups despite having no self-reported or observed signs 
of dryness and correspondingly no additional signs of atrophy. 
 
Figure 2-4. Heatmap of vaginal epithelial gene expression of 10 samples 
A clustered heatmap of differential gene expression (>2-fold change, p<0.05) between 
the control and dryness groups. Samples are labeled as participant number-time point 
(week). Samples assigned to the dryness or control groups based on physiological 
examination of the vagina are well separated by gene expression differences with 
exception of 4-8 which has an intermediate gene expression profile and clusters closer 
to the dryness group. 
Then, the top 20 genes in either direction with the greatest fold change between the 
dryness and control groups were further analyzed (Table 2-1) to determine where the 
59 
 
most dramatic changes occurred. The most up-regulated genes in the dryness group were 
MMP7 (13.75-fold), and the choline transporter SLC44A4 which was interrogated by 
three separate probe sets, all up-regulated 9.19-fold with identical p-values. The most 
down-regulated genes in the dryness group were SPINK7 (-38.65-fold) and TGM3 (-
21.86-fold). 
Table 2-1. The top 20 genes up- and down- regulated genes (p<0.05) in the vaginal 
dryness group compared to controls. 
Gene Symbol Gene Assignment RefSeq ID p-value Fold Change 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) NM_002423 7.73E-03 13.75 
SLC44A4 solute carrier family 44, member 4 NM_025257 2.23E-02 9.19 
SLC44A4 solute carrier family 44, member 4 NM_025257 2.23E-02 9.19 
SLC44A4 solute carrier family 44, member 4 NM_025257 2.23E-02 9.19 
CFH complement factor H NM_000186 4.79E-03 8.72 
PIGR polymeric immunoglobulin receptor NM_002644 2.01E-02 8.64 
IL19 interleukin 19 NM_153758 3.25E-02 8.31 
 Transcript ID: 8158684  9.50E-03 8.28 
 Transcript ID: 8180303  2.26E-02 7.73 
CFB complement factor B NM_001710 4.69E-02 7.33 
PLAT plasminogen activator, tissue NM_000930 2.23E-02 7.19 
 Transcript ID: 8138487  2.08E-03 7.10 
CFB complement factor B NM_001710 4.78E-02 6.93 
WFDC2 WAP four-disulfide core domain 2 NM_006103 8.32E-03 6.61 
CXCL6 chemokine (C-X-C motif) ligand 6 NM_002993 1.81E-02 6.50 
TSPAN1 tetraspanin 1 NM_005727 2.46E-02 6.30 
AGR2 anterior gradient homolog 2 (Xenopus laevis) NM_006408 1.50E-02 6.18 
TRIM31 tripartite motif-containing 31 NM_007028 4.77E-02 5.85 
ASS1 argininosuccinate synthetase 1 NM_000050 3.05E-03 5.70 
PLAC8 placenta-specific 8 NM_016619 2.03E-02 5.51 
SPINK7 serine peptidase inhibitor, Kazal type 7 (putative) NM_032566 4.81E-04 -38.65 
TGM3 transglutaminase 3 NM_003245 4.24E-05 -21.86 
SBSN Suprabasin, part of a gene complex including dermokine NM_198538 3.28E-05 -20.93 
ALOX12 arachidonate 12-lipoxygenase NM_000697 4.43E-04 -19.61 
KPRP keratinocyte proline-rich protein NM_001025231 2.30E-04 -17.43 
GYS2 glycogen synthase 2 (liver) NM_021957 1.66E-03 -16.78 
DSG1 desmoglein 1 NM_001942 5.02E-03 -16.61 
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LCE3E late cornified envelope 3E NM_178435 6.78E-04 -15.35 
LCE3D late cornified envelope 3D NM_032563 3.27E-03 -14.61 
SERPINB12 serpin peptidase inhibitor, clade B NM_080474 1.42E-03 -14.11 
PNLIPRP3 pancreatic lipase-related protein 3 NM_001011709 3.06E-04 -13.69 
KRTDAP keratinocyte differentiation-associated protein NM_207392 2.16E-03 -13.08 
CLDN17 claudin 17 NM_012131 1.99E-03 -12.88 
KRT1 keratin 1 NM_006121 1.16E-03 -11.99 
LOC441178 hypothetical LOC441178 AL832737 4.66E-03 -10.89 
LOC441178 hypothetical LOC441178 AL832737 4.66E-03 -10.89 
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic NM_002395 1.32E-03 -10.57 
 Transcript ID: 8020347  1.70E-03 -10.26 
CRCT1 cysteine-rich C-terminal 1 NM_019060 3.86E-03 -9.80 
CRISP3 cysteine-rich secretory protein 3 NM_006061 8.76E-03 -9.75 
 
To assess the relationship of differentially expressed genes, a GeneOntology (GO) 
enrichment analysis of the filtered list of 960 probe sets was performed using Partek GS 
6.5. The top 10 GO-functions enriched are displayed in Table 2-2, and demonstrate 
changes in epithelial remodeling and immune response. Cornified envelope had the 
highest enrichment score with 62.50% (10 genes) in this process and was down-regulated 
in the dryness group. 
Table 2-2. Enrichment of GO terms in the filtered gene list (n=960). 
Function GO ID Enrichment Score 
Enrichment 
p-value 
No. of 
Genes 
% of total genes in 
GO term group 
differentially 
expressed 
Cornified envelope 1533 21.81 3.37E-10 10 62.50 
Keratinocyte 
differentiation 30216 20.01 2.04E-09 11 47.83 
Immune response 6955 19.20 4.60E-09 38 13.52 
Cell differentiation 30154 17.96 1.59E-08 24 17.91 
Epidermis 
development 8544 17.55 2.38E-08 17 23.94 
Tissue development 9888 17.48 2.55E-08 23 18.11 
Cellular 
developmental 
process 
48869 15.29 2.28E-07 30 13.45 
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Extracellular region 5576 13.99 8.37E-07 37 11.28 
Epithelial cell 
differentiation 30855 13.12 2.01E-06 6 60.00 
Innate immune 
response 45087 13.03 2.18E-06 11 26.83 
 
2.4 Discussion and Concluding Remarks 
The microbiota of this set of post-menopausal women was quite stable with 1 out of a 
possible 62 transitions between normal and BV Nugent scores, unlike another study of 
pre-menopausal women that observed 226 transitions out of a possible 1365 opportunities 
(p = 0.003) (20). If indeed further studies confirm that the microbial profiles of post-
menopausal women are relatively stable, perhaps it is due to lack of menstruation which 
is known to cause stage-dependent variations in the microbiota (21).  
The Illumina sequencing method identified double or triple the number of bacterial types 
per subject compared to previous denaturing gel electrophoresis methods (7). Similar to 
recent deep sequencing studies of pre-menopausal women (8-10, 22, 23), we noted 
Lactobacillus iners and Gardnerella vaginalis were universally present and possibly 
represent core members of the vagina. However, there were much lower abundances 
(<1%) of Mobiluncus, Staphylococcus, Sneathia, Bifidobacterium, and Gemella in our 
study set of post-menopausal women. This could be due to our smaller sample size rather 
than micro-environmental changes associated with menopause and so the physiological 
significance is not known. As more information emerges about the different organisms in 
the microbiota, the types of clones and virulence properties of them, for example 
differences in the expression of various toxins and mucus-degrading enzymes by G. 
vaginalis (24), will allow a better understanding of which strains equate to health versus 
disease.  
Vaginal dryness, a condition that is associated with significant changes in the 
transcription of genes associated with cellular structure and immune function as shown 
here by the human microarray data, is a symptom of atrophy which afflicts large numbers 
of menopausal women and has been linked with depletion of estrogen (25). The muscular 
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layer of the vaginal wall tends to be thicker in postmenopausal than premenopausal 
women, while the epithelial layer is much thinner (26). Having developed a method to 
use Affymetrix arrays to read epithelial cell gene expression changes in the vagina (27), 
we applied this here and found down-regulation of genes involved in maintaining 
proliferation and barrier function of the vaginal epithelium in the dryness group. Without 
a cornified envelope, epithelial cells are much more sensitive to drying, chemical agents 
and microbial infection (28). Many of the genes in this group encode structural 
components of the cornified envelope so lowered expression in the dryness group implies 
reduced structural integrity of the tissue. This is mirrored in the down-regulation of 
adhesion molecules such as SBSN and DSG1, implicated in maintaining proper epithelial 
barrier function (29, 30). Similarly, ALOX 12 (-19.61-fold) has also been shown to be a 
positive regulator of epidermal barrier function (31), and keratin is an important 
structural molecule in the epidermis imparting mechanical stability to the tissue (32).  
The most down-regulated gene in the dryness group was SPINK7 (alias ECRG2), a 
member of the SPINK family of proteases, which is known to regulate invasion and 
migration by preventing extracellular matrix (ECM) degradation through inhibiting the 
action of urokinase-type plasminogen activator (33). Matrilysin-1 protein (MMP) 7 
opposes the SPINK family proteins, and its up-regulation by 13.75-fold and cleaves ECM 
components and up-regulate inflammation (34). Thus, it is possible that the combination 
of increased ECM degradation with decreased inhibition of protease inhibitors 
contributes to vaginal thinning. 
Both complement factors B and H (CFB and CFH) and other components of the 
complement system were up-regulated in the dryness group. Since dryness is 
accompanied by inflammation, this suggests that the up-regulation of the regulatory 
molecules (CFH and CFI), although perhaps capable of protecting host cells, is not 
sufficient to dampen the inflammatory response. This potential for dysregulation of the 
complement system in vaginal dryness warrants further study. 
Differential expression of many cytokines and chemokines, the messengers of 
inflammation and chemotaxis, was noted. Three CXCL-family chemokines, known to 
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recruit monocytes and leukocytes to the vaginal epithelium, were observed to be up-
regulated 4.11 to 6.5 fold in the dryness group. Polymeric immunoglobulin receptor 
(PIGR) was up-regulated 8.64-fold in the dryness group; indicative of increased mucosal 
immune activity.  
Two highly up-regulated genes, SLC44A4 and PLAT, could be associated with the 
symptoms of vaginal dryness and atrophy. The SLC44A4 gene product is a sodium-
dependent transmembrane transport protein involved in the uptake of choline in neurons, 
which is used in neurons in the production of acetylcholine, which is one of the main 
neurotransmitters of the parasympathic nervous system (35). As the vaginal epithelium is 
rich in nerve endings and these can increase in density with reduced estrogen (35), it is 
possible that increased activity of this transporter may contribute to the sensation of pain 
and irritation through cholinergic nerve endings. The PLAT gene product is a serine 
protease which converts plasminogen to plasmin, and functions in cell migration and 
tissue remodeling as well as reducing blood clotting. Up-regulation of this gene may play 
a role in the increased bleeding and tissue sensitivity associated with vaginal dryness. 
Our gene array findings agree with data obtained by Cotreau et al. (36) on vaginal 
biopsies from 19 women with vulvovaginal atrophy (VVA) before and after treatment 
with 17β-estradiol. The similarity in results suggests that many of the genes being 
differentially regulated between dryness and healthy women may be as a result of 
differential estrogen levels between the groups. This is further supported by the up-
regulation of one of the vaginal epithelial cornified envelope genes (LCE3D) following 
estrogen replacement therapy (37), that was 14-fold down-regulated in women with 
vaginal dryness.  
In summary, the vaginal microbiota of 16 post-menopausal women showed little 
fluctuation over time, unlike that of pre-menopausal women reported previously. There 
was an inverse correlation between Lactobacillus ratio and dryness, a condition 
commonly found after menopause, which shown here to be associated with changes in 
vaginal epithelial cell integrity and inflammation.  
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3.1 Introduction 
The vaginal microbiota of premenopausal women with no symptoms or signs of disease 
comprises primarily Lactobacillus species. The consistency of this finding is quite 
remarkable given the several hundred other microbial species that have been detected in 
the vagina (1-5) and the accessibility of even more from the rectal-anal skin and through 
bathing and sexual contact. For decades, lactobacilli have been regarded as beneficial to 
the vagina by preventing infections through production of organic acids, hydrogen 
peroxide (H2O2) and other anti-microbial substances, and by the fact that depletion of 
Lactobacillus populations often coincides with bacterial disease onset. 
The fastidious Lactobacillus iners is consistently the most common Lactobacillus sp. in 
the vagina (1, 3, 6, 7), yet little is known about its characteristics. The detection of L. 
iners in women with, and recovering from, bacterial vaginosis (BV) has led to the 
suggestion that it is not protective against disease (8). However, unlike other species that 
appear to be easily displaced by pathogens and infectious conditions, L. iners’ ability to 
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persist (9) may prove it to be important commensal, which may have a role in recovery of 
the microbiota, post-disease resolution. Interestingly, through 16S microbial community 
profiling, the L. iners sequences recovered from different women show homogeneity and 
suggests a lack of strain diversity in this species (10). Here we report the genome 
sequence and annotation of a representative of the species, L. iners AB-1, and through 
comparative genomics, show that it is the smallest lactobacilli discovered to date (11) 
differing markedly from intestinal and other urogenital species. 
3.2 Materials and Methods 
3.2.1 Organism 
Lactobacillus iners AB-1 is a vaginal isolate from a healthy woman. For DNA isolation 
for genome sequencing, it was cultured on Columbia blood agar (VWR, DF0792-17) 
supplemented with 50ml/L sheep’s blood (Cedarlane, DSB050) at 37oC under strict 
anaerobic conditions. 
3.2.2 Genome assembly 
We received 621,824 reads from 454 pyrosequencing ranging between 100bp and greater 
than 600bp (Next-Gen Sequencing Facility at Iowa State University, Iowa). The reads 
were trimmed for low quality bases and leftover adapter sequences using the python 
script, sff_extract.py (downloadable at http://bioinf.comav.upv.es/sff_extract/index.html). 
Of the total reads after trimming, the 68,626 reads greater than 500bp were used to 
generate a preliminary assembly using the Minimus assembler (AMOS package) (12). 
The resulting contigs were used as long reads in combination with the approximately 12 
million short (35nt) paired reads from Illumina (Illumina, Inc. San Diego, California) for 
paired-end assembly by the Velvet assembly program (13). Contigs greater than 200bp 
were retained, and these 47 contigs were used as the backbone for gap closure and 
scaffolding. 
3.2.3 Gap closure and scaffolding 
To close gaps between contigs, a method of “read walking” was employed. A BLAST 
database of all 454 reads greater than 500bp was created using formatdb. Contig ends 
69 
 
were BLASTed (14) against the database to find reads with a perfect overlap of at least 
300bp. If no reads matched, the end of the contig was trimmed back until a match could 
be found, or the required overlap was reduced. Reads matching the ends of contigs were 
compared to the database of 454 reads using BLAST in order to extend the contig ends 
until another contig was reached. If no matching reads were uncovered in the dataset of 
reads greater than 500bp, a second database including reads greater than 400bp (262,847 
reads) was used. Once inter-contig reads were obtained, gaps between contigs were 
joined using Minimus (12). This read-walking approach was similarly used to place the 
rRNA operons by walking out of the contigs identified as 16S and 23s sequence by 
BLAST to the NCBI non-redundant database. Reads matching the ends of these contigs 
were imported into JalView (15) where the multiple sequence alignments could be 
partitioned into separate sequence paths into contig ends. Additional contig joinings used 
sequence information from an unfinished Lactobacillus iners project in the GenBank 
database (GenBank accession number: ACLN00000000). Mauve was used to evaluate 
the alignment and contig order between the two datasets (16). Initially, a coverage of 5 
reads was required to extend a contig, and upon completion of gap filling all contigs were 
evaluated for expected sequence coverage and “mate-happiness” between Illumina reads 
as described below. 
By read-walking, the genome was assembled into seven contiguous pieces which were 
then ordered into a single scaffold. Scaffolding order was determined based on maximum 
synteny with the most closely related organisms, L. johnsonii and L. gasseri, using the 
PGA platform (17). The contigs were also oriented and ordered based on expected 
positions of the rRNA operons (18). Optical Mapping (OpGen, Inc., Madison, 
Wisconsin) validated contig order and orientation, as well as the expected genome size of 
1.3Mb (Figure S6). Primers were designed for the ends of each scaffolded contig and 
long-range PCR (Expand Long Template PCR System, Roche) was used to verify 
connections between neighboring contigs as predicted by optical mapping. PCR products 
were electrophoresed on a 1% agarose gel and bands were isolated, gel purified, and 
submitted for dideoxy chain termination sequencing (London Regional Genomics 
Institute, London, Ontario). Sanger reads were used to extend contig ends, and read-
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walking was again performed to close remaining gaps. The majority of contig ends were 
rRNA operons and the PCR and Sanger sequences confirmed these rRNA placements. 
3.2.4 Validating genome coverage 
The final scaffold was independently validated by separately mapping the original 
Illumina paired reads and the 454 reads and then assessing the expected read coverage. 
Using Novopaired (www.novocraft.com), 97.7% of the Illumina paired reads mapped 
back to the scaffold with unique alignment. The expected distance between read pairs, 
termed “mate-happiness”, was also evaluated from the Novopaired output to identify 
areas of compression (mates too close together) or expansion (mates too far apart). We 
used in-house developed software and the BLAST algorithm to map the 454 reads to the 
scaffold using cutoffs of 98% ID, 95% read length excluding reads with insertions or 
deletions compared to the scaffold. Coverage and mate happiness for each final scaffold 
was visualized using R (19) (Figures S8 and S9). One region identified by optical 
mapping suggested ~12,000 bases missing in the final assembly (Figure 6). This region 
had good coverage and mate-happiness by the Illumina reads, but low coverage of 454 
reads suggesting short tandem repeats which could not be resolved. 
3.2.5 Annotation  
Open reading frames (ORFs) greater than 100nt were predicted using GeneMark (20) and 
by Glimmer (21). The translated ORF predictions were compared to the NCBI non-
redundant database (nrdb) using BLASTp to evaluate gene predictions. There were 
several cases of GeneMark predicted ORFs that were shorter in length compared to 
homologous sequences in the database, and the corresponding Glimmer prediction better 
matched the length of the proteins in the database. In these instances, the Glimmer 
prediction was preferentially retained over the GeneMark prediction in order to prevent 
overestimation of truncated pseudogenes. 
Several tools combined with custom-created Perl scripts were used for the manual 
annotation of predicted ORFs including: BLAST to NCBI nrdb, COG (Clusters of 
Orthologous Groups of proteins) (22), and LaCOG (Lactobacillales-specific Clusters of 
Orthologous protein coding Genes) (23) databases. In addition, automatic annotation 
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results were collected from RAST (Rapid Annotation using Subsystem Technology) (24). 
Metabolic predictions were made by KAAS (KEGG Automatic Annotation Server) (25). 
HMMER (http://hmmer.org/) was used to search the sortase database 
(http://bamics3.cmbi.kun.nl/sortase_substrates) for sortase substrates (26). The predicted 
ORFs were also submitted to Pfam (27) and TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM/) for conserved domain and transmembrane 
domain predictions respectively. A list of Pfam domains related to adhesion adapted from 
Kankainen et al. (28) was used to search the predicted ORFs with E values of 1e-3 or less 
considered significant (Table S6). A summary of Surface and exported proteins were 
identified using SLEP (29). Transporter genes were predicted and annotated by 
TransAAP (http://www.membranetransport.org/). Transfer RNA (tRNA) genes were 
identified using tRNAscan-SE (30) Annotation predictions were manually validated. 
3.2.6 Prediction of highly expressed genes (using the codon 
adaptation index, CAI)  
Highly expressed genes show a biased codon usage pattern, and the CAI provides an 
indication of expression (31). Using the EMBOSS (32) cai tool, the ORF sequence of the 
generally highly expressed small and large subunits of the ribosomal proteins were used 
as a reference for calculating the codon adaptation index (CAI) of all the predicted genes 
in the L. iners genome. 
3.2.7 Comparative genomics  
Comparative genomics of L. iners was performed largely using sequence acquired from 
the GenBank database for L. crispatus JV-V01 (GenBank accession: ACKR00000000), 
L. johnsonii NCC 533 (NC_005362), L. gasseri ATCC 33323 (NC_008530), L. 
acidophilus NCFM (NC_006814), and L. delbrueckii subsp. bulgaricus ATCC 11842 
(NC_008054). 
Ortholog predictions for each pair of organisms was predicted by InParanoid (33) using 
the default settings, and custom Perl scripts were developed in-house to merge the 
datasets into a four-way comparison of overlapping ortholog predictions. The lists were 
submitted to the 4-way Venn Diagram Generator 
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(http://www.pangloss.com/seidel/Protocols/venn4.cgi) and the predicted values were 
used to generate a figure. Unique proteins were defined as those without ortholog 
predictions. For simplicity, excluded from the total count were predicted orthologous 
groups between organism pairs that were not a one-to-one orthologous pairing (if a 
protein from organism A had more than one predicted ortholog from organism B, and 
vice versa). Other homology predictions are based on BLAST results to the NCBI nrdb. 
3.2.8 Prediction of horizontally acquired genes  
Predicted protein sequences from L. iners AB-1 and from the organisms listed 
above were compared to the NCBI nrdb by BLAST. Excluding self-hits and hits to the 
same species, genes were identified as foreign if the three most significant hits (E <= 1E-
20) were a genus other than Lactobacillus with the most significant hit having at least 
60% protein identity to the query sequence. 
3.2.9 Construction of phylogenetic tree of select lactobacilli 
Ribosomal protein sequences were chosen and tested for vertical transmission as outlined 
by Ciccarelli et al. (34). The following sequences contained clear orthologs in all the 
organisms and were vertically transmitted: ribosomal protein L1, L10, L11, L13, L15, 
L16, L17, L18, L2, L20, L21, L22, L23, L24, L27, L29, L3, L4, L5, L6, S10, S11, S12, 
S13, S20, S3, S4, S5, S7, S8, S9. These concatenated sequences were sent for 
phylogenetic analysis using the 'one click' mode at www.phylogeny.fr (35). This is a 
"default" mode which uses a pipeline already set up to run and connect programs 
recognized for their accuracy and speed (MUSCLE for multiple alignment, Gblocks for 
alignment curation, PhyML for phylogeny and finally TreeDyn for tree drawing) to 
reconstruct a robust phylogenetic tree from a set of sequences. The trees of cholesterol-
dependent cytolysins (Figures S2 and S3) were created by the same method. 
3.2.10 Cell-wall protein isolation 
Protein isolation was performed using the method adapted from Cole, et al. (36). Briefly, 
L. iners was grown in 25ml MRS broth for 96 hours. The culture was spun down, the 
supernatant was removed, and the pellet was frozen at -20oC until isolation. After 
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thawing, the pellet was washed two times using TES buffer, resuspended in a 10% 
lysozyme solution in TES, and incubated at 37oC with shaking for 2h. After 
centrifugation, the supernatant containing the solubilized cell wall-associated proteins 
was collected. Proteins  
were precipitated using 10% TCA before separating by size by electrophoresis on SDS-
PAGE, and bands were visualization by coomassie blue staining. For Western Blot 
analysis, the SDS-PAGE electrophoresed proteins were transferred to a polyvinylidene 
difluoride (PVDF) membrane for immuno-blotting as described below. 
3.2.11 Mass spectrometry 
After isolation of proteins, separation of by SDS-PAGE, and coomassie staining as 
described above, the visibly stained bands were isolated for mass spectrometry. In-gel 
digestion was performed using a MassPREP automated digester station (PerkinElmer).  
Gel pieces were Coomassie destained using 50mM ammonium bicarbonate and 50% 
acetonitrile (silver de-stained using a 50 mM sodium thiosulphate 5 hydrate and 15 mM 
potassium ferricyanide solution), which was followed by protein reduction using 10 mM 
dithiotreitol (DTT), alkylation using 55 mM iodoacetamide (IAA), and tryptic digestion.  
Peptides were extracted using a solution of 1% formic acid and 2% acetonitrile and 
lyophilized.  Prior to mass spectrometry analysis, dried peptide samples were re-
dissolved in a 10% acetonitrile and 0.1 % TFA (trifluoroacetic acid). 
MALDI matrix, α–cyano–4–hydroxycinnamic acid (CHCA), was prepared as 5 mg/mL 
in 6mM ammonium phosphate monobasic, 50% acetonitrile, 0.1 % trifluoroacetic acid 
and mixed with the sample at 1:1 ratio (v/v). 
Mass Spectrometry data were obtained using a 4700 Proteomics Analyzer, MALDI TOF 
TOF (Applied Biosystems, Foster City, CA, USA). Data acquisition and data processing 
were respectively done using 4000 Series Explorer and Data Explorer (both from Applied 
Biosystems). The instrument is equipped with a 355 nm Nd:YAG laser; the laser rate is 
200 Hz. Reflectron positive ion mode was used and the instrument was calibrated at 50 
ppm mass tolerance.  Each mass spectrum was collected as a sum of 1000 shots. 
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Protein identification was made using a local MASCOT (www.matrixscience.com) server 
and a custom-build peptide mass database constructed from the predicted protein 
sequences of L. iners AB-1. Search criteria allowed for up to 3 missed cleavage sites and 
a 50 ppm tolerance, and searches were performed using constant carbamidomethyl and 
variable oxidation modifications. 
3.2.12 Rabbit polyclonal antisera 
Polyclonal antisera was raised in rabbits using formalin-fixed whole cells of 
Lactobacillus iners AB-1, by ProSci Incorporated (Poway, CA) following a standard 
two-month protocol. 
3.2.13 Absorption of polyclonal antisera 
Whole-cell lysates were prepared from overnight cultures of each of the following ten 
strains: Staphylococcus aureus subsp. Newman, Escherichia coli subsp. Nissle, 
Atopobium vaginae, Gardnerella vaginalis, Lactobacillus rhamnosus GR-1, 
Lactobacillus reuteri RC-14, Lactobacillus crispatus, Lactobacillus gasseri 33323, 
Lactobacillus jensenii RC-28, and Lactobacillus johnsonii ATCC 11506. For each 
culture, the cells from 1 ml of overnight culture were harvested by centrifugation, 
resuspended in phosphate-buffered saline (PBS), then lysed using a bead beater. Unlysed 
cells were subsequently removed by centrifugation and the lysates from all ten cultures 
were combined. Nitrocellulose membranes (5 × 5 cm squares) were incubated in the 
lysate for 1 h at room temperature, with the membranes being turned every 15 min. After 
removing the lysate and washing the membranes 3 × 10 min with tris-buffered saline 
(TBS), the membranes were blocked for 1 h in 10% skim milk. The polyclonal antisera 
was incubated with 5 blocked membranes for 60 to 90 min, with the membranes being 
turned over every 15 min. The membranes were replaced with 5 new membranes and 
incubation repeated. This process was repeated for a total of 20 membranes, with 100 µL 
samples being taken after each 5-membrane incubation for analysis by dot blotting. 
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3.2.14 Immuno-blot assay 
Immuno-blot assays were performed using the Bio-Rad Goat Anti-Rabbit IgG (H+L) AP 
Immun-Blot® Assay Kit and the Bio-Rad Alkaline Phosphatase Conjugate Substrate Kit 
according to the recommendations of the manufacturer. The completeness of the 
absorption procedure was analyzed using the same ten strains that were used for the 
absorption protocol (see above) plus Lactobacillus iners AB-1.  
3.2.15 Transmission electron microscopy and immunogold 
labeling 
Overnight monocultures of L. iners grown in MRS and self-collected vaginal swabs from 
healthy volunteers were prepared using a standard method for electron microscopy and 
immunogold labeling at the Transmission Electron Microscopy Facility, Department of 
Microbiology and Immunology at the University of Western Ontario. After embedding 
samples in LR white resin and thin slicing, the sections were placed on 400 mesh nickel 
grids and treated with the anti-L. iners primary rabbit antisera. After washing, samples 
were then incubated with goat anti-rabbit IgG conjugated to 10nm gold particles (British 
Biocell International, EM.GAR10) for labeling. Samples were stained with 2% uranyl 
acetate and examined with a Philips EM 410 microscope. 
3.2.16 Growth assays 
A modified MRS (37) broth was made lacking carbohydrates and with the addition of 
bromocresol purple as a pH indicator. Carbohydrates were added at a final concentration 
of 20mg/ml and a final total broth volume of 10ml for each experiment. The 
carbohydrates tested were: glucose, lactose, mannose, fructose, maltose, and porcine 
stomach mucin type III (Sigma: M1778) which has a glycoprotein content similar to 
vaginal mucin (38, 39). Growth was compared to the standard MRS medium used to 
grow the strain (Difco™ Lactobacilli MRS Broth). Colony forming units (CFU) were 
enumerated by drop plating serial dilutions of the broth culture onto Columbia blood agar 
plates every 24h after inoculation. 
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This Whole Genome Shotgun project has been deposited at DDBJ/EMBL/GenBank 
under the accession ADHG00000000. The version described in this paper is the first 
version, ADHG01000000. 
3.3 Results and Discussion 
3.3.1 Phylogeny 
A phylogenetic tree was constructed from concatenated ribosomal subunit protein 
sequences of several Lactobacillus species available from the NCBI database with the 
addition of sequence for L. iners AB-1. The relationship between the species is in 
agreement with previous predictions (40) and places L. iners in the group known as the 
“acidophilus complex” (41) (Figure 3-1 and Figure S1). This clade contains two other 
Lactobacillus species, L. gasseri and L. crispatus, that colonize the vaginal tract, the 
predominantly gut microbes L. johnsonii and L. acidophilus, and one dairy culture, L. 
delbrueckii subsp. bulgaricus (referred to here as L. bulgaricus). L. gasseri and L. 
johnsonii are sister species to L. iners within this clade, although L. iners is markedly 
more distantly related, which indicates a divergent evolutionary step. This small clade of 
organisms formed the basis for genomic comparisons with L. iners due to sequence 
similarity and, in the case of L. crispatus and L. gasseri, the shared vaginal environment. 
 
Figure 3-1. Subset of a phylogenetic tree representing L. iners as part of the 
acidophilus complex 
Phylogeny was constructed using conserved ribosomal proteins and the default mode 
at phylogeny.fr (35). Key genome features are summarized for each species. The full 
dendrogram and detailed methodology is presented in Supporting Online Materials. 
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Size in Mbp; CDS, coding sequences, HA(n), number horizontally acquired genes; 
HA(%), HA(%), percent of CDS horizontally acquired. 
 
3.3.2 General genomic features 
The L. iners AB-1 genome is the smallest Lactobacillus genome reported to date (11). 
Optical mapping demonstrated a circular chromosome of 1.304 Mbp, a size which agreed 
with our assembled genome scaffold of 1.301 Mbp with no plasmids (Figure 3-2 and 
Figure S3). Comparison of the optical map and the assembled scaffold suggests that there 
are 3 kb separating the two scaffolded contigs. The size of the L. iners genome places it 
within the range of several obligate symbionts and parasites (42, 43). In comparison, the 
smallest genome of any free-living organism is that of Pelagibacter ubique at 1,308,759 
bp. The L. iners genome has a low GC content of 32.7% which is similar to the most 
closely related species L. johnsonii (34.0%) and L. gasseri (35.3%) (23). Surprisingly, the 
small genome still contains 6 rRNA gene operons which likely provides a competitive 
mechanism for responding to environmental pressures and resource availability (44). The 
L. bulgaricus genome also contains an exceptionally high number of rRNA operons 
relative to genome size. This was attributed to a recent phase of genome reduction (45).  
As L. johnsonii (18) and L. gasseri (46) each have 6 rRNA operons, the L. iners genome 
may have undergone a large genome reduction phase after splitting from the L. johnsonii 
and L. gasseri lineage, but the rRNA clusters were retained. 
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Figure 3-2. Genomic atlas of Lactobacillus iners AB-1 
From the outer circle inward: coding regions are marked on the first two rings: 
outside the dividing line if encoded on the positive strand, and inside the dividing line 
if encoded on the negative strand. The third ring (dark green) marks ORFs predicted 
to be horizontally acquired. The fourth ring (orange) shows ORFs predicted to be 
among the top 10% most highly expressed based on CAI. The fifth ring shows local 
CG content measured in a sliding window as a black plot. The innermost graph shows 
the CG-skew with sharp changes in skew occurring at the origin and terminus of 
replication. Genes of interest, as described in text, are marked on the outside of the 
atlas. Adhesins are marked in red. The atlas was constructed using the CGView 
Server (47) and a large-scale version can be found in the SI Appendix (Figure S2). 
The L. iners genome was predicted by GeneMark (20) and Glimmer (21) to encode 1190 
Open Reading Frames (ORFs) greater than 100 nt with an average length of 998 nt.  A 
large fraction of the genes (85.7%) had one or more homologs with an E-value of 1e-20 
or lower in the NCBI non-redundant database.  Functional classification of the 1190 
predicted genes by Clusters of Orthologous Genes (COGs) (22) showed that 956 (80.3%) 
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were homologous to known gene families, including 201 “poorly characterized” genes. 
The number of pseudogenes was estimated by identifying ORFs that were truncated by at 
least 10% compared to the full length of the best protein match in the NCBI database 
(Table S1). To account for gene miscalls by GeneMark, the truncated ORFs were verified 
with Glimmer predictions and corrected where appropriate when Glimmer predictions 
produced better alignments with predicted proteins in the NCBI nrdb. The analysis 
resulted in 95 possible pseudogenes with approximately half predicted as hypothetical 
proteins or phage-related (Table S2). Notable horizontally acquired genes are described 
in the relevant sections following. 
3.3.3 Comparative genomics 
The InParanoid tool (33) was used to identify groups of orthologous proteins between L. 
iners and three other species of the clade (Figure 3-3). There were a predicted 766 genes 
shared between all four species, representing a large proportion of the L. iners coding 
sequence (64%) compared to L. crispatus (37%), L. acidophilus (44%), and L. gasseri 
(44%). This illustrates the unique nature of L. iners as most of its reduced genome 
contains core genes of the clade. Similar predictions were obtained when L. johnsonii 
was substituted for L. gasseri (Figure S4). 
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Figure 3-3. Venn diagram representing orthologous proteins between select species 
of the L. iners clade 
Values are the number of orthologous genes between overlapping species as predicted 
by InParanoid (33). The 789 genes conserved between the four species represent a 
relatively large proportion of L. iners’ total gene content (69%). 
The distribution of genes with a COG functional category was compared between L. iners 
and the four other species within the clade for which there were COG functional 
predictions available from the NCBI database (Figure 3-4). L. iners was considered to be 
significantly different within a category if the value was not within two standard 
deviations of the mean of the other four organisms. L. iners has significantly fewer genes 
in 13 of 20 COG functional categories, and it has the fewest number of genes of all five 
organisms in 15 categories, tying for lowest in two additional categories. 
As observed previously (45), L. bulgaricus had approximately one half the number of 
carbohydrate transport and metabolism (COG category G) genes as the mean of the 
remaining three lactobacilli (excluding L. iners) creating an unusually high variance in 
this category. The severely reduced number of genes in L. bulgaricus is due to its long 
use as a milk starter culture, and its adaptation to this specific nutrient rich, but 
carbohydrate limited environment. The authors noted many instances of loss or 
inactivation of carbohydrate metabolizing enzymes other than lactose, in this rapidly 
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evolving organism. The vaginal environment is much more complex due to fluctuation of 
hormones affecting mucus and glycogen production, pH, and microbial species, so 
although L. iners also exhibited gene loss related to carbohydrate transport and 
metabolism, it was not to the extent of L. bulgaricus. 
 
Figure 3-4. Comparison of the distribution of genes by COG functional category 
The white bar represents the mean and standard deviation of the number of genes in 
each COG functional category for four species of the L. iners clade (L. johnsonii, L. 
gasseri, L. acidophilus, L. bulgaricus). The values for L. iners are plotted in the black 
bar. Marked with asterisks are values in L. iners that are at least two standard 
deviations away from the mean of the other organisms in the same COG category. 
COG Functional Categories: (J) Translation, ribosomal structure and biogenesis; (K) 
Transcription; (L) DNA replication, recombination and repair; (D) Cell division and 
chromosome partitioning; (O) Posttranslational modification, protein turnover, 
chaperones; (M) Cell envelope biogenesis, outer membrane; (N) Cell motility and 
secretion; (P) Inorganic ion transport and metabolism; (T) Signal transduction 
mechanisms; (C) Energy production and conversion; (G) Carbohydrate transport and 
metabolism; (E) Amino Acid transport and metabolism; (F) Nucleotide transport and 
metabolism; (H) Coenzyme metabolism; (I) Lipid metabolism; (Q) Secondary 
metabolites biosynthesis, transport and catabolism; (R) General function prediction 
only; (S) Function unknown; (V) Defense mechanisms; (U) Intracellular trafficking 
and secretion. 
3.3.4 Horizontal gene transfer (HGT) 
Genes in L. iners and the other five lactobacilli of the same clade (Figure 3-1) were 
identified as foreign if the first three significant hits (E-value of 1e-20 or less) to the 
NCBI nr database were to a genus other than Lactobacillus. L. iners has a striking 
number of predicted genes likely acquired from organisms outside its genus, with 65 
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genes identified accounting for 5.5% of protein-coding genes (Figure 3-1 and Table S3). 
The next highest number was 24 foreign genes in the L. bulgaricus genome accounting 
for 1.5% of protein-coding genes. For the other organisms in the group, less than 1% of 
their protein-coding genes are of putative foreign origin. Even more striking, 26 of the 
foreign genes in the L. iners genome have at least 80% amino acid identity to a non-
lactobacillus organism indicating a recent large-scale introduction of these genes. Many 
of the horizontally acquired genes are most similar to a gene found in an organism that 
shares the vaginal environment, possibly indicating the origin of the L. iners gene (Table 
S3). Interestingly, of the six members of the acidophilus group, L. iners and its sister 
species, L. johnsonii and L. gasseri, lack both CRISPR (clustered regularly interspaced 
short palindromic repeats) regions and the associated cas genes (48). Since CRISPR loci 
are a defense mechanism that excludes foreign DNA, this may explain, in part, why L. 
iners was able to acquire a large number of foreign genes. Several competence-related 
proteins were identified (LINAB1_1090 ComEB, LINAB1_0944 MecA, LINAB1_0943 
CoiA, LINAB1_0502 ComEC, LINAB1_0501 ComEA, putative ComGC protein 
LINAB1_0373, LINAB1_0372 PulF, LINAB1_0371 PulE) suggesting L. iners has 
components of the machinery for natural competence. 
It is not uncommon to find subjects colonized by one of either L. crispatus or L. iners (4, 
8), suggesting there may be competition between the organisms. Pressure to compete 
with other organisms, including lactobacilli, may have been a reason for L. iners to 
acquire foreign genes, such as the adhesins and cytolysin described below. Interestingly, 
instillation of probiotic L. rhamnosus GR-1 with L. reuteri RC-14 or candidate probiotic 
L. crispatus CTV05 on its own were not inhibited by indigenous L. iners nor did they 
displace the L. iners from the vagina, indicating in vivo persistence of indigenous L. iners 
strains (1, 49). 
3.3.5 Cholesterol-dependent cytolysin 
The L. iners AB-1 genome contains a cluster of related genes making up a complete 
horizontally-acquired type I restriction modification (RM) system: restriction subunit 
(LINAB1_0222), methyltransferase subunit (LINAB1_0217), and three specificity 
proteins (LINAB1_0218, LINAB1_0220, LINAB1_0221). There is one additional 
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isolated restriction endonuclease encoded in the genome (LINAB1_1155). Neighboring 
the RM system is a putative integrase, and a predicted cholesterol-dependent cytolysin 
(LINAB1_0216) that belongs to the family of gram-positive pore-forming cholesterol-
dependent cytolysins (CDC), formerly known as thiol-activated cytolysins. These 
proteins are typically found in pathogenic bacteria, and when expressed and secreted they 
use cholesterol in host cell membranes as a receptor for binding. Upon binding, a 
conformational change in the protein causes cell lysis by forming large pores in the 
membrane (50). This is the first instance of a putative cholesterol-dependent cytolysin 
occurring in a Lactobacillus genome. 
LINAB1_0216 is 519 AA long, and has 55% amino acid identity to vaginolysin 
of Gardnerella vaginalis. A neighbor-joining tree derived from a multiple sequence 
alignment of representative CDCs shows that the putative L. iners AB-1 CDC is most 
closely related to the CD59-dependent intermedilysin class (Figure S5). CDC proteins 
have a well-conserved undecapeptide in the last domain of this four domain protein that 
is important for host interaction and pore formation. Hughes et al (51) recently 
demonstrated in Streptococcus that a short peptide sequence adjacent to the 
undecapeptide was responsible for specific interaction to the complement regulatory 
protein, CD59. Figure 3-5 shows an alignment of the undecapeptide and the CD59 
interaction motif for LINAB1_0216 and its most closely related proteins. The putative 
cholesterol-dependent lysin was found to contain the consensus undecapeptide motif for 
cholesterol binding, but to lack the CD59 motif.  Thus, although intermedilysin and 
vaginolysin use the human complement factor CD59 as a dependent co-factor with 
cholesterol to mediate binding (52), the sequence differences in the L. iners AB-1 lysin 
indicate the protein does not have the specificity to bind to CD59. We noted that domain 
4 of LINAB1_0216, the membrane interaction domain, was more closely related to 
tetanolysins than to intermedilysins (Figures S6), supporting the conclusion that 
LINAB1_0216 is not dependent on CD59 for membrane binding. This putative lysin is 
predicted to be highly expressed by L. iners AB-1 based on a codon adaptation index 
(CAI) that ranks in the top 10% of this predicted measure of gene expression (Table S4). 
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Figure 3-5. Alignment of conserved motifs in the putative cholesterol-dependent 
cytolysin (LINAB1_0216) with related cytolysins 
The cholesterol-binding undecapeptide extends for the first 11 residues. The residues 
beginning at the R in intermedilysin compose the CD59 motif. The affinity of the 
SKN peptide for CD59 is four fold higher than is the NRT peptide. LINAB1_0216 
has one or more differences from the intermedilysin at each of the two positions, the 
most drastic being the SKN to DEQ difference that changes a polar-basic-polar trio to 
an acidic-acidic-polar trio. 
L. iners is the predominant component of the vaginal microbiota in a significant 
proportion of healthy women (6, 53, 54). There is no clinical evidence to date that the 
presence of L. iners is associated with induction of discharge, inflammation, or 
discomfort. Therefore, we speculate that the cytolysin could be used to acquire nutrients 
from the host in a symbiotic way, or may exert antimicrobial activity against eukaryotic 
organisms in the environment, such as Candida species, or that it may contribute to 
attachment to host cell membranes. However, the exact function and role of 
LINAB1_0216 remains to be determined. 
3.3.6 Carbohydrate transport and metabolic capabilities 
Perinatally and until menopause, increased estrogen induces anaerobic metabolism of the 
large amounts of glycogen on the vaginal epithelium, causing an acidic environment in 
which the major unbound carbon sources are glucose, mannose and glucosamine (55) all 
of which L. iners AB-1 is predicted to metabolize. The vaginal mucosa consists primarily 
of mucin glycoproteins composed of monosaccharide chains of L-fructose, N-
acetylneuraminic acid (sialic acid), galactose, N-acetyl-galactosamine, and N-
acetylglucosamine (39). Growth assays (Figure S7) determined that L. iners AB-1 
preferred carbon source is mucin with maximum growth occurring within 24-48h of 
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initial inoculation. Lactose, glucose, and maltose also supported growth but peaked after 
a longer incubation of 72-96h. We speculate that L. iners is adapted for an easily 
accessible component of the mucin polysaccharide which once depleted in culture 
resulted in loss of viability. In the natural vaginal environment mucin turnover (56) 
would provide new moieties of carbohydrates for L. iners to access. No growth was 
observed in fructose or mannose. 
          Complete phosphotransferase systems (PTS) were found for lactose 
(LINAB1_0229, LINAB1_0230 plus LINAB1_0228: LacI regulator), galactitol 
(LINAB1_0173, LINAB1_0174, LINAB1_0175), glucose (LINAB1_00303, 
LINAB1_00304, LINAB1_00306), and fructose (LINAB1_0669). The lactose-specific 
PTS system has greater than 75% protein identity to several Streptococcus strains, while 
being less than 50% identical to other lactobacilli. There were two complete PTS systems 
initially annotated as members of the mannose family of PTS transporters 
(LINAB1_0058 to LINAB1_0060, and LINAB1_0223 to LINAB1_0226), and one 
system predicted to be a mannose/fructose transporter with the most protein identity to 
Streptococcus spp. (LINAB1_0650 to LINAB1_0647). The mannose class of PTS 
transporters are structurally and functionally distinct from other PTS transporters, most 
notably for their ability to transport a wide variety of sugars including mannose, glucose, 
glucosamine, fructose, galactosamine and N-acetylgalactosamine (57). Two separate 
EIIA subunits encoded without other neighboring PTS components and have predicted 
specificity to mannose/fructose (LINAB1_0226) and glucitol/sorbitol (LINAB1_0935). 
Clusters of ABC-type transport genes composing complete transport machinery for 
general sugar transport (LINAB1_0031, LINAB1_0032, LINAB1_0033, LINAB1_0035, 
LINAB1_0036 and LINAB1_0341, LINAB1_0339, LINAB1_0338, LINAB1_0337) and 
specifically for maltose (LINAB1_0077 and LINAB1_0080) were found in addition to 
the carbohydrate PTS systems. 
Complete metabolic pathways are present to convert each transported sugar to glucose for 
entry into glycolysis, with the exception of galactitol. The enzyme galactitol-1-
phosphate-5-dehydrogenase is missing in L. iners and related species L. johnsonii and L. 
gasseri despite predicted galactitol transport ability.  Unlike L. johnsonii and L. 
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gasseri, L. iners is lacking PTS systems and enzymes for sucrose and for cellobiose 
metabolism. A predicted exported O-sialoglycoprotein endopeptidase (LINAB1_0262) 
contains a conserved glycoprotease motif (Pfam: Peptidase_M22) and the ORF protein 
sequence has greater than 80% identity to protein sequences in other vaginally-associated 
lactobacilli. Four ORFs initially annotated as pullulanases (LINAB1_0206, 
LINAB1_0331, LINAB1_0631, LINAB1_0626) have predicted glycosidase activity due 
to several carbohydrate-binding and glycosidase domains. These findings of predicted 
carbohydrate metabolism and transport suggest that L. iners is adapted to hydrolyzing 
and extracting the carbohydrates of the vaginal mucosa. 
All glycolytic enzymes are present to convert glucose to pyruvate, and from pyruvate 
exclusively into L-lactate, but not into other metabolites such as D-lactate, oxaloacetate, 
Acetyl-CoA or acetate. L. iners has an incomplete TCA cycle containing only fumarate 
reductase. Like most other lactobacilli, the organism is unable to synthesize or metabolize 
fatty acids. 
3.3.7 Other transport and metabolism 
Consistent with a limited metabolic capability and other members of the lactic acid 
bacteria, L. iners AB-1 dedicates a large proportion of its genome (186 (15.6%) of 
protein-encoding genes) to transport (Table S5). The closely related L. johnsonii is 
known for its auxotrophic nature, but in comparison only 10.7% of protein-coding genes 
are related to transport. Other lactobacilli in the same clade range from 4.0% for L. 
bulgaricus, and 8.0% and 9.1% for L. gasseri and L. acidophilus respectively.  Unique to 
L. iners compared to L. johnsonii and L. gasseri, is a complete metal ion transport system 
likely transporting zinc or manganese. The system appears to be horizontally acquired 
and each component has from 56 to 73% amino acid identity to Anaerococcus, and 
Finegoldia species based on homology to proteins in the NCBI database. Manganese has 
long been known as an important protectant for lactobacilli against oxidative stress and 
has been demonstrated as a required component for growth of several Lactobacillus 
species (58, 59).  
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Lactobacillus iners AB-1 lacks enzymes for the biosynthesis of nearly all cofactors and 
vitamins. However, unlike a number of other lactobacilli including L. johnsonii and L. 
gasseri, L. iners AB-1 appears to have the complete biosynthesis pathway for folate with 
a number of the enzymes clustered together in the genome (Figure S8). It remains to be 
determined if folate is produced and secreted by these bacteria into the vagina. 
L. iners AB-1 has the complete pathway for de-novo synthesis and salvage of 
pyrimidines. A partial purine metabolism pathway is present containing the enzymes 
required for de-novo synthesis of PRPP, but no subsequent enzymes for conversion into 
IMP. All genes are present for salvage of purines. 
3.3.8 Amino acid biosynthesis 
The strain is unable to synthesize any amino acids de-novo, with the possible exception 
of serine from pyruvate using a L-serine dehydratase (LINAB1_0514 and 
LINAB1_0513). Two genes allow for the interconversion of L-aspartate and L-aspargine: 
asparagine synthetase (asnB), and aspartate-ammonia ligase (asnA). Also present is a 
glutamine synthetase (LINAB1_0635) that can convert glutamate to glutamine in the 
presence of NH3. Three enzymatic steps are present to catabolize L-methionine into L-
homocysteine and ultimately into O-succinyl-L-homoserine, a process unique to L. iners 
in comparison to L. johnsonii and L. gasseri. This allows L. iners to form the methyl-
donating coenzyme S-adenosyl-L-methionine (SAM) from methionine or homocysteine. 
It is unknown what further role the met pathway plays in L. iners. Compensating the 
inability of L. iners to synthesize most amino acids, several peptidases are predicted to be 
highly expressed based on CAI (SI Appendix Table S4). There are also several genes 
involved in peptide transport, including a predicted highly expressed oligopeptide (Opp) 
transport system (LINAB1_0408 to LINAB1_0412). 
3.3.9 Adherence and host interaction 
The ability of lactobacilli to adhere to vaginal epithelial surfaces is believed to be 
important to allow colonization, host interaction, and to exclude pathogens (60). The BV-
associated microbes, G. vaginalis and Atopobium vaginae, are able to form dense 
biofilms recalcitrant to standard metronidazole treatment (61, 62). However, L. iners AB-
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1 can interfere with, and displace, G. vaginalis biofilms in vitro, suggesting a role in 
restoration of a healthy vagina post-BV (63). 
 Examination of the genome for potential adhesion factors surprisingly showed the 
L. iners genome lacks most of the known adhesion factors and conserved adhesion 
domains commonly found in the lactobacilli (Tables 1 and S6). Two fibronectin-binding 
proteins (LINAB1_0564, LINAB1_0800) and one fibrinogen-binding protein 
(LINAB1_0798) were found, but no mucus-binding proteins common to lactobacilli that 
colonize the gastrointestinal tract were identified(64, 65), thus suggesting that L. iners 
uses different adherence mechanisms in the vagina. 
 The predicted ORFs were evaluated for cell-wall anchor motifs that indicate the 
protein is exposed on the surface of the cell. Sortase-dependent proteins (SDPs) often 
have a role in bacterial-host interactions and adhesion (66), and many gram-positive cell-
wall anchored proteins contain a conserved C-terminal LPXTG motif that is cleaved by 
the sortase A enzyme between the threonine and glycine residues. The cleaved protein is 
then covalently linked to the peptidoglycan of the cell wall (67). Recently, the probiotic 
L. rhamnosus GG was shown to have genes for three secreted LPXTG-like pilins 
(spaCBA) and a pilin-dedicated sortase that mediates binding to mucus (28). 
Bereft of pili (Figure 3-6), one ORF of L. iners was identified as sortase A 
(LINAB1_0482), and Table 1 shows that 6 ORFs were identified as possible SDPs 
containing the sortase cleavage motif LPXTG (Pfam ID PF00746). Two of the proteins 
(LINAB1_0273, LINAB1_0795) have several tandemly repeated Rib domains 
(PF08428), which may function as adhesion and biofilm factors to human epithelial cells 
(68, 69). All the SDPs have multiply repeated domains of unknown function within the 
protein which we speculate are involved in adhesion. 
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Figure 3-6. Transmission electron micrograph of immunogold labeled L. iners AB-
1 (black arrows) in association with human vaginal epithelial cells 
Vaginal swab samples collected from healthy women were prepared for EM by thin-
sectioning. The L. iners cells were labeled with a polyclonal antiserum raised in 
rabbits against formalin-fixed whole cells of L. iners followed by a secondary goat 
anti-rabbit gold-conjugated antibody (10 nm gold particles). An even surface 
distribution of gold particles is expected for L iners but not other bacteria because 
antibodies not specific to L. iners AB-1 were absorbed out of the serum as described 
in the Supplemental Text. The scale bar represents 500 nm. 
A large fraction of Streptococcus and Staphylococcus SDP surface proteins with the 
LPXTG anchor motif also contain the YSIRK signal motif (70, 71). Deletion and 
substitution mutations of the YSIRK motif in cell-wall-anchored protein A 
of Staphylococcus reduced secretion and sorting of the protein. Except for 
LINAB1_0273, all of the LPXTG proteins identified (Table 1) in L. iners also contained 
the YSIRK motif (PF04650) and another two proteins had the N-terminal YSIRK-type 
signal motif without an associated LPXTG motif.  The combinational signal and anchor 
motifs in these proteins suggest they are under tight regulation to be properly secreted 
and anchored to the cell surface. 
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In addition, several of the putative adhesion factors show weak similarity to adhesion 
proteins. Two of the five SDPs have a significant hit (E-value of 1e-20 or less) to the 
NCBI nr database: LINAB1_0273 and LINAB1_0701 are similar (26 and 47% 
respectively) to a possible biofilm-associated protein of BV pathogen Atopobium 
vaginae. Six putative binding proteins had significant hits to the nr database, however, 
only two of these had greater than 50% amino acid identity. LINAB1_0796 had 65% 
identity to a possible mucus binding protein precursor of L. jensenii. However, 
LINAB1_0796 itself does not contain a mucus-binding domain, and there is no 
significant similarity to any other mucus-binding protein in the database suggesting that 
the L. jensenii protein is mis-annotated. 
 To determine if any putative cell-surface proteins were expressed, cell-wall 
protein extract from L. iners was separated by SDS-PAGE electrophoresis and analyzed 
by Western Blot with antisera raised against L. iners AB-1. Bands were isolated for mass 
spectrometry peptide mass fingerprinting. Isolated proteins were putatively identified 
based on predicted size in kDa (Figure S10) and the peptide mass coverage. One band 
(marked with a black arrowhead in Figure S10) was predicted to be LINAB1_0950 based 
on 6 matched peptides, and 15% peptide mass coverage. When search options included 
variable lysine acetylation, 16 peptides covered 25% of the protein. The 48294 Da 
predicted mass of this protein is consistent with the size of the band. The protein 
sequence contains a YSIRK signal sequence supporting its predicted location outside the 
cell, but has no significant similarity to proteins in the NCBI non-redundant database. 
 In order to further confirm the localization of the isolated proteins to the cell 
surface, transmission electron microscopy (TEM) of L. iners monoculture was prepared 
with a rabbit polyclonal antisera was raised against formalin-fixed whole cells of L. iners 
and labeled with IgG conjugated to 10 nm gold particles. This showed specific labeling 
distributed around the cell membrane (Figure 3-6 and Figure S9). Vaginal swab samples 
collected from healthy women were confirmed by PCR to contain L. iners (72) and TEM 
and immunogold-labeling using the L. iners antisera, showed L. iners to be consistently 
closely associated with vaginal epithelial cell surfaces (Figure 3-6). 
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The lack of proteins containing adhesion domains and several cell-anchored proteins 
lacking sequence conservation to known proteins suggest that L. iners has a unique and 
unknown method of adherence. In support of this assertion, 7 of the 14 putative adhesion 
proteins have a CAI greater than the mean CAI, and two are predicted to have gene 
expression levels among the highest 10% of all genes. Taken together, these observations 
suggest that these genes may provide a competitive advantage in its specialized 
environment, but further characterization is required. 
3.3.10 Stress tolerance and environmental response 
L. iners AB-1 has the ability to survive both the low pH (3.6 to 4.5) conditions of a 
healthy vagina and the higher pH (greater than 4.5) conditions associated with BV (73, 
74). The genome contains two alkaline-shock proteins (LINAB1_0403 and 
LINAB1_0434), also present in L. crispatus, which may aid in pH tolerance of the 
vaginal environment.  The genome contains a heat-shock operon with a heat-inducible 
transcriptional repressor, HrcA, and molecular chaperones GrpE, DnaK, and DnaJ, plus a 
second stress-induced operon controlled by a redox-sensing transcriptional repressor and 
the chaperonins GroES and GroEL. Two universal stress proteins (LINAB1_0760 and 
LINAB1_0227), and a cold-shock protein (LINAB1_0419) were identified. Collectively, 
these may aid in allowing the organism to tolerate different pHs, mucus changes, and 
stress associated with infection. 
RNA polymerase contains four standard subunits and an additional sigma factor that 
directs the enzyme to a specific promoter.  Alternative sigma factors are active under 
different stress conditions to regulate the transcription of various stress response genes. In 
addition to the typical RpoD (LINAB1_0602) sigma factor, L. iners has three alternative 
sigma factors identified as RpoE (LINAB1_0946), RpoH (LINAB1_1028), and RpoN 
(LINAB1_0645).  Interestingly, RpoE is used by the opportunistic intracellular pathogen 
Burkholderia cenocepacia for growth under stress (75). Another intracellular Gram 
negative pathogen Brucella melitensis uses RpoH and RpoN to cope with stress from 
elevated temperature and exposure to H2O2 (76). These factors may contribute to the 
ability of L. iners to survive in the presence of H2O2-producing strains in the vagina, and 
oxidative stresses associated with infection. LINAB1_0645 (RpoN) is adjacent to a 
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complete mannose/fructose PTS system with high amino acid identity to strains of S. 
pyogenes. Upstream is an unknown conserved protein (LINAB1_0651) with an RpoN 
interaction domain. Recent work by Stevens et al. (77) characterized an RpoN-dependent 
mannose PTS system of Lactobacillus plantarum with a similar operon structure and 
RpoN acted is a major regulator of carbohydrate uptake.  
There were four complete two-component systems identified, each consisting of a 
histidine kinase and a response regulator. Three of the paired systems have high 
similarity to proteins from other lactobacilli, while one system (LINAB1_0792, 
LINAB1_0791) appears to be horizontally acquired with 50-60% amino acid identity to 
proteins from either Anaerococcus prevotii or Oribacterium sinus. In addition to the 
complete coupled systems, three more response regulators without a corresponding 
histidine kinase were found (LINAB1_0366, LINAB1_0143, LINAB1_0785).  
We noted that a cluster of genes shared between L. iners, L. crispatus, and L. johnsonii 
encode an iron-sulfur (Fe-S) cluster assembly system (LINAB1_0712 to LINAB1_0717). 
We examined homologs in the NCBI database and found these proteins to be most 
similar to these lactobacilli known to colonize the vaginal tract, but the complete system 
was rare in lactobacilli inhabiting other niches. Three of the L. iners’ proteins in the 
cluster (LINAB1_0712, LINAB1_0714, LINAB1_0716) did not match any of the 
proteins in the NCBI non-redundant database at greater than 60% protein identity, 
suggesting they have a specified or unique function in L. iners. 
The Fe-S clusters were first characterized as proteins needed to carry iron and sulfur to 
appropriate areas of the cell and as electron transfer molecules (78). The so called Suf 
system in E. coli is activated under conditions of limiting iron or oxidative stress, such as 
the presence of H2O2 (79). Because of the sensitivity of a Fe-S cluster to oxygen, they can 
act as environmental sensors and regulate a response by the organism (80). This could be 
an important mechanism for resistance to oxidative stress in L. iners where an abundance 
of H2O2 is produced by other lactobacilli in the vagina (81). Although iron is a required 
element for nearly all living organisms, it has commonly been accepted that lactobacilli 
do not require iron for growth and instead use manganese and cobalt as cofactors for 
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biological processes (58, 82). However, Elli et al. (83) found that depleting iron from a 
nucleotide limited growth media resulted in no growth of certain Lactobacillus species, 
while Duhutrel et al. (84) reported the acquisition and use of iron in Lactobacillus sakei, 
an organism especially well adapted to meat. There were no apparent iron uptake systems 
in L. iners, but a ferrochelatase (LINAB1_0037) was detected and is not present in the 
other species of the clade. This enzyme plus an oxygen-independent coproporphyrinogen 
III oxidase (hemN) could break down heme for transport (85), although no transport 
system has yet been characterized and the hemN protein is lacking in L. iners. The 
potential for L. iners to sequester iron in the Fe-S complex could limit the availability of 
iron to vaginal pathogens, and provide a competitive advantage against organisms unable 
to use iron in this iron-rich environment. 
Finally, we noted that all steps in the oxidative branch of the pentose phosphate pathway 
are present for the production of NADPH, an important molecule for the prevention of 
oxidative stress. 
3.3.11 Defense mechanisms 
The vagina harbors a highly diverse community of competing microbes. Bacteriocins are 
produced by vaginal lactobacilli and enterococci (86, 87) and the ability to resist their 
antimicrobial effects would be advantageous for L. iners survival.  No complete 
bacteriocin synthesis genes were found in the L. iners AB-1 genome, but three genes 
were found to encode putative bacteriocin immunity proteins. LINAB1_0852, identified 
by RAST as a microcin self-immunity protein, has 91.5% amino acid identity to a 
putative bacteriocin immunity protein of Finegoldia magna and greater than 60% identity 
to MccC microcin immunity family protein from various strains of S. pneumoniae. 
Resistance to microcin may be significant as it is an antimicrobial peptide produced by 
uropathogenic E. coli associated with aerobic vaginitis and urinary tract infection (88). 
This along with a bacitracin resistance protein (LINAB1_0937), and putative enteroicin 
A immunity protein supports the assertion that L. iners incorporates foreign genes that 
may contribute to its ability to resist vaginal eradication by these pathogens. Of note, L. 
iners AB-1 has an additional putative pore-forming hemolysin gene (LINAB1_0545) of 
Lactobacillus origin in addition to the horizontally-acquired cholesterol-dependent 
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cytolysin described previously. Three other proteins contain domains of the hemolytic-
related Tly family (89, 90) (LINAB1_0440, LINAB1_0684, LINAB1_0698). The 
hemolytic potential of L. iners speculatively may be used for defense, or may play a role 
in providing nutrients and surviving through menstruation.  Interestingly, L. iners AB-1 is 
exhibits clearing of sheep’s red blood cells in culture (Figures S11), but it is unclear 
whether the putative hemolysins or cholesterol-dependent cytolysin are responsible. 
3.4 Concluding remarks 
This study describes the smallest Lactobacillus genome reported to date, with a genome 
that appears highly adapted for a specialized niche environment. The genome contains 
the largest fraction of genes composed of conserved proteins within the clade, and it also 
has the largest fraction, and absolute number, of genes predicted to be acquired from 
foreign sources. The conserved genes are largely core metabolic proteins shared between 
lactobacilli. L. iners is present in the vagina that is deemed healthy, infected with BV, or 
has just been subjected to antimicrobial therapy (5, 7). Recent quantification of bacterial 
numbers in these different stages of vaginal health has demonstrated that the abundance 
of L. iners remains relatively constant despite fluctuating environmental conditions (9). 
This remarkable ability to survive under a range of conditions suggests that rather than L. 
iners being somehow associated with an aberrant microbiota, it may be an important 
member of the host’s defenses by being a persistent commensal lactobacilli involved in 
restoration and maintenance of the normal microbiota. Further analysis of the functional 
characteristics associated with the L. iners’ genome may uncover desirable characteristics 
of a commensal microbe that contributes to the maintenance, and potentially restoration, 
of a healthy and stable vaginal microbiota. 
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Chapter 4  
4 Comparative meta-RNA-seq of the vaginal microbiota 
and differential expression by Lactobacillus iners in 
health and dysbiosis 
This chapter is reproduced with permission (Appendix C) from: 
Macklaim, J.M., Fernandes, A.D., Di Bella, J.M., Hammond, J., Reid, G., and Gloor, 
G.B. (2013). Comparative meta-RNA-seq of the vaginal microbiota and 
differential expression by Lactobacillus iners in health and dysbiosis. 
Microbiome 1, 12. 
Supporting material for this chapter including Tables and Figures (labeled as S#) and 
supporting Material and Methods are available as a PDF online: 
http://www.microbiomejournal.com/content/supplementary/2049-2618-1-12-s1.pdf 
 
4.1 Introduction 
Studies using high-throughput metagenomic and 16S rRNA sequencing have identified 
over 250 bacterial types in the human vagina. Microbial profiles in women who are 
clinically healthy most often have a low diversity microbiota dominated by lactobacilli 
with the most common species being Lactobacillus crispatus, Lactobacillus iners, 
Lactobacillus jensenii, and Lactobacillus gasseri  (1-4). Conversely, for bacterial 
vaginosis (BV), an aberrant condition associated with increased risk of sexually 
transmitted infections and preterm labor (5, 6), several high-diversity, multi-species 
profiles have been reported (3, 7).  This makes the human vaginal microbiota different 
than other human microbial ecosystems where a high species diversity correlates with 
healthy conditions. For example and in contrast, inflammatory bowel disease is 
characterized by a loss of diversity (8). The vaginal microbiota is highly dynamic and 
bacterial populations can change rapidly between the healthy and BV states (1, 4, 9), but 
the cause for these transitions is unknown. The most frequently detected organism, 
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Lactobacillus iners, appears to have a streamlined genome adapted for persistence in the 
vagina (10). This organism is detected in women regardless of BV status (7, 11), but not 
much is known about how L. iners can adapt to these differing environments or its role in 
the etiology and pathogenesis of BV. 
Although there are numerous 16S rRNA studies of the vaginal microbiome that analyze 
the relative microbial composition (e.g. (1, 3, 12)), none have yet attempted to 
characterize the function of the microbiota using culture-independent methods. We 
therefore chose a meta-transcriptomic approach using RNA-seq to address the functional 
contribution of the bacterial community. We further sought to understand the function of 
Lactobacillus iners, an organism found nearly ubiquitously in the vagina. 
4.2 Materials and Methods 
4.2.1 Clinical samples 
Premenopausal women between the ages of 18-40 years were recruited at the Victoria 
Family Medical Center in London, Canada. The Health Sciences Research Ethics Board 
at the University of Western Ontario granted ethical approval for the study under HSREB 
#16183E. Participants were excluded from the study if they reached menopause, had a 
urogenital infection other than BV in the past 6 months, were pregnant, had a history of 
gonorrhoeae, chlamydia, estrogen-dependent neoplasia, abnormal renal function or 
pyelonephritis, were taking prednisone, immunosuppresives or antimicrobial medication, 
or had undiagnosed abnormal vaginal bleeding. Participants were asked to refrain from 
oral or vaginal intercourse and consuming probiotic supplements or foods for 48 hours 
prior to the clinical visit. No participants were menstruating at time of the clinical visit. 
After reviewing details of the study, participants gave their signed informed consent 
before the start of the study. Vaginal swabs were collected from four women: two with 
BV and two considered to have a non-BV vaginal microbiota (N) as diagnosed by Nugent 
scoring (13), and vaginal pH (Table S1).  A nurse obtained vaginal samples for RNA-seq 
using a Dacron polyester-tipped swab rolled against the mid-vaginal wall and 
immediately suspended in RNAprotect (Qiagen) containing 100 ug/ml rifampicin. A 
second swab collected in the same way was smeared onto a slide and air dried for Nugent 
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scoring (13) of bacterial vaginosis (Nugent scoring is presented in Table S1). Vaginal pH 
was measured using the pHem-alert applicator (Gynex). Samples for RNA extraction 
were incubated at room temperature for at least 10 minutes (to a maximum of 3 hours), 
and then centrifuged before discarding the supernatant and freezing the remaining pellet 
at 80˚C. Lysis and RNA extraction were performed within 3 weeks of storage. 
4.2.2 RNA isolation, mRNA enrichment, and sequencing 
Cell pellets were lysed in a 700 ul solution of 20 mg/mL lysozyme and 50 U/mL 
mutanolysin for 20 minutes at 37°C with periodic vortexing. After lysis, the samples 
were centrifuged (5500 x g for 15 minutes) and the supernatant was discarded.  The 
remaining pellet was used for RNA extraction by TRIzol (Invitrogen) according to the 
manufacturer’s protocol. After RNA isolation by TRIzol, 8-9 ug of total RNA was used 
for rRNA depletion using a single round of MICROBExpress (Ambion) according the 
manufacturer’s protocol. RNA quality and subsequent rRNA depletion was verified 
before and after the MICROBExpress treatment by Agilent 2100 Bioanalyzer 
(Bioanalyzer results before and after MICROBExpress treatment shown in Figure S1). 
Samples were DNase treated with the TURBO DNA-free kit (Ambion). Samples were 
sent to the Toronto Center for Applied Genomics (TCAG, Toronto, Ontario, Canada) for 
library preparation and sequencing by ABI SOLiD 4. 
4.2.3 Reference sequence library and mapping 
A total of 110 accessions representing 103 organisms (of 31 genera, and 63 species) 
isolated from or detected in the vagina were included in a reference sequence set for 
mapping (Table S4). The dataset represents the partial or complete genomes available 
from the NCBI database as of March 2011. These 234,991 sequences (including 230,031 
coding sequences) were clustered by sequence identity (95% nucleotide identity over 
90% sequence length) using CD-HIT-EST (14) to remove redundancy in the reference 
mapping set. A representative sequence (“refseq”) from each of the resulting 163,014 
clusters was used to build a Bowtie (15) colorspace reference library for mapping the 
RNA-seq reads. Reads mapped uniquely by Bowtie to a coding refseq were included in 
the differential expression analysis (all other unmapped reads were discarded). Reads 
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were trimmed from the 3’ end to 40 nt, and up to 3 mismatches were allowed. Reads with 
equal best hits were mapped at random to one of the locations. 
4.2.4 Functional assignment of refseqs 
SOLiD colorspace format precludes direct functional assignment of sequenced reads, and 
therefore annotations were assigned to the refseqs following mapping. Amino acid 
translations of predicted coding sequences were compared to the Clusters of Orthologous 
Groups of proteins (COGs) database (16) by rps-blast using an e-value cutoff of 1e-3 to 
assign a COG function. SEED Subsystems (17) were similarly assigned by blastp with an 
e-value cutoff of 1e-3. The KEGG Automatic Annotation Server (KAAS) (18) was used 
for annotation of enzyme functions (KOs) and mapping of metabolic pathways. All 
database comparisons and annotations were performed on the data available as of April 
2011. 
4.2.5 Statistical analyses for differential expression 
We used the ANOVA-Like Differential Expression (ALDEx) R package version 1.3.0 
(19) for differential expression analysis. Refseqs belonging to L. iners were used to 
evaluate differential gene expression at the single organism level. For differential 
expression of the meta bacterial community we modified the ALDEx package to group 
refseqs into higher functional levels (SEED subsystem4, and KEGG KO assignments). 
For genes or functional groups to be considered differentially expressed, we required a 
log2 relative difference ( ) of at least 2 for function-level analysis and at least 1.5 for 
L. iners gene-level analysis. To be considered differential we also required that  ≤ 
0.01, implying that less than 1% of the values in distributions between conditions 
overlap.  A brief description of the statistical framework is in the supplemental materials 
and presented in Figure S9. 
4.2.6 CRISPR spacer analysis 
CRISPR spacer sequences were downloaded from the CRISPRs database 
(http://crispr.u-­‐psud.fr/crispr/) and RNA-seq reads were mapped to these sequences 
as described for refseq mapping.  
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4.2.7 cpn60 reference mapping 
Sequences belonging to the cpn60 gene were downloaded from cpnDB (20) and were 
manually curated to remove redundant sequences (sequences with 100% identity to 
another sequence in the database) so that one representative sequence remained. RNA-
seq reads were mapped to this reference set as described for refseq mapping. 
4.3 Results and Discussion 
Vaginal swabs from four women were collected for RNA-seq of the bacterial 
transcriptome. Two women were diagnosed with BV and two with a non-BV (or 
“Normal”) vaginal profile according to Nugent score, vaginal pH, and signs and 
symptoms of the condition as noted by the examining clinician (see Table S1 for Nugent 
scoring). Sequenced reads were mapped against a reference coding sequence library 
(“refseqs” - See Methods) resulting in 5,487,128 to 10,635,713 uniquely mapped reads 
per sample; far exceeding the sequencing depth of recent RNA-seq studies (21-23). The 
number of unique refseqs mapped ranged from 10,770 to 22,860 per sample; with more 
refseqs expectantly identified in BV samples due to the higher microbial diversity 
(mapping is summarized in Table S2). Among all four samples, 33,412 unique refseqs 
were identified in total. To verify the completeness of our reference library and ensure no 
major known taxon was missing from analysis, we performed an independent mapping 
against a reference cpn60 gene database. The highly expressed cpn60 (or groEL) gene is 
nearly universally conserved in bacteria and contains variable sequence which allows for 
taxonomic discrimination (20), and unlike the rRNA molecules, is not depleted by the 
mRNA enrichment process. Mapped cpn60 reads representing at least 0.1% of the total 
cpn60 mapped reads are presented in Table S3. The data suggested that our reference 
library contained representative genomes for the most abundant organisms detected in 
our samples, and that any unavailable genomes would not make up an appreciable 
fraction of the bacterial or mRNA population. 
The fraction of mapped reads per taxon for each sample is represented in Figure 4-1A. 
The microbiota associated with health, samples N4 and N30, were dominated by 
lactobacilli (L. iners and L. crispatus) while those associated with BV, B27 and B31, 
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were a mixed population composed of lactobacilli and anaerobic organisms that included 
Prevotella, Gardnerella, and Megasphaera. The profiles are consistent with those from 
healthy and BV subjects studied by others (1-4), and corresponded to the Nugent profile 
for each sample (Table S1). 
 
Figure 4-1. Bacterial community structure and function 
(A) The distribution of all mapped mRNA reads for each taxon per sample. The two 
samples that were considered healthy (N4 and N30) are dominated by Lactobacillus 
crispatus with lesser amounts of L. iners and L. jensenii detected. The two samples 
having bacterial vaginosis (BV) have a lower relative proportion of lactobacilli and 
large proportions of Prevotella amnii, Gardnerella vaginalis, Megasphaera, and other 
anaerobic organisms. (B) Selected subsystem 2 and subsystem 3 categories showing 
enriched subsystem 4 functions under N or BV conditions. Each point represents a 
specific subsys4 function, and the magnitude of change in expression in plotted on the 
x-axis relative to the BV condition. Points are colored blue (non-BV) or red (BV) if 
significantly differentially expressed between conditions whereas grey points are not 
differential between the conditions. (C) Representation of the fractional taxon 
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contribution to functions significantly upregulated in BV (red points in B). Pairs of 
bars represent the two samples (B27 and B31) and each color is the fraction of reads 
for that function contributed by a particular taxon. 
Butyrate kinase, as part of the “Acetyl-CoA fermentation to Butyrate” subsystem, is 
highlighted to show the relationship between the differential functions in 1B and the 
taxonomic composition of the function in 1C. 
Gly: Glycerol, Gly-3P: Glycerol-3-phosphate, GL: Glycerolipid, GPL: 
Glycerophospholipid. 
The multi-organism composition of our samples, and the resulting gene diversity, violates 
assumptions of current differential RNA-seq analysis methods. These methods generally 
perform well when used to study the transcriptome of single organisms, however they 
implicitly assume that the expected between-condition difference is essentially a fixed 
effect (24, 25). Since each sample in this study was obtained from a different subject, a 
random-effect-type model is more appropriate. However, it can be problematic to use this 
model when there are not enough samples to accurately estimate the additional 
parameter(s) required by random-effect models. We therefore developed a specialized 
statistical framework termed “ANOVA-Like Differential Expression” or “ALDEx” (19) 
that infers differential expression by estimating the magnitude of between-condition 
expression difference with respect to within-condition expression difference. Thus genes 
(or functional groups) identified as differentially expressed between the N and BV 
conditions have a between-condition (N vs. BV) expression difference that is large in 
comparison to the within-condition (B27+B31 and N4+N30) variability. Furthermore, 
since we posit that biochemical function, not organism is the major unit of analysis for 
the vaginal microbiome the data were grouped via refseqs into functional groups (KO or 
SEED subsys4) unless otherwise noted. Functional-level analyses of metagenomic data, 
as opposed to gene-level, has been used previously (26). Unsupervised hierarchical 
clustering showed that samples were more similar when refseqs were grouped by 
function (Figure S2B) than clustering by refseq expression (Figure S2A).  We also noted, 
regardless of refseq grouping, the two BV samples were most similar to each other based 
on gene expression and were separable from the two N samples that also clustered 
together. Estimated between vs. within expression ratios along with read counts and 
annotations are presented in Table S8 (iners refseqs), Table S9 (subsys4), and Table S10 
(KEGG KOs). 
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4.3.1 Lactobacillus iners’ response to BV 
Lactobacillus iners is the most frequently detected vaginal organism, and is known for its 
consistent presence in N and BV states (1, 3, 27). We detected L. iners in our samples 
with an average coding sequence (CDS) coverage per sample ranging from 
approximately 5-fold to 117-fold (Table S5). This allowed us to uncover gene expression 
differences in this organism between the two vaginal conditions. 
We mapped a total of 1653 unique L. iners’ CDS with at least one read and refer to this 
set as the L. iners “pan-transcriptome” (Figure 4-2). There were 954 of the 1653 CDS 
present in all 12 L. iners genomes that represent the “core” expressed CDS set. The core 
functions, in general, had a high relative expression and low fold-change between 
conditions (Figure 4-2). A total of 207 CDS were inferred to be differentially regulated 
due to their large estimated between vs. within expression ratios. These ratios, along with 
read counts and annotations, are presented in Table S8. 
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Figure 4-2. Circular representation of RNA-seq data for the Lactobacillus iners 
pan-transcriptome 
RNA-seq reads were mapped to 12 available L. iners’ genomes (listed in Table S3) 
after clustering redundant coding sequences by nucleotide identity (see Materials and 
Methods). Breaks in the circle separate blocks of contiguous coding sequences (CDS) 
ordered by scaffolding on the genome assemblies (Ring ). The height of the plot 
represents how many of the 12 genomes the CDS occurs. The first contiguous block 
(dark blue) are the 954 CDS present in all genomes and are considered the “core” L. 
iners gene set. Ring  shows the COG color-coded function of each CDS. Ring  
The differential expression of each CDS between Non-BV and BV samples. The 
absolute height of the bar shows the fold-change (log2) in expression (positive for up 
BV, and negative for up non-BV). Bars are colored if significantly differential (red for 
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BV and blue for non-BV). Regions of interest are labeled in the centre of the circle. 
Rings  and  show a heatmap representation of the median CDS expression in 
BV and Non-BV respectively. Darker blue represents higher expression. Regions of 
interest noted in the results are marked by lettered triangles. 
Amongst the most highly differentiated CDS were eight contiguous genes encoding the 
proteins for the CRISPR anti-bacteriophage defense system and include the 5-member 
(CasA-CasE) protein complex, Cascade (CRISPR-associated complex for antiviral 
defense) (28). These CRISPR-related genes were highly expressed only under BV 
conditions (Figure 4-1BC and Figure 4-2) suggesting that L. iners is responding to an 
altered environmental phage load. Interesting, the cas proteins were only present in 4/12 
L. iners genomes (Figure 4-2) which raises the question of strain-specific adaptations to 
the vaginal environment that could not be identified by 16S rRNA profiling. It is also 
possible that these differences reflect different genome assembly qualities.  We noted that 
restriction-modification systems were also highly upregulated by L. iners in BV (Figure 
S3), perhaps as further defense against bacteriophage infection. 
The cas proteins, as part of the CRISPR anti-bacteriophage system, regulate the insertion 
and presentation of small pieces of DNA spacer sequences in the bacterial chromosome 
used to inactivate attacking phage DNA (29). We therefore probed our RNA-seq data for 
evidence of CRISPR spacer sequences and detected between 21,477 and 225,242 
potential CRISPR spacers per sample of which the vast majority corresponded to known 
sequences of Lactobacillus origin (Table S6).  Examining the meta-RNAseq data also 
revealed 6 highly upregulated CRISPR-associated proteins (Figure 4-1B). Most of the 
reads were contributed by L. iners (as described above), but there was shared expression 
of these functions by Gardnerella vaginalis and Megasphaera, and one of the cas 
proteins was expressed only by Prevotella species (Figure 4-1C). Our observations are 
supported by recent evidence that several Lactobacillus-specific bacteriophage have been 
isolated from women in South Africa with and without BV (30), and that metagenomic 
data from the Human Microbiome Project has also revealed a diversity of CRISPRs in 
every body site with an abundance of Lactobacillus-targeting phage sequence in the 
vagina (31). 
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A notable core CDS, a cholesterol-dependent cytolysin (CDC) encoded by L. iners (10), 
was upregulated at least 6-fold in BV (Figure 4-2B).  This CDCis active between pH 4.5 
and 6 (32) which corresponds to the elevated pH range of BV (33). The predicted protein 
is similar to vaginolysin, another CDC present in Gardnerella vaginalis that is 
upregulated at least 256-fold in the meta-RNA-seq analysis (Table S9). Vaginolysin has 
been shown to have cytotoxic activity towards human erythrocytes, vaginal epithelial, 
and cervical cells (34). This raises the possibility that the L. iners-encoded CDC may play 
an unappreciated role in BV and might contribute to the pathogenesis of the condition. 
Examination of the distribution of expressed reads assigned to COG functions showed an 
increase in transcriptional effort by L. iners for Carbohydrate Transport and Metabolism 
and a number of individual CDS under this category were upregulated in BV (Figure S4). 
In the genomic context, three separate loci involved in carbohydrate uptake were up-
regulated 3- to 9-fold in BV (Figure 4-2: two loci are marked in the region labeled A and 
the third by C). The first is a broad-specificity phosphoenolpyruvate-dependent transport 
system (PTS) of the mannose-family along with a putative regulator of the mannose 
operon, ManO, possibly targeting carbohydrate moieties of the vaginal mucosa (10). This 
PTS is conserved in all 12 genomes of L. iners suggesting its functional importance to the 
organism in the vagina. A second region, also conserved across all sequenced L. iners 
genomes, contains an ABC-type maltose transport system next to a maltose 
phosphorylase suggesting a preference for maltose uptake under BV. The source of 
maltose could be from breakdown of glycogen by L. iners, and consistent with this, there 
are four upregulated glycosylases predicted to target α-1,6-glucocidic linkages that bridge 
the branching points in glycogen. The third locus related to carbohydrate utilization 
contains a second mannose-family PTS flanked by an oligo-1,6-glucosidase de-branching 
enzyme and a LacI family transcriptional regulator. This region is present in only 6 of the 
12 available L. iners genomes and suggests that only a subset of strains are able to use 
these genes for adaptation during BV.  
Though glycogen is thought to be the major carbon source for vaginal bacteria (35), we 
surprisingly noted under BV conditions the up-regulation of a tandem set of three genes 
related to glycerol metabolism including a glycerol kinase, a glycerol-3-phosphate 
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dehydrogenase, and a glycerol facilitator (glpF) (region marked “D”  in Figure 4-2). The 
genes together suggest that L. iners is able to uptake glycerol for conversion to glycerol-
3-phosphate and then glycerone phosphate for entry into glycolysis or 
glycerophospholipid metabolism. 
We examined the glycerol utilization genes in the context of the meta-transcriptome 
(Figure 4-1B and C). The glpF glycerol transporter and downstream glycerol kinase are 
highly expressed by both L. iners and L. crispatus and therefore results in no differential 
expression of these genes at the community level. In addition to the glpF transporter, L. 
iners and L. crispatus express a UGP-type glycerol-3P transporter more strongly under N 
conditions.  Prevotella amnii, a BV-associated organism, also expressed an independent 
glycerol-3P uptake system (glpT) (Table S9). Bypassing the ATP-using phosphorylation 
of glycerol by glycerol kinase, glpT and ugpB/E allows direct uptake of glycerol-3-
phosphate which the organism can use for phospholipid biosynthsis or conversion to 
glycerone-P using glycerol-3-phosphate dehydrogenase (expressed highly in BV) for 
entry into glycolysis. Two enzymes (Glycerol-3-phosphate cytidylyltransferase and 
Glycerol-3-phosphate O-acyltransferase) are expressed highly under N conditions by L. 
iners and L. crispatus and indicate glycerol-3P is also converted into products for 
lipoteichoic acid and glycerophospholipid synthesis. The overall high expression and the 
differential transcription of these glycerol-related genes suggests glycerol is an 
underappreciated molecule in the vaginal bacterial ecosystem. 
As an additional evaluation of gene expression by L. iners, we collected and sequenced 
mRNA from a single L. iners strain, AB-1, grown to mid-log phase in MRS broth (Difco, 
BD). Figure S10 and Table S8 summarize the mapping and gene expression for this 
sample. Similar to the in vitro expression data, core genes were highly expressed in vitro 
and many potentially strain-specific genes were not detected. Regions for carbohydrate 
uptake and metabolism (marked A, C, and D in Figure 4-1 and Figure S10) were amongst 
the most highly expressed. One notable difference between the in vitro expression 
compared to the clinical samples was the lack of CRISPR expression (region E in Figure 
4-1A and Figure S10).  Also notable, the cytolysin is highly expressed under culture 
conditions. These data show that genes that may be key for L. iners’ survival in the 
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vagina are induced under in vitro conditions opening possibilities for future experiments 
to test gene expression and the responding phenotype. 
4.3.2 The vaginal community in BV 
As described in Materials and Methods, we grouped refseqs (representing genes from one 
or multiple organisms) by their annotated function in order to evaluate functional 
differences between N and BV that may be contributed by multiple organisms. Using 
SEED Subsystem annotations, we estimated expression differences for subsys level 4 
functions using ALDEx (output is presented in Table S9). The expression of subsys4 
level functions were visually represented in two ways: 1) As strip plots where the subsys4 
functions were plotted by absolute fold-change between conditions (Figure 4-1B, and 
Figures S5ABC) colored by significance and 2) as heatmaps where the summed 
expression value for each subsys4 was averaged over the number genes per function 
(Figures S6ABC). The strip plot allows us to visualize under which functional category 
the subsys4 functions are binned, while the heatmaps demonstrate the transcriptional 
effort by the community for each function based on the subsys4 expression relative to the 
average expression of all subsys4. In addition to identifying differential functions, we can 
show the taxonomic composition of the function (Figure 4-1C and Figures S7 and S8) 
allowing us to discern which organisms are producing transcripts for each function. 
At the broadest functional level (SEED subsystem 1), the most highly expressed subsys4 
functions in both conditions belong to general cell maintenance and information 
processing functions such as Cell Division and Cell Cycle, Nucleosides and Nucleotides, 
and RNA and DNA metabolism (Figure S6A). However, many of the differentially 
expressed subsys4 functions for these categories were more highly expressed under the N 
condition (Figure S5A).  The trend was conserved at the more specific SEED subsystems 
level 2 and level 3 (Figures S5BC and S6BC). This management of cell growth and 
proliferation is consistent with known constraints on apportioning cellular resources (36). 
We suggest that some of the transcriptional resources are necessarily diverted from 
housekeeping tasks to other functions in BV because of the greater diversity of organisms 
with a wider array of metabolic capabilities. 
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Similar to the findings for L. iners, several functions related to carbohydrate metabolism 
were found to differ between N and BV at the SEED subsystem 2 and 3 levels 
(Summarized in Figure 4-1B and Figure S5BC). The BV samples were enriched at 
subsystem 2 functional categories of Glycoside hydrolases, and Polysaccharides, and also 
at subsystem 3 in Cellulosome, and Glycogen metabolism. The functions belonging to 
these categories are enzymes involved in uptake, degradation, and metabolism of glycans. 
Considering the context of the vagina, these glycan targeting genes are likely used for the 
metabolism of glycogen which accumulates in the vaginal epithelium (37). The genes 
involved in these functions largely belong to Prevotella amnii and some to Gardnerella 
vaginalis (Table S7). In addition to several glycosidases and glycosyltransferases, there 
are components of an outer membrane-bound “starch utilization system” (Sus), belonging 
to Prevotella amnii, which are expressed in BV and have been implicated in binding and 
transporting of starch by several intestinal bacteria (38). Interestingly, the upregulation of 
a “starch phosphorylase” gene by Prevotella amnii indicates it may be able to synthesize 
glycogen via UDP-glucose; a phenomenon observed in other Prevotella isolated from the 
ruminal gut (39). This could allow Prevotella to control carbohydrate resources by 
storing excess for a time when it might be needed due to growth needs, or limits in 
environmental carbon sources.  Supporting glycogen as an important carbon source for 
the BV organisms is the up-regulation of oligo-1,6-glucosidase and glucokinase: the 
enzymes responsible for directing glycogen into glycolysis via alpha-D-glucose. 
Similar to the SEED subsystem analysis, we next grouped the refseqs by KEGG KO 
numbers for differential expression analysis. We used the KO and EC assignments to 
place differential functions in corresponding KEGG pathways to examine the community 
gene functions in the context of linked metabolic pathways.  Examined this way, the two 
conditions differed primarily in energy metabolism. The major steps of glycolysis and the 
conversion of pyruvate to lactic acid was upregulated under N indicating that lactic acid 
was the main metabolic end-product; consistent with the predominance of lactobacilli in 
these samples. In contrast, for the BV state SEED subsystem 2 (Figure 4-1B and Figure 
S5B) showed a number of upregulated functions in electron donating reactions belonging 
to steps of the TCA cycle and oxidative phosphorylation leading to the production of 
succinate. A high ratio of succinate to lactic acid was the original marker of BV (40, 41), 
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and high succinate concentrations distinguish BV from the similar but distinct condition 
of aerobic vaginitis (AV) (42). Increasing succinate at the expense of lactate results in a 
self-perpetuating condition whereby an elevated pH and a more reduced environment 
(43) supports the growth of the anaerobic bacteria noted in BV. In addition to succinate, 
we observed an up-regulation of butyryl-CoA dehydrogenase and butyrate kinase leading 
to butyrate production from acetyl-CoA under BV conditions. Examination of these 
functions linked to butyrate production in SEED subsystems showed these were 
expressed largely by Prevotella amnii and by Megasphaera. Butyryl-CoA dehydrogenase 
and butyrate kinase are shown as first and second enzymes in the “Acetyl-CoA to 
Butyrate” function in Figure 4-1C. These short-chain fatty acids have been shown to 
modulate immune function in the vagina and these anti-inflammatory properties may 
contribute to the non-inflammatory nature of BV in contrast to the inflammatory aerobic 
vaginosis (AV) condition (42, 44, 45). 
One of the distinctive characteristics of symptomatic BV is the “fishy” odor upon 
application of 10% KOH attributed to increased polyamines in the vaginal fluid produced 
by amino acid breakdown (46). Prevotella amnii expressed an arginine decarboxylase 
under BV conditions which could facilitate the synthesis of putrescine from arginine. 
Interestingly, we also noted a spermidine synthase gene expressed by Dialister and 
Megasphaera in BV which can convert putrescine to another polyamine, spermidine. 
Although Dialister is a minor constituent of our samples, it has been detected in vaginal 
studies and associated with diverse microbiota profiles indicative of BV (1, 7). This could 
indicate that production of odor is a cooperative process depending on the particular 
microbiota composition. Indeed, odor is not universally detected in women who are BV-
positive by Nugent (47), and previous studies suggest that particular taxa are more 
associated with odor (3, 48). Symbiotic relationships may be common in the vaginal 
environment as another has been described where Gardnerella vaginalis produces amino 
acids that promote the growth of Prevotella bivia (49). 
4.4 Concluding Remarks 
We used a novel method to characterize the conserved differences between the meta-
transcriptome of two healthy and two BV microbial communities. Despite having four 
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distinct microbial populations, our results show that each condition displays a set of 
conserved metabolic capabilities that, while influenced by the organisms present, is 
largely conserved between samples of differing structure. A summary of major findings 
is presented in Figure 4-3. The predicted metabolic end-products are known to produce 
the acidic or strongly reduced environments associated with health or BV respectively. 
Surprisingly, glycerol may have an underappreciated role in this environment with 
expression profiles suggesting upregulation of pathways to use glycerol as a carbon 
source under BV conditions. The source of glycerol is unknown, but it is an abundant 
component of mammalian and bacterial cell membranes, and extracellular glycerol levels 
are used in clinical practice to measure loss of cellular integrity. Thus, the rupture of cells 
by cytolysins expressed by L. iners and G. vaginalis, as well as lipase activity could 
release glycerol and glycerol components into the environment. 
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Figure 4-3. Overview of predicted differential functions of the vaginal microbiota 
based on RNA-seq analysis 
The predominant lactobacilli present in the healthy condition results in a relatively 
simple environment where carbohydrates are converted to lactic acid. This results in a 
low pH and inhibition of the growth of other anaerobic organisms.  The more 
complex microbial composition in BV results in an increase in cell lysis, and an 
increase in carbohydrate availability. In this case, the carbohydrates are converted to 
succinate and other short chain fatty acids that can modulate host immunity, increase 
the pH and increase the reducing environment. Concomitant with this is an increase in 
bacteriophage load, and the potential for several organisms to co-operate to produce 
the malodorous compounds found in some cases of BV. 
The BV-associated organism Prevotella amnii showed enhanced glycogen extraction 
during BV, as well as the ability to synthesize its own glycogen. We posit a possible 
symbiotic relationship between the BV-associated organisms in our samples for the 
production of polyamines responsible for vaginal odor during BV. 
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We additionally found that the vaginal microbiota is responding to bacteriophage 
populations differently in healthy and BV conditions. Several longitudinal studies show 
rapid unexplained shifts in the vaginal microbiota (4, 9), and one study suggested that 
phage have a role in the depletion of lactobacilli during episodes of BV (50). This idea is 
supported by a recent study of viruses in the human fecal microbiota which proposed that 
phage populations may be markers of change in the bacterial community (51). 
We describe a different expression profile of Lactobacillus iners in health and BV. The 
persistence of L. iners under these drastically differing environments (different pH, 
different bacterial population composition, and different bacterial load) could be due to 
its ability to respond and regulate its genomic functions. We suggest some of these 
regulated functions, such as specific carbohydrate uptake, bacteriophage defense, and a 
cytolysin, could be adapted for survival during episodes of BV. Some expressed 
functions were attributed to a subset of the L. iners genomes. Strain-specific functions of 
the microbiota, often overlooked by current 16S rRNA sequencing studies, can be 
extracted using function-based sequencing. Further investigation into the role of L. iners 
as a passive or active participant in the etiology and pathology of BV could help us 
understand this highly prevalent condition. 
Overall, examining the meta-vaginal transcriptome has highlighted the complexity of this 
environment. The large difference in bacterial function between the two conditions 
emphasizes our need to better understand the interactions between species in the context 
of the rest of the community and of the host. It is likely that examination of additional 
microbiota types associated with health and BV will identify similar broad patterns, but 
will provide additional insights into the association between host symptoms and the 
action and products of the microbiome. 
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Chapter 5  
5 Effect of antimicrobial and probiotic therapy on the 
vaginal microbiota 
This chapter is based on a manuscript under editorial consideration for publication at 
Science Translational Medicine. 
Supporting Table S5-1 is available for download as an additional file (.xlsx) 
5.1 Introduction 
The vaginal microbiome plays an important role in health and disease. Two of the most 
common medical problems for women are bacterial vaginosis (BV) and vulvovaginal 
candidiasis (VVC) (1, 2). Therapy for these conditions has changed little in over 40 
years, and recurrences of both conditions are extremely common, reducing quality of life 
for many women (3-5). The antimicrobial failures are likely due to drug resistance, 
failure of the agents to penetrate and eradicate biofilms, and inability to restore bacterial 
homeostasis. Our recent clinical studies reported that adjunctive oral use probiotic 
Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 for 28 days with 2g 
single dose of tinidazole resulted in a higher cure rate (87.5% by Amsel criteria and 
75.0% by Nugent criteria) versus 50.0% (Amsel) and 34.4% (Nugent) with tinidazole and 
placebo (6). The same dosage of probiotics and single dose of fluconazole (150 mg) 
improved the cure rate of VVC (defined as having no vaginal discharge, itching and/or 
burning vaginal feeling, dyspareunia and/or dysuria, and Candida recovered by culturing) 
from 10% to 35% compared to fluconazole treatment alone (7). 
We hypothesized that the probiotics therapy helped restore a Lactobacillus-dominated 
microbiota, based upon previous clinical and in vitro studies (8, 9). We investigated this 
by performing targeted sequencing of the V6 region of the 16S rRNA gene from the 
vaginal samples we had collected before and after the tinidazole therapy in 62 
premenopausal women with BV. In the case of VVC, the condition is not associated with 
depletion of lactobacilli or an abnormal microbiota profile per se (10), so the aim of the 
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sequencing of samples from 55 women was to confirm these previous findings and 
generate a testable hypothesis that would explain why probiotics can increase the cure 
rate for this condition. 
5.2 Materials and Methods 
5.2.1 Clinical samples and study design 
Vaginal swabs were collected from Brazilian women as part of previous clinical studies 
(6, 11, 12), and were stored at -80°C until DNA extraction for amplification and 
sequencing. The samples were obtained from subjects diagnosed with bacterial vaginosis 
(BV) (N=62) by Amsel (13) and Nugent (14) criteria before treatment, and a second 
sample was collected four weeks following randomized treatment. Patients were 
randomized into one of two treatment groups, either probiotic or placebo. For both 
groups, treatment consisted of a single 2g dose of tinidazole plus either two oral capsules 
of L. rhamnosus GR-1 and L. reuteri RC-14 or two placebo capsules taken daily in the 
morning, for twenty-eight days starting on the first day of tinidazole use as per the 
published study (6). The placebo group received two gelatin capsules containing cellulose 
and magnesium stearate that were also taken daily in the morning for twenty-eight days 
starting on the first day of tinidazole treatment. Due to failure of PCR amplification, we 
dropped 2 patients (one from each treatment group) from the dataset compared to the 
original study by Martinez et al., 2009 (6) resulting in 62 patients in this study compared 
to 64 originally. 
In a separate but similar study, vaginal swabs were obtained from women diagnosed with 
vulvovaginal candidiasis (VVC) (N=55) by positive Candida and signs of vaginal 
irritation and discharge and excluding women having BV as assessed by Nugent scoring. 
Women were randomized into two groups where both groups received a single 150 mg 
dose of fluconazole (an anti-fungal). Women in the probiotic group were also 
administered two oral capsules of L. rhamnosus GR-1 and L. reuteri RC-14 taken daily in 
the morning for twenty-eight days starting on the first day of fluconazole use (7). The 
placebo group received two gelatin capsules containing cellulose and magnesium stearate 
that were also taken daily in the morning for twenty-eight days starting on the first day of 
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fluconazole treatment. Swabs for biota profiling were collected at the end of the 28-day 
period. Single time point vaginal swabs were also collected from a population of healthy, 
age-matched Brazilian women (N=63) with no signs or symptoms of vaginal irritations or 
infections, and with a low, or “normal”, Nugent score of 0-3. 
Each subject signed an informed consent under a protocol (Protocol No. 0146) approved 
by the Ethics Review Board at the CSE-FMRP-USP. This study was registered online at 
Comissão Nacional de Ética em Pesquisa (CONEP; Document No. 070202), Brazil. The 
details of the clinical study design are described in the original study paper by Martinez 
et al. (6) as follows: 
“Identical vials containing probiotics and placebo were received from the manufacturer in 
separated boxes with 2 different colors and they were random numbered, by staff not 
participating in the study, in the laboratory at Universidade de São Paulo, Brazil. 
Investigators were blinded to the randomization code until all data were analyzed. Equal 
parts of probiotics and placebo vials were placed in plastic bags and given to 
investigators to take to their health centers and randomly distribute to patients enrolled in 
the study. The subjects were treated on a firstcome basis with a single dose of tinidazole 
(2 g) plus either 2 oral capsules of L. rhamnosus GR-1 and L. reuteri RC-14 or 2 placebo 
capsules taken daily in the morning for 28 days, starting on the first day of tinidazole use. 
Assuming an anticipated cure rate of 60% in the control group arm, a minimum of 25 
subjects per group was required to detect an increase in the cure rate as compared with 
90% in the group supplemented with the probiotic microorganisms, assessed at the 2-
sided 5% level of significance with 80% power. 
After 4 weeks of treatment, the same procedure adopted during the first appointment with 
the gynecologist was performed. The presence of any symptoms and signs (vaginal 
discharge, fishy odor, or burning and itching vaginal feeling) or possible side effect 
related to the drug and (or) probiotic were recorded. The investigators remained blinded 
to the study codes until all analyses had been completed.” 
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5.2.2 V6-targeted 16S rRNA gene sequencing 
Swabs were vigorously shaken in 1mL PBS (pH 7.5) to dislodge cell material. DNA 
extraction was performed using the InstaGene Matrix (Bio-rad) according to 
manufacturer instructions. Amplification of the V6 region of the bacterial 16S rRNA 
gene was performed as described previously (15), using unique barcode sequences 
embedded in the V6 primers for each sample. The V6 region was chosen specifically due 
to length restrictions on the Illumina GAIIx, which was the platform available to us at the 
time of sequencing, and for the ability to easily distinguish Lactobacillus and 
Gardnerella species (15, 16). The amplified products were pooled for Illumina GAIIX 
100bp paired-end sequencing at the Next Generation Sequencing Facility at The Centre 
for Applied Genomics (TCAG) at the Hospital for Sick Children in Toronto, Canada. 
5.2.3 Sequence processing 
Paired reads were overlapped using Xorro (https://sourceforge.net/projects/xorro-
overlap/) (17) to give full-length V6 sequence. Sequences with at least 97% identity were 
clustered into operational taxonomic units (OTUs) using UClust v. 3.0.617 (18). The 
most abundant sequence in each OTU cluster was used for taxonomic assignment by 
RDP SeqMatch (19). From the top 20 matches to the RDP named isolates database, the 
full taxonomy was retained for matches with the highest S_ab score. For multiple top 
matches with equal scores, the lowest common ancestor in the taxonomy was retained 
(e.g. genus level if multiple species matched equally well). Taxonomy assignment was 
verified by BLAST (20) to a custom V6 vaginal organism database. Up to 1 mismatch 
was accepted as a hit. The read counts table and OTU taxonomy are presented in a 
Supplementary Data File: Table S5-1. 
5.2.4 Data analysis 
Weighted UniFrac distances (21) between samples were calculated in QIIME (22) by 
using a phylogenetic tree of OTU sequences built with FastTree (23). The phylogeny was 
based on an OTU sequence alignment with MUSCLE (24) since alignment to a 
consensus model was not possible with the short hypervariable V6 sequences. Shannon’s 
diversity was calculated for each sample in QIIME. Figures were generated and statistics 
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were performed in R (25). Welch’s two-sample t-test was used to compare UniFrac 
distances before and after treatment between groups. 
5.3 Results 
5.3.1 The normal vaginal microbiota in pre-menopausal 
Brazilian women 
The healthy, asymptomatic vaginal samples set the baseline for the expected bacterial 
profiles in the population (Figure 5-1). Most of 63 samples showed a dominance of 
Lactobacillus spp. with 44/63 samples (69.9%) having at least 60% of the sequences 
belonging to the Lactobacillus genus. Lactobacillus iners and L. crispatus were the 
predominant species. As expected, this population had a low Shannon diversity (Figure 
5-2) because the microbiota composition is dominated by a few abundant organisms. 
After Lactobacillus, Gardnerella spp. was the next most abundant genus, and along with 
Prevotella and Megasphaera sequences, were abundant in samples with < 60% 
Lactobacillus. 
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Figure 5-1. Genus-level bar plot of vaginal bacterial abundance measured by V6 
sequencing in 63 healthy, asymptomatic Brazilian women 
Lactobacillus iners and L. crispatus are plotted at the species level. Since sequences 
belonging to Lactobacillus are plotted first (from the bottom). The average-linkage 
dendrogram at the top represents the weighted UniFrac distance between samples. 
The major clusters defined by the major branch points are samples dominated by L. 
crispatus, L. iners, or a mixture of organisms. Most samples (44/63 = 69.9%) are 
dominated by at least 60% Lactobacillus sequences. The color legend shows the top 
14 most abundant taxa and applies to Figure 5-1, Figure 5-3, and Figure 5-6. 
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5.3.2 Vulvovaginal candidiasis (VVC) study 
As shown in Figure 5-3 (top row) women with VVC generally had Lactobacillus-
dominated profiles (40/55 = 72.7% with >= 60% Lactobacillus spp.) with L. iners and L. 
crispatus being the most predominant species. The distribution of profiles was similar to 
those in the healthy, asymptomatic group. The bacterial diversity in the VVC group 
before treatment, as measured by Shannon’s diversity index in Figure 5-2, was similar to 
that of healthy women (median value of 1.76 in VVC and 1.88 in healthy).  
 
Figure 5-2. Distribution of Shannon diversity 
The Shannon diversity index was calculated for all biota samples at time 0 (before 
treatment) plotted by group. The bacterial diversity of women with BV was much 
higher than the healthy women or women with VVC. 
The UniFrac phylogenetic distance metric was used to measure the phylogenetic distance 
between each before/after treatment pair in the placebo and control groups. A lower 
UniFrac score indicates more similarity between the compared biota with a score of 0 
representing biota profiles exactly the same in bacterial presence and abundance, while a 
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score of 1 represents profiles with no overlapping bacterial sequences (21). Figure 5-4 
shows box plots of the paired UniFrac distance measures for the placebo and probiotic 
treatment groups. 
 
Figure 5-3. Genus-level bar plot of vaginal bacterial abundance measured by V6 
sequencing in women diagnosed with vulvovaginal candidiasis (VVC) 
Lactobacillus iners and L. crispatus are plotted at the species level. Since sequences 
belonging to Lactobacillus are plotted first (from the bottom) the dashed line at the 
0.6 fraction represents 60% Lactobacillus abundance in the samples. Like the healthy 
asymptomatic women (Figure 5-1) most profiles show a dominance of lactobacilli 
before treatment (top row). Women were randomized into two groups to receive 
fluconazole plus either a placebo (“placebo” group) or oral probiotic L. reuteri RC-14 
+ L. rhamnosus GR-1 (“probiotic” group) with the biota after treatment plotted on the 
bottom row. Patient biota before and after treatment are vertically aligned and patients 
are plotted in the same order. The taxonomy figure legend is presented as part of 
Figure 5-1. 
After treatment with fluconazole and probiotic or placebo, there was little change in the 
bacterial microbiota as measured by the UniFrac distance. The low UniFrac distance 
between paired samples before and after treatment (probiotic group median = 0.08, 
placebo group median = 0.17) indicates there is high similarity in the bacterial profiles 
before and after treatment. Additionally, there was no significant difference between the 
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probiotic and placebo groups (t = -1.5189, df = 49.13, p-value = 0.1351 and 95% 
confidence interval (CI) = -0.22 to 0.03). Plotting the change in relative abundance for 
the top most abundant organisms also showed there was little shift in either the placebo 
or probiotic group (Figure 5-5). We also examined the UniFrac distances between all 
pairs of samples before treatment vs. between all other samples and noted that the median 
distance between samples of different individuals was greater (probiotic = 0.26, placebo 
= 0.31) than the distance between the same individual before and after treatment 
(probiotic = 0.08, placebo = 0.17). This indicates there was less intrapersonal variation in 
the bacterial profiles before and after treatment than interpersonal variation in the 
population. 
 
Figure 5-4. Paired UniFrac distance between individual patients before and after 
treatment for BV or VVC 
The weighted UniFrac distance was calculated for each sample pair before and after 
treatment as described in the Materials and Methods. There is no significant 
difference between treatment groups in the VVC study. A significant difference in 
UniFrac distance was found between the placebo and probiotic treated BV groups (p 
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= 0.0009187 by Welch’s two sample t-test) suggesting a larger shift in the microbiota 
occurred in the probiotic group compared to the placebo group. 
 
Figure 5-5. Violin plots showing the change in bacterial abundance within patients 
before and after treatment 
The top 6 most abundant genera are plotted for BV (top row) and VVC (bottom row). 
Organism colors match the bar plots (Figure 5-1, Figure 5-3, Figure 5-6) and legend 
(Figure 5-1). The white dot represents the median, and the thicker black line is the 
range from the lower to upper quartile. The thickness of the plot represents the density 
of points at that value. The plots show there is little change in abundance following 
treatment for both VVC groups and BV treated with tinidazole + placebo, but an 
increase in Lactobacillus abundance in the probiotic-treated BV group at the expense 
of Gardnerella vaginalis, Prevotella, Megasphaera, Atopobium, and Sneathia spp. 
5.3.3 Bacterial vaginosis (BV) study 
As shown in Figure 5-6 top row, the initial BV microbiota profiles were similar to those 
of other women with BV as previously reported (26, 27). In general, Lactobacillus-
dominated profiles were rare compared to the healthy and VVC groups with only 6/62 = 
9.7% women having >= 60% Lactobacillus sequences. The BV group had far more 
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bacterial diversity (as measured by Shannon diversity) than the VVC or healthy 
populations (Figure 5-2). 
 
Figure 5-6. Genus-level bar plot of vaginal bacterial abundance measured by V6 
sequencing in women diagnosed with bacterial vaginosis (BV) 
Lactobacillus iners and L. crispatus are plotted at the species level. Since sequences 
belonging to Lactobacillus are plotted first (from the bottom) the dashed line at the 
0.6 fraction represents 60% Lactobacillus abundance in the samples. Profiles before 
treatment show a lack of lactobacilli and an abundance of Gardnerella vaginalis, 
Prevotella, Megasphaera, and Atopobium. Women had been randomized into two 
groups to receive tinidazole plus either a placebo (“placebo” group) or oral probiotic 
L. reuteri RC-14 + L. rhamnosus GR-1 (“probiotic” group) with the biota after 
treatment plotted on the bottom row. Patient biota before and after treatment are 
vertically aligned and patients are plotted in the same order. The symptomology as 
measured by Amsel and Nugent are indicated in the heat map below the bar plots. The 
top row is presence (dark grey)/absence (white) of pH > 4.5, 2nd row is 
presence/absence of fishy odor from application of KOH, 3rd row is presence/absence 
of milky white discharge. The final row represents the Nugent status (BV = dark grey, 
intermediate = light grey, Normal = white). The taxonomy figure legend is presented 
as part of Figure 5-1. 
As with the VVC group, we analyzed the change in microbiota by measuring the UniFrac 
distances between paired samples before and after treatment (Figure 5-4). We found that 
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the variation in the initial time point for the treatment groups was similar with a median 
UniFrac distance of 0.35 for both the probiotic and placebo group and an interquartile 
range (IQR) of 0.29 and 0.31 respectively. We observed that the tinidazole with placebo 
treatment had a very small effect on the microbiota composition relative to the initial 
composition, with a median UniFrac distance of 0.22 with an IQR of 0.18. In contrast, the 
tinidazole with probiotic treatment resulted in a large shift in UniFrac distance with a 
mean distance of 0.57 with an IQR of 0.52. The range of values in the two treatment 
groups were distinct with a mean difference of 0.22, 95% CI of 0.09 to 0.36, indicating a 
large effect of the probiotic treatment. Because each sample contributed to only one 
UniFrac distance (before/after treatment for the same subject), and the placebo and 
control groups were non-overlapping, the usual concerns about lack of statistical 
independence in sets of distances isolated from a distance matrix do not apply here. We 
therefore used a Welch’s two sample t-test to test the hypothesis that the placebo and 
probiotic treatments resulted in equivalent shifts in the microbiota, and observed that they 
were statistically different, p-value = 0.0009187 (t = 3.4216, df = 56.934). We conclude 
that the probiotic plus tinidazole treatment had a significantly larger effect in altering the 
microbiota composition than tinidazole treatment alone, and led to the final communities 
closely resembling the healthy communities (Figure 5-1). 
Examination of the taxonomic bar plots (Figure 5-6) suggests that the major reason for 
the large shift in the microbiota was the acquisition of lactobacilli in many members of 
the probiotic cohort, and specifically L. iners. The change in abundance can be seen more 
easily in Figure 5-5 top row, where the relative change of the most abundant organisms is 
plotted. Here it is obvious that the relative abundance of L. iners, and L. crispatus, 
increased in the probiotic cohort after treatment at the expense of G. vaginalis, Prevotella 
spp., Megasphaera spp. Atopobium spp., and Sneathia spp. In contrast, there is very little 
change in these organisms in the placebo group. Correspondingly, after treatment the 
median Shannon’s diversity was lower in the probiotic group (median = 2.15) compared 
to the placebo group (median = 2.78). 
Clinical signs of BV were measured before and after the intervention by Nugent (14) and 
Amsel (13) criteria. The Nugent scoring system involved a Gram-stained vaginal smear 
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where bacterial morphotypes presumable Lactobacillus, Gardnerella, and Mobiluncus are 
enumerated. The scores are weighted heavily on the number of lactobacilli and not 
surprisingly a low or “normal” Nugent score corresponded with recovery of 
Lactobacillus abundance after treatment (Figure 5-6, bottom). Amsel criteria indicate BV 
if three of four criteria are present: pH greater than 4.5, presence of thin, white, 
homogenous discharge, a positive “whiff test” - the release of fishy odor after addition of 
potassium hydroxide, and the presence of “clue cells” (epithelial cells covered in 
bacteria) by microscopy. Like the Nugent score, presence of the Amsel criteria generally 
corresponded with Lactobacillus-depleted biota (Figure 5-6, below colored taxonomic 
bar plots). 
Of note, the administered probiotics L. rhamnosus and L. reuteri were not detected at the 
relative abundance cutoff of 1% after treatment indicating that in these 61 women the 
probiotic strains did not become dominant colonizers of the vagina following one month's 
treatment. 
5.4 Discussion 
The relative V6 profiles for the VVC study emphasizes that this condition is not 
associated with a disruption of the bacterial microbiota and a depletion of lactobacilli. 
These organisms were highly abundant both during VVC and after anti-fungal therapy 
(Figure 5-3). Although we did not target sequencing for the yeast, the previous report of 
the clinical study showed a significant reduction in yeast following therapy (7), and the 
bacterial profiles show a lower bacterial diversity compared to the BV groups which is 
more representative of the healthy biotas (Figure 5-2). It has been suggested that amines 
produced by BV organisms can inhibit Candida and prevent concomitant yeast infection 
(28), but the reverse has not been investigated where Candida might inhibit BV 
organisms. Candida are known to produce a number of metabolites that might be 
inhibitory to bacteria (29), but none would explain why the Gram-negative bacteria 
appeared inhibited not the Gram-positive lactobacilli. In this clinical cohort, BV was an 
entry exclusion, so the outcome of VVC therapy on concomitant BV could not be 
evaluated. 
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If the bacterial profiles per se did not influence the Candida and yet the cure rate was 
improved by probiotic use compared to antifungal alone (7), what mechanism of action 
might be involved? A recent study showed that Candida albicans lost metabolic activity 
and eventually were killed in the presence of L. rhamnosus GR-1 (30). Furthermore, a 
genome-wide transcriptional analyses showed significantly lower expression of the 
CDR1 gene encoding an important drug efflux pump involved in fluconazole resistance, 
suggesting the Candida may not regard the lactobacilli or lactic acid as a threat to 
viability, and this might explain why conjoint probiotic therapy increased eradication of 
the fungi. The lactobacilli repressed the PHR1 and ALS12 genes involved in biofilm 
formation, and increased expression of stress-related genes. In addition, oral probiotic 
therapy with the two strains used here has been shown to decrease transfer of yeast from 
the rectum, suggesting another means of stopping the reseeding process (31). 
It is known that oral administration of L. rhamnosus GR-1 and L. reuteri RC-14 can 
restore health to patients with BV (31-33), but the present study demonstrated that this 
treatment also restores an indigenous lactobacilli-dominated biota. Our results support a 
recent study (34) showing restoration of Lactobacillus-dominated profiles after treatment 
for BV with intravaginal metronidazole and probiotic L. delbrueckii subsp. lactis 
DM8909. In our study, the significant tenfold increase in subjects with dominant 
lactobacilli compared with only twofold change with antibiotic and placebo reiterates that 
the current gold standard of antibiotics to treat BV is not sufficient to restore bacterial 
homeostasis in the vagina. 
The sequence data showed some discrepancy with the clinical outcome reported 
previously for BV (6). Examination of the Nugent scores after treatment showed that 
11/31 patients (35.5%) of the placebo group and 23/31 patients (74.2%) of the probiotic 
group had a normal Lactobacillus-dominated Gram stain after treatment. Examination of 
these Lactobacillus-dominated samples by sequencing showed that Lactobacillus was not 
the predominant organism in every case. Only 7/11 = 63.6% (placebo) and 21/23 = 
91.3% (probiotic) of those previously reported as cured by Nugent had at least 50% 
relative abundance of lactobacilli sequences (Figure 5-6). This discrepancy may be 
caused by the different protocols: Nugent scoring counts absolute numbers of cell 
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morphotypes visible on select microscopic fields, while amplicon sequencing determines 
the relative abundance of lactobacilli compared to the rest of the sampled sequences and 
not absolute numbers. 
These findings also show that even without colonizing the vagina in high numbers, orally 
administered lactobacilli can still influence the vaginal ecosystem. This may be through 
lowering pathogen ascension from the vagina, disrupting the BV biofilms (9) or 
promoting recovery of the indigenous lactobacilli via immune modulating effects (35) or 
by affecting the mRNA expression of the community (36). The cause of BV has not been 
established, but as with other microbial ecosystems an exogenous disturbance could lead 
to ecosystem degradation allowing a number of species to grow and outcompete the 
typically healthy lactobacilli. By administering probiotics the system is again disturbed 
but in a way that displaces the BV-associated organisms and allow the indigenous species 
to re-establish, ideally creating a stable microbiota (37). 
5.5 Concluding Remarks 
In this study we have shown that oral tinidazole and probiotic Lactobacillus reuteri RC-
14 + L. rhamnosus GR-1 restores the indigenous vaginal lactobacilli in women with BV 
resulting in a better cure rate than tinidazole treatment alone. Additionally, this is the first 
high-throughput 16S rRNA gene sequence study of the vaginal microbiota in relation to 
active vulvovaginal candidiasis (38). Despite an apparent lack of change in the bacterial 
microbiota structure and abundance, oral probiotics with fluconazole resulted in better 
cure of VVC compared to fluconazole alone. The results underscore our lack of fully 
understanding the interactions between the vaginal microbiota, other pathogens, and the 
host immunity and environment.  
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Chapter 6  
6 General discussion 
Extending back to 1683 when Antonie van Leeuwenhoek observed bacteria for the first 
time from the scrapings of his teeth (1) there has been a fascination with the microbial 
world associated with the human body. Though important for understanding function, 
culturing approaches don’t allow for the entirety of the microbial ecology to be examined 
at once. A number of species are inaccessible because we haven’t yet been able to 
adequately create a favourable environment in vitro to culture them. High-throughput 
sequencing has changed the course of microbiology and our understanding of the 
influence the microbes have on our health. The human vaginal microbiome has long been 
of interest for its impact on reproductive and sexual health. 
6.1 Defining normal 
It’s apparent from studies presented in this thesis and by others in the field that in the 
majority of reproductive-aged women the healthy vaginal microbiota is dominated by 
Lactobacillus (2). We have found that for Brazilian (Chapter 5) and African women with 
HIV (Section 1.4.2) the healthy biota had a predominance of L. iners that was detected in 
every sample. In other cases, healthy biota had a dominance of L. crispatus and rarely did 
another Lactobacillus species dominate. These findings are common in other studies 
we’ve examined of asymptomatic, healthy Canadian women (data not published). 
However, as exemplified by the 63 Brazilian women without signs or symptoms of 
vaginal abnormalities, not every individual is dominated by Lactobacillus, and some have 
a biota with increased bacterial diversity. Using a 60% Lactobacillus abundance cutoff, 
we reported that 30% of these healthy women had a mixed-species vaginal profile. The 
taxa associated with non-Lactobacillus-dominant healthy profiles included organisms 
traditionally associated with BV like G. vaginalis, Prevotella, Megasphaera, Atopobium, 
Leptotrichia. This represents a large inter-personal variation in the apparently healthy 
vaginal microbiota. Without longitudinal sampling it is unclear whether these diversified 
profiles are stable or possibly represent a risk for these women to develop BV. Ravel et 
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al. (3) reported a cohort of asymptomatic women who had a multi-species 
microbiological profile, and these were more likely to be ethnically Hispanic and black. 
Although the aim of the work presented in this thesis was not to compare ethnic 
differences, subjects from three continents were examined (unlike Ravel's study of only 
North Americans), and the findings help us better address the clinical dilemma of how to 
define an abnormal vaginal microbiota. The 'gold standard' Nugent score for evaluating 
BV is entirely based on the premise of a normal vaginal microbiota being dominated by 
Lactobacillus. If Brazilian and African women represent cohorts where mixed-species 
biota are more prevalent, then Nugent scoring could over diagnose BV. Indeed, in women 
of African descent there is a higher report of so-called 'asymptomatic' BV (4). Possibly 
there are differences in genetics, changes in the local immunity or environment, or 
cultural practices and socio-economic factors, or the biota is less stable leading to higher 
risk of BV, AV, or infectious conditions. 
For post-menopausal women, “normal” is less clear. Previous studies report that post-
menopausal women have a lower prevalence of Lactobacillus due to lacking glycogen 
produced by the vaginal epithelium (5). However, this appears an over-simplification, 
and indeed lactobacilli are clearly present in such women (Heinemann et al; Devillard et 
al.). In Chapter 1, partial 16S rRNA sequencing revealed an association between the 
microbiota composition and the severity of vaginal dryness and atrophy in menopausal 
women. In fact, the biota were relatively stable over 10 weeks and the symptoms did not 
vary considerably (Figure 2-3). Dryness was rated on a four-point scale as none, mild, 
moderate, and severe. Six of the seven women who experienced only mild or no vaginal 
dryness had profiles dominated by Lactobacillus iners or L. crispatus. Of the nine women 
who experienced moderate or severe dryness, only one maintained a Lactobacillus-
dominated profile of >60% relative abundance for the 10 weeks. This supports the view 
that lactobacilli abundance still plays a role in health at menopause, despite the 
physiological changes that have occurred. Although we didn’t measure glycogen levels, a 
microarray analysis of the vaginal epithelial transcriptome indicated genes involved in 
maintenance of the epithelial cell barrier were dysregulated in the moderate/severe 
dryness group. Although cause and effect are not determinable, the depleted glycogen 
and lower abundance of lactobacilli are associated with aberrant vaginal health.  
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Another cause of illness and discomfort in post-menopausal women is UTIs, and this can 
be associated with and increase the risk of urinary incontinence (6). It’s been proposed 
that the persistent colonization of E. coli in post-menopausal UTI is due to the vaginal 
absence of protective Lactobacillus species (7). This is supported by the finding that 
Lactobacillus were absent by culture in 93 post-menopausal women with a history of 
recurrent UTI, but were recoverable in 61% of the 36 women who received intravaginal 
estriol and none of the 24 receiving placebo (8). The estriol group also had a significant 
drop in pH and Enterobacteriaceae colonization while the placebo group was unchanged 
for both. This indicated the potential to restore the lactobacilli population as a means of 
reducing recurrence of UTI. Not only did estrogen therapy achieve this, but also the 
administration of probiotic L. rhamnosus GR-1 and L. reuteri RC-14 (9, 10). 
There is a clear indication that estrogen has a modulating effect on the vaginal microbiota 
of post-menopausal women. A study of the temporal variability of in reproductive-aged 
women over a 16-week period suggested there were large changes in the community 
associated with points in the menstrual cycle (11), confirming earlier work by Keane et 
al. (12). Clearly, more studies are needed to understand the role of host factors in 
temporal dynamics of the vaginal microbiota clearly need further study, particularly if we 
are to differentiate a 'normal' or 'healthy' status to one that requires intervention. 
It is now evident that 'normal' can have many contexts and it represents a network of 
interactions between the host and the resident microbes. Once inter-personal variations 
and the factors associated are better understood, as well as the variations within an 
individual over time, it will be easier to differentiate the normal fluctuations from high-
risk profiles. 
6.2 Bacterial vaginosis 
The data presented in Chapter 5 and Figure 1-1 show a diverse array of vaginal profiles 
during clinically diagnosed (Amsel and Nugent) BV. We previously reported (13) the 
profiles of 272 vaginal samples clustered into distinct groups representing the dominating 
organisms. For BV, there were four groups represented by Prevotella bivia, BVAB1 
(previously reported Lachnospiraceae), Gardnerella vaginalis, and one group of mixed 
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species. The profiles from the Brazilian BV cohort in Chapter 5 had a similar array of 
dominating BV organisms. The distribution of the measured diversity as calculated by 
Shannon’s diversity index for both studies had a median value of ~2 for non-BV/healthy, 
and ~3 for BV (Figure 5-2) indicating the increased complexity of the microbiota during 
BV. These findings agree with those reported by others, namely that health and BV are 
not simple conditions with single end-points of bacterial species. 
Being able to survey the vaginal microbiota at sequencing depth allows one to investigate 
the question of a so-called “rare microbiome”, and how many species are present in small 
numbers in an environment. In a large dataset of women with HIV and BV we 
determined there were approximately 60 OTUs, and the 272 samples we studied had a 
median sequence depth of >40,000 reads per sample (13). For the 323 samples 
composing the data in Chapter 5, the average sequencing depth was >38,000 reads per 
sample and we reported 77 OTUs. These studies far exceed the sequencing depth of other 
vaginal microbiota studies. For example, the 396 samples described by Ravel et al. (3) 
were sequenced at an average depth of 2,000 reads per sample and reported 282 taxa and 
Srinivasan et al. (14) reported a median 1,779 reads for 220 samples identifying 796 
species. The discrepancy in the reported number of OTUs could be explained by the 
difference in sequencing platform and the accumulation of errors. The pyrosequencing 
method used by Ravel et al. and others has a notoriously high error rate resulting in 
spurious reads divergent from the original sequence population (15). In addition, 
amplifying multiple variable regions across a constant region (e.g. V1-V2, or V3-V4 used 
in the studies mentioned above) creates more opportunity for chimeric reads comprising 
sequence fragments from two different genomes (16). In our Illumina datasets, the 
dominant error originated from PCR amplification and chimeric sequences, and other 
sequence errors were exceedingly low and did not contribute to the segregation of OTU 
clusters (17). Measures of species richness with ACE and Chao1 methods and rarefaction 
curves supported sufficient depth of sampling to reach near saturation. Regardless of the 
number of rare organisms in the vagina, the top abundant organisms we report in health 
and BV have a high congruence with those reported by other groups (3) using different 
methodologies and sequencing platforms. This suggests we have a relatively 
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comprehensive picture of the “who’s there” for the major players in the vaginal 
microbiome. 
What we clearly don’t understand yet are the interactions between the organism 
components of the microbiota. Castro et al. (18) examined the adherence ability of two 
strains of G. vaginalis, one isolated from healthy conditions and the other from BV, and a 
strain of L. iners and L. crispatus isolated from healthy women. The BV G. vaginalis 
isolate had a higher capacity for binding cervical epithelial cells and could displace L. 
crispatus but not L. iners, whereas the healthy isolate had no effect on displacement. 
Furthermore, L. iners enhanced the adhesion of the BV strain but did not affect the 
healthy isolate. This study suggests some mechanisms for co-occurrence and exclusion 
between organisms in the vagina. The cumulative effect of co-occurrence and exclusion 
amongst all the organisms in an environment can be used to build predicted ecological 
networks describing the interactions of the community. Recent attempts have been made 
to use high-throughput 16S sequence data to predict these relationship with interaction 
networks (19, 20). 
In terms of clinically defining BV, the current “gold standard” Nugent and Amsel criteria 
do not appear to encompass our new molecular understanding of the vaginal microbiome. 
As the cost of sequencing continues to drop, future clinical practices may use these 
techniques to profile the vaginal biota for diagnosis. Understanding the function 
(described below) and interactions between the host and microbes will make treatment 
planning more efficient and effective. The lack of progress from the medical industry has 
been stark, and clearly better diagnostic and more targeted therapeutics are needed to 
lower the immense burden of BV which impacts the quality of life of so many women 
(21). In the very near future, high throughput sequencing methods will make it feasible to 
obtain a vaginal microbiome profile of a patient during a doctor's visit. Armed with this 
information, the doctor will then be faced with its interpretation. Research is needed to 
determine which profiles require which, if any, intervention. For example, if a female is 
at higher than normal risk of STI through unsafe sex practices, and she has for example a 
Prevotella and Lachnospiraceae dominated microbiome, and if research shows this 
species increase risk of viral infection, then a treatment targeting depletion of Prevotella 
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and Lachnospiraceae would be optimal. Likewise for pregnant women, it may be that co-
association of Atopobium and Gardnerella increase risk of preterm labour, in which case 
they might be targeted. At the same time as depleting pathogens, any therapy needs to 
help restore a 'healthy' state, in most cases the recovery of indigenous lactobacilli. 
6.3 The role of Lactobacillus iners 
Lactobacillus iners remains an enigma in the context of the vaginal microbiome. This 
organism was long missed by the failure of culture techniques, but molecular methods 
have unequivocally defined its predominance in the vagina. During BV, we detected L. 
iners at 10% relative abundance or more in nearly all cases, while other Lactobacillus 
species were rare (Chapter 5 and Section 1.4.2). Even in menopause, L. iners remains a 
major component as well as during acute VVC (Chapter 1 and Chapter 5). Very little 
description of this organism existed until we sequenced and described the genome of L. 
iners AB-1. 
The reduced genome in comparison to other lactobacilli, had evidence of gene loss and 
an exceptionally high number of predicted horizontally acquired genes. The data overall 
suggest L. iners has a long evolutionary history of adaptation to the human vagina. An 
arsenal of unique adhesins were predicted, including a number of cell-wall anchored 
proteins and two fibronectin/fibrinogen binding proteins. A follow-up study I conducted 
with another graduate student confirmed that L. iners bound immobilized human 
fibronectin in vitro and the adhesion was significantly reduced after protease treatment 
(22). Fibronectin concentrations range from 90 to 140 pg/mL during menses to 3 to 5 
pg/mL at the end of the menstrual cycle (22). As L. iners reportedly increases in 
abundance during menses while L. crispatus is less abundant (23), the fibronectin-
binding protein may represent an adaptation for L. iners to persist during fluctuations in 
the environment. 
We were the first to predict a cholesterol-dependent cytolysin in the genome of L. iners, 
and later reported this gene was upregulated 6-fold in BV compared to healthy (Chapter 
4). The cytolysin shares considerable protein sequence similarity with another cytolysin 
present in G. vaginalis and known to be a key virulence factor (24). Rampersaud et al. 
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(25) reported in vitro production of the L. iners cytolysin from a number of clinical 
isolates. The size of the pore is predicted to allow movement of small molecules from the 
cell cytoplasm to the extracellular space and vice versa. One possibility of why the 
organism uses this compound is to release nutrients from the human cells. Some 
researchers have interpreted this to mean that L. iners lyses cells and therefore 
participates in the onset of BV (26), and more likely AV in which lysed epithelial cells 
are present (27). 
Although lactobacilli reportedly don’t require iron for cellular processes like most 
organisms, the genome sequence of L. iners revealed a predicted ferrochelatase not 
present in related lactobacilli. These features are usually described as 'virulence' factors 
for pathogenic organisms, but although L. iners could have a role in the aetiology of BV 
there is no evidence that it is a truly pathogenic organism. 
The transcriptome profile of L. iners presented in Chapter 4 is the first general 
comparison of genomic content for this species. As shown in Figure 4-2, approximately 
60% of the mapped coding sequences were conserved across 13 genomes while the 
remaining 40% was variable. Several highly differential coding sequences (e.g. CRISPR-
associated) were only detected in one of the conditions (2 of the 4 samples). This offers 
another explanation for L. iners’ persistence, as perhaps there are different strains more 
adapted to BV while other strains preferentially colonize healthy conditions. However, 
we were not able to assemble the CRISPR locus in the genome of L. iners AB-1 and 
similar assembly problems in the other strains could mean the differences are due to 
mapping to the reference sequences. Future studies using transcriptome or metagenome 
sequencing of different vaginal conditions with L. iners would provide information on 
differential strain abundance. Of note, although the sample size in this study is small, the 
strength of the data was such that the findings could be carried forward to larger 
comparative groups. Indeed, I am currently completing an analysis of 24 transcriptomes 
and with Amy McMillan comparing these to metabolomic profiles, and the results 
confirm the 4-subject study, plus reveal associations between bacterial types and their by-
products. This work will be completed within the next few months but was not 
sufficiently developed for inclusion in this thesis.  
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Clearly L. iners is a vaginal organism that warrants more scrutiny, and indeed 45 of the 
75 papers reporting on the organism in PubMed have come out in the past four years, 
compared to 30 papers between its discovery in 1999 and 2008. The differential 
transcriptomics has provided clues for the changing environment from a healthy to BV 
microbiota and L. iners may have a complex symbiotic relationship with its host ranging 
from mutualistic to pathogenic. Furthermore, it may be that different clones of L. iners 
encode different host outcomes. 
6.4 What are the bacteria doing? 
We described the first transcriptional analysis of the vaginal microbiome in Chapter 4 
using metaRNAseq. The power of this study is limited by the sample size of four samples 
(for logistical and cost reasons), but we specifically chose and developed methodologies 
that would find robust, conserved results and to avoid over fitting the data. To overcome 
the obvious difference in gene content between samples due to differing taxa membership 
(Figure 4-1) the community-level analysis was performed at the functional level and not 
on individual genes belonging to individual species. We accomplished this by grouping 
the mapped genes by sequence identity and then assigning a broader functional 
classification to the group of genes with SEED subsystem annotation. For assessing 
differential expression, we grouped all the reads belonging to the same SEED functional 
subsystem for comparison. This accounts for redundancy in gene functions that may be 
constant despite population changes. For example, Gajer et al. (11) in reporting the 
vaginal microbiota and metabolome using 1H NMR (nucleic magnetic resonance) 
spectroscopy over time showed that a shift from L. iners abundance to L. crispatus 
abundance had no effect on the total metabolome. In their case, metagenomic 
quantification of the gene abundance would likely show a large change in gene content 
during this population shift despite the apparent functional conservation. In our study, we 
noted several functionally conserved features that were differential despite discordance in 
the organism contributing to the function (Figure 4-1). This presents an interesting 
ecological hypothesis that several species have overlapping niches in the vagina and can 
fulfill the same functional role.  
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The statistical framework, developed specifically for this study but applicable to any 
high-throughput sequencing experiment (28), reports significantly different features that 
are consistently higher in one defined condition or another (healthy or BV). Therefore, 
although this provides a level of confidence for the reported data, in order to strengthen 
conclusions drawn from four samples, we have performed a follow-up to Chapter 4 that 
included an additional 24 vaginal samples in addition to the original four (Figure 6-1). 
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Figure 6-1. Summary of mRNA and V6 16S rRNA gene sequence data for 28 
vaginal samples 
The mRNA samples presented in Chapter 4 (marked with a filled circle) were 
compared to a larger dataset of 24 samples. All samples were re-mapped to an 
updated refseq database and an updated SEED subsys4 level database was used to 
assign function. Heat map: Expression of each functional group (SEED subsys4 
level) as derived by ALDEx is plotted. Euclidian distance was calculated between 
samples and the dendrogram represents complete linkage clustering. Nugent status 
(red=BV, grey=intermediate, blue=normal) is plotted below the heat map. Bar plots: 
The top bar plot is the fractional composition of the mapped mRNA reads for each 
sample. In contrast, the bottom bar plot is the fractional composition of V6 16S rRNA 
gene sequencing. 16S sequence data are not available for the samples presented in 
Chapter 4 (marked with a filled circle) and so the bars are hatched out. 
Plotting the inferred subsys4 level expression of these data and performing hierarchical 
clustering suggested a major split between predominantly Lactobacillus-dominated 
samples and samples with mixed species. This corresponded with the Nugent BV status. 
Importantly, the four samples presented in Chapter 4 (marked with a closed circle in 
Figure 6-1) clustered with the additional 24 samples by BV status and microbiota 
composition. This indicates the similarity is being driven by the overlap in gene 
expression and is independent of the platform used for sequencing. Interestingly, 
clustering by expression data suggested two major clusters for Nugent BV/intermediate 
samples. One cluster (samples on the far left of Figure 6-1: 019A, 003A, 008B, 001A) 
had a relatively high abundance of lactobacilli reported by V6 sequencing (bottom bar 
plot) and included two of these samples with L. gasseri/johnsonii as the predominant 
species, while other BV samples had L. iners, G. vaginalis, Prevotella, BVAB1, and 
Megasphaera. Within the healthy/non-BV cluster, sub-clusters consisted of L. iners or L. 
crispatus dominated profiles. Although preliminary, these data support overlapping 
conserved functions within BV or healthy conditions. Within healthy, there are possible 
subclasses defined by the different dominating Lactobacillus species. 
Many of the transcriptional changes associated with BV (reported in Chapter 4 and 
unpublished data from Figure 6-1) were related to central carbohydrate metabolism and 
production of different metabolic end products (lactic acid in healthy conditions, and 
succinate, butyrate, acetate, propionate in BV conditions). These products have been 
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reported in association with BV and shown to promote a pro-inflammatory response in 
vitro (29). Although up to 30-40% of women with a BV Nugent profile report no 
symptoms (3, 30), the production of these metabolic products by the bacteria may still 
activate an immune response resulting constitute an increased risk for infection. 
6.5 Considerations for modulating the ecosystem 
Antibiotic treatment for BV fails in approximately 30% of patients, and up to another 
30% of patients with initial recovery have a recurrent episode within 3 months and over 
50% within one year (31). In cases of recurrent BV and VCC the treatment and 
prevention strategies are woefully inadequate, yet no new therapies are on the horizon 
(32). The concept of replenishing the vaginal lactobacilli through probiotics has been 
discussed and developed since 1988 to prevent recurrent UTI (33) and more recently to 
resolve recurrence of BV (34). 
Our study reported in Chapter 5, is the first on three counts: it shows that probiotic 
therapy can modulate the vaginal microbiome, while others have reported it does not do 
so to the gut (35); it showed that the clinical recovery matched restoration of indigenous 
lactobacilli in BV patients; and it was the first report of the effects of VVC on the vaginal 
microbiome. Intriguingly, the host recovery did not require the two probiotic strains to 
universally reach or dominate the vagina. On the contrary, their oral administration 
induced a restoration of L. iners and L. crispatus for reasons that are only conjecture at 
present. Unlike L. iners, strains GR-1 and RC-14 do not adhere to fibronectin (22), which 
might reduce their ability to colonize the vagina since they reach the location in lower 
numbers compared to when they are intravaginally instilled (36). The ability to reduce 
pathogen ascension from the rectum to the vagina along the perineum might reduce 
pathogen seeding and thus allow better recovery of the indigenous lactobacilli (37). 
Another factor might be the well-known ability of lactobacilli to enhance mucosal 
immunity. Two previous studies from our laboratory showed that an aberrant vaginal 
microbiota may reduce the effectiveness of the immune response and the instillation of 
probiotic lactobacilli might to some extent restore the host's ability to counter pathogens 
(38, 39). There are several hypotheses for the role of the immune system in BV. Vaginal 
epithelial cells produce antimicrobial compound (defensins, lectins, proteases) and use 
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Toll-like receptors to recognize the microbial components in the environment and signal 
the immune system (40). The absence of an inflammation response in BV is considered 
an enigma (41), but is likely due to suppression of the immune response by the bacteria 
(42). The alterations in innate immunity has been proposed as a factor for the 
development of adverse effects, like pre-term labour, in some women with BV and not 
others (42). The cross-talk between host and microbes could have enormous effects on 
the development and resolution of conditions like BV and VVC, and changes in the 
microbiota. 
The ability to enhance the host's defenses while also depleting pathogens, represent a 
different approach to those taken for the past 50 years where administration of 
antimicrobial agents have been designed solely to kill microbes, disregarding the 
implications for restoring homeostasis. The fact that in some cases probiotic therapy 
alone can better cure BV than antibiotics (43) further emphasizes that such approaches 
warrant more serious consideration. Of course, the long-term health of the female is 
equally as important as addressing an immediate acute infection. Understanding why 
some women never suffer from UTI, BV or VVC is an important future goal, and 
whether it is due to microbiome stability, immune efficiency and/or an ability to self-cure 
infection or another factor (44) will lead to improvement in care and quality of life. The 
idea that there are passenger organisms that simply adapt to fluctuations, and others that 
drive the change, is worth pursuing and is now feasible given the tools described herein. 
6.6 Future directions 
This thesis has put into place a number of techniques and experimental protocols that 
have provided great insight into the vaginal microbiome and Lactobacillus in particular. 
These now allow a series of investigations to be undertaken, which previously would not 
have been possible. The following outlines some areas that I think could prove fruitful.  
High-throughput sequencing of the vaginal microbiome has revealed an unprecedented 
amount of information about the diversity, interactions, and functions of the bacterial 
residents. It is clear that BV is not one disease, and the possibility that differential 
functions of the microbes constitute different outcomes for the host needs to be further 
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investigated. Centres with high patient loads will be well placed to analyze BV patients 
and acquire sufficient numbers who fit into the different 'healthy' and 'BV' categories. 
Using transcriptomics merged with metabolomics, it will then be possible to look at what 
the bacteria are doing in real time, and by combining this with human microarrays and 
immune studies, to find out the effects on the host. This might possibly reveal early 
changes that increase the risk of preterm labour or viral infection. For example, studies 
using GCMS at Imperial College in London UK have shown that markers of cancer can 
be detected at sites a few centimeters from an actual tumour and that the identity of the 
tumour can be made along with its primary and/or secondary site (Dr. Jeremy Nicholson, 
personal communication). This was made possible by collecting thousands of metabolic 
readouts. The same should be possible for the vagina through collaborations with Dr. 
Ravel (St. Louis), Dr. Bocking (Toronto), Dr. Money (Vancouver) and others to collect 
and match profiles with disease outcomes and predict which ones will be problematic. In 
our transcriptomic and matching metabolomic studies, we have identified markers for BV 
such as odor compounds that likely are responsible for patients seeking medical attention. 
In other cases of BV if odor production is less, we will be able to determine whether risk 
of complications is also lowered or not. Such information is vital for caregivers to 
determine if patients require treatment or if therapy has been effective.  
Longitudinal studies, like the one performed by Ravel's group, will help identify the 
normal day-to-day fluctuations of the microbiota in response to exogenous disturbances, 
and differentiate benign changes with ones that have pathological implications. 
Other than the bacteria, the vaginal microbiome consists of the viruses and eukaryotic 
organisms either transiently present during infection (Trichomonas, Candida) or 
established members of the community. We reported the bacterial microbiota during 
VVC was undisturbed compared to normal, but the coexistence of Candida causing host 
response and symptoms may still affect the response of the bacteria in the environment, 
and therefore affect the host. Transcriptional profiling of L. iners revealed the 
upregulation of several phage defense systems, notably CRISPR regions, that suggest 
viral influence on the population. Indeed, the idea has been proposed that Lactobacillus-
targeting phage could be responsible for their depletion leading to BV (45). Another 
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hypothesis is that bacteriophage adherent to the human mucosa can act as a non-human 
component of immunity (46). Viral diversity is only beginning to be explored with 
metagenomic techniques in the human gut (47), and these approaches could be extended 
to the vaginal microbiome. Similarly, the eukaryotic microbiota of the vagina is not well 
defined with only one study to date (48) using high-throughput sequencing to examine 
the diversity of the vaginal mycobiome. 
Current two-species biofilm models have already shown the effects of exogenously 
applied lactobacilli (49), but growing a multispecies biofilm or culture is limited with 
standard laboratory techniques. An in vitro artificial model, like the “robogut” used to 
model the gut microbiota (50) could provide a useful tool to develop and test concepts. 
Currently, apart from primates that are expensive to work with, there is no animal model 
to test the effects of exogenous disturbances on different vaginal communities. Many 
scientists use mouse models, but these are often too far removed from the human system, 
and therefore conclusions are difficult to transfer. 
The challenge remains to turn the hypothesis-generating results from microbiome studies 
into predictive values for health and disease. In the case of the vaginal microbiome, we 
need to be able to correlate the bacterial actions to outcomes like pre-term birth, 
development of BV, and acquisition of infections diseases. The data presented in this 
thesis begin to answer some of these biological questions, and the tools developed for 
high-throughput sequence analysis will further our understanding in future studies. The 
reliance on pharmaceutical and diagnostic companies coming up with new products has 
so far proved hollow, and meanwhile millions of women around the world continue to 
receive sub-optimal care. The use of probiotics, especially through food, could be a faster 
route to patient care as it does not require extensive drug studies and animal toxicity 
assessment. Our studies clearly show this has benefits for restoring and maintaining 
vaginal health even when administered with antimicrobial agents. Indeed, when 
administered to HIV patients in the Tanzanian community which I studied, there have 
been gut and vaginal benefits, including reducing recurrence of BV (51-53). Our findings 
indicate that the vaginal microbiome of HIV patients is not significantly different from 
those of other women in terms of the types of bacteria present, and others have shown 
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that they too can benefit from probiotics (54). Whether or not such probiotics should 
include L. iners remains to be determined, and with the species being difficult to 
propagate, the manufacture of such products may prove difficult. But, more studies will 
needed to investigate clonal differences between strains and see if some are better 
predictors of health than others.  
Much of my thesis was involved in developing computational tools for these studies. This 
is far from complete, and improving the quality of samples, the depth of coverage, the 
degree to which silent or unidentified genes, or transcriptional regulators like 
riboswitches and anti-sense transcripts are involved in lactobacilli colonization and host 
defense is worthy of further effort (55).  
At the end of the day, the driving force for these studies is the health of women. Given 
the impact on quality of life, reproductive health and outcomes of pregnancy caused by 
the vaginal microbiota, it is fundamentally essential that we continue to apply the 
findings of this thesis to improving female well-being. I feel confident that this thesis has 
at least provided some pathways to making that a reality. 
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